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Over 65,000 people acquired renal cell carcinoma (RCC) and over 13,500 people 
died from the disease in the United States in 2012. The median survival for individuals 
with metastatic disease is 13 months. Limited therapeutic strategies exist for the 
treatment of RCC. Recent research has identified new targets for this disease and new 
targeted therapies have been developed. Despite this, the overall survival remains poor, 
and there remains a need for additional new therapies for RCC. Benzaldehyde dimethane 
sulfonate (BEN, DMS612) is a bifunctional alkylating agent with activity against renal 
cell carcinoma cell lines. The goal of the research conducted was to evaluate the 
preclinical and clinical pharmacology of BEN.  
Benzaldehyde dimethane sulfonate is stable in plasma but is metabolized in blood 
by aldehyde dehydrogenase into an acid that decomposes in aqueous and biological 
matrices. Furthermore, the acid product decomposes into 6 different species of which 
none are as active as BEN in the renal carcinoma cells that we have tested. We also found 
that BEN had greater activity in renal carcinoma cell lines that expressed higher levels of 
aldehyde dehydrogenase. This led us to believe that BEN acts as a pro-drug with its main 
carboxylic acid metabolite exerting the activity against renal carcinoma cell lines. 
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We determined that BEN is rapidly metabolized in mice and that the pretreatment 
of mice with the aldehyde dehydrogenase inhibitor disulfiram greatly increases the 
exposure to BEN. Furthermore the carboxylic decomposition products that were detected 
in vitro were also found in the mice along with corresponding glucuronides. Also, we 
found that BEN when administered to patients is very rapidly metabolized and the same 
glucuronides generated in mice were also detected in humans. The maximum tolerated 
dose in a phase I clinical trial in humans was 9.0 mg/m
2
. The dose limiting toxicity was 
thrombocytopenia and neutropenia.  
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1.0  INTRODUCTION 
Renal cell carcinomas (RCC) originate within the renal cortex and comprise 80 to 
85% of all renal neoplasms.
1
 Patients with localized disease can be cured with surgery, 
however, in most cases the disease is not identified until it has metastasized. At this point 
surgery is not curative. In addition, many patients that have had surgery to remove a local 
lesion have recurrence of the disease. The median survival for persons with metastatic 
disease is 13 months.
1
 Recent research has identified new targets for this disease and new 
targeted therapies have been developed.  Despite this fact, the overall survival remains 
poor, and there remains a need for new therapies for RCC. 
1.1 EPIDEMIOLOGY  
In 2011, 65,000 people acquired RCC in the United States and in the same year 
nearly 13,500 died from the disease.
2
 In 2008, there were 270,000 cases and 116,000 
deaths worldwide.
3
 The incidences of RCC vary widely worldwide.  The highest 
incidences are seen in Europe and North America, while the lowest incidences are seen in 
Africa (Figure 1).
3
 
 In the United States, the incidence of RCC has increased over time (Figure 2).
4
 
Between 1975 and 1995 incidence rates per 100,000 person-years increased by 2.3, 3.1, 
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3.9, and 4.3 annually for white men, white women, black males and black females 
respectively. More recent data obtained from 1997 to 2007 shows a similar trend of a 2.6 
percent yearly increase in the overall incidence of RCC (5).
3
  
  
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. International variation in age-adjusted incidence rates (world) per 100,000, for 
histologic verified renal cell cancer in selected countries. (Reprinted from Hematology/Oncology Clinics of 
North America with permission from Elsevier©)
3
 
 
 
 4 
 
Between 1970 and 1998, the incidental discovery of asymptomatic RCC increased 
from 10 to 60 percent, respectively.
5
  The Surveillance, Epidemiology and End Results 
(SEER) database shows that while the incidence of RCC has increased in recent years 
this increase has been associated with a decrease in the average size of the tumor at first 
presentation (6.7 cm vs. 5.9 cm in 1988 and 2002, respectively). It may be that the 
widespread use of modern imaging techniques account for part of the increase in the 
observed incidence. 
6,7
 
Older studies show that RCC was at least twice as frequent in men than women, 
however newer data show that the gender gap is narrowing.
8
 Data analyzed from the 
National Cancer Database from 1993 to 2004 show that the ratio of RCC in men 
compared to women is 1.65. The median age at diagnosis is 64 years. The disease is rare 
in people younger than 40 years old. The most recent study shows those patients younger 
than 40 make up less than 5 percent of the new cases.
9-11
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Figure 2. Incidence of renal cell carcinoma in the United States between the years 1973 and 1998. 
Whites incidence (♦), black incidence (■), whites mortality (▲), and black mortality (×). (reprinted from 
The Journal of Urology with permission from Elsevier©)
4
 
 
1.2 ETIOLOGY 
There are a number of environmental, genetic and clinical risk factors that are 
associated with the development of renal cell carcinoma. Environmental risk factors 
include cigarette smoking, analgesic abuse and occupational exposure.
12-14
 
There is a statistically significant dose response for cigarette smoking and RCC 
for both males and females.
12
 Cigarette smoking can be attributed to cause nearly one 
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third of all cases of RCC. Furthermore, the use of cigarettes by individuals with RCC is 
associated with more advanced disease at first presentation.
15
 
Analgesic abuse and analgesic abuse nephropathy has been linked to the increased 
risk of RCC.
13,16,17
  Data from a study from approximately 128,000 individuals found that 
the risk for RCC was increased among subjects that used non-aspirin non-steroidal anti-
inflammatory agents (NSAIDs) on a regular basis.
16
 The authors in this study defined 
regular use as more than 2 doses per week for 16 years. 
There are a number of studies that have found an association between 
occupational exposure to chemicals and RCC. High levels of the industrial solvent 
trichloroethylene correlated with RCC.
18
  In addition, exposure to cadmium, asbestos, 
gasoline and petroleum products have been shown to increase the risk of RCC.
14,19,20
 
There are a number of clinical factors that are associated with RCC.  These 
include hypertension, diabetes mellitus, obesity, and acquired cystic disease of the 
kidney.
21-25
 A number of studies have found an association between hypertension and 
increased risk of developing RCC. A Korean study composed of 576,562 men found that 
hypertension (systolic > 160 mm) lead to an increased risk of mortality from RCC (RR 
2.43) compared to individuals with normal blood pressure (systolic < 120 mm).
26
 
Another study composed of 296,638 European men and women found a relative risk of 
2.48 when comparing persons with a systolic pressure of >160 mm with those having a 
pressure of <120 mm.
24
 This study did not find a significant difference of risk estimate 
between sexes, and individuals taking anti-hypertensives were not at increased risk unless 
blood pressure was poorly controlled. 
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It has been shown that a history of diabetes mellitus has been associated with an 
increased risk of RCC. Studies conducted in the United States and Europe found a 
significant increase in the incidence of RCC in both men and women with a history of 
diabetes.
25,27,28
 However, this increase in incidence may be due in part to obesity and 
hypertension. 
Obesity is a risk factor in both men and women.
21,29,30
 One study that divided 
body mass index (BMI) into 8 cohorts, showed that men with a BMI in the middle three 
cohorts had a 30 to 60% greater risk than men in the lower three cohorts to develop RCC.  
In addition, men in the highest two cohorts had nearly double the risk, when compared to 
the men in the lowest three cohorts.
21
 There is also an increased risk of RCC in obese 
women. In a large European study, it was found that woman in the top 20% of weight had 
a significant increase in risk (2.13 RR) when compared to women in the lowest 20%.
29
 
Another clinical condition that is associated with an increased risk of RCC is 
acquired cystic disease of the kidney. It is estimated that between 35 and 50% of patients 
who require chronic dialysis will develop cystic disease of the kidney and that 6% of 
these patients will develop RCC.
31
 Malignant RCC usually develops after 8 to 10 years of 
dialysis. It has been found that among chronic dialysis patients males are at an increased 
risk for RCC with a male to female ratio of 7 to 1.
32
 
Renal cell carcinoma can occur sporadically and through hereditary means.
3
 
There are genetic contributions that predispose individuals to RCC.
33,34
 Although most 
cases of RCC are sporadic, there are several syndromes that can cause RCC such as: Von 
Hippel-Lindau (VHL) disease, hereditary papillary renal carcinoma (HPRC), hereditary 
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leiomyomatosis and renal cell cancer (HLRCC) syndrome, and Birt-Hogg-Dube (BHD) 
syndrome. These conditions will be explained in more detail in the pathology section. 
There are other factors which have not been previously described above that 
predispose individuals to RCC. There is an increased risk of RCC in those individuals 
that have a first degree relative with the onset of disease before the age of 40.
35
. In 
addition, those that have been infected with hepatitis C have a significantly increased risk 
of developing RCC.
36
 
 
1.3 PATHOLOGY 
Renal cell carcinoma (RCC) is not a single disease. It consists of five different 
diseases which occur in the kidney. The five types of RCC and their prevalence are: clear 
cell (75%), type 1 and type 2 papillary (15%), chromophobe (5%), and oncocytoma 
(<5%).
37
  In addition, less than 5% of RCC are considered unclassified. These diseases 
have different histology and are caused by different genetic abnormalities and/or genetic 
mutations.  
Clear cell renal carcinoma originates in the proximal tubule and typically has a 
deletion in chromosome 3p.
38
 These tumors are usually solid but may also be cystic in 
structure. Most cases of clear cell carcinoma are sporadic; however, this carcinoma is 
associated with von Hippel-Lindau disease. 
Papillary carcinomas, which also originate in the proximal tubule, are divided into 
two groups based on histology and gene expression profiles.
39
  The tumors of papillary 
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type 1 are well differentiated (low-grade) whereas tumors classified as type 2 tend to be 
less differentiated (high-grade).
39
 There are molecular differences associated with type 1 
and type 2 papillary carcinomas. Type 1 tumors tend to overexpress c-Met and have cell 
cycle G1-S checkpoint dysregulation, whereas type 2 carcinomas tend to have G2-M 
dysregulation.
40
 The prognosis for patients with papillary type 1 carcinomas is much 
better than that of those with type 2 carcinomas.
40-43
  A study that analyzed 130 patients 
showed that after 48 months the overall survival was 89% for type 1 carcinoma compared 
to 44% for type 2 carcinoma.
41
 
Chromophobe carcinomas originate from the intercalated cells of the collecting 
system. Histologically, these tumors are very different from clear cell and papillary 
carcinoma. These cells are comprised of sheets of cells, are darker in color, and lack the 
lipids and glycogen found in other types of RCCs.
44-46
  Also, chromophobe carcinomas 
have a hypodiploid number of chromosomes.
47,48
  Most chromophobe cell carcinomas 
lack a variety of chromosomes. One study found that 17 of 19 tumors tested had a 
combination of chromosomes absent. In this study a combination of chromosome 1, 2, 6, 
10, 13, 17 and 21 were found to be absent.
48
  The median survival of patients suffering 
from chromophobe cell carcinoma is currently 29 months which is better than the average 
for RCC (13 months).
49
 
Oncocytomas are very rare and originate from the collecting duct cells.
50
 These 
cells tend to be large and well-differentiated with an overabundant number of 
mitochondria.
51
 Renal oncocytoma is usually benign. However, in 10 to 30% of patients 
that have renal oncocytoma it is associated with other types of RCC.
52
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1.3.1 Hereditary forms of renal cell carcinoma 
Although 96% - 98% of cases of RCC are sporadic there are four main hereditary 
syndromes which may lead to the development of RCC.
3
  These are von Hippel-Lindau 
(VHL) syndrome, hereditary papillary renal carcinoma (HPRC), hereditary 
leiomyomatosis and renal cell cancer (HLRCC) syndrome, and Birt-Hogg-Dube (BHD) 
syndrome. There is a keen interest in these syndromes, and especially VHL, because the 
pathways involved in these familial diseases may be similar to the ones responsible for 
sporadic cases of RCC.
53,54
 
1.3.1.1 Von Hippel-Lindau Syndrome 
Von Hippel-Lindau (VHL) syndrome is an inherited syndrome.
34
  Individuals 
with this syndrome inherit a defective allele of the VHL gene from a parent. The 
condition arises when the remaining wild type allele becomes inactivated through 
mutation or deletion.
37
  Inactivation of the VHL gene has also been found in a high 
percentage of patients that have sporadic clear cell renal carcinoma. Mutations of the 
VHL gene have not been detected in individuals with other types of hereditary cancer 
syndromes. The gene abnormality that is the cause of VHL is present in 1 in 36,000 
newborns.
55
  The von Hippel-Lindau gene is located on chromosome 3p25.
56
  This gene 
codes a protein, pVHL, which functions as a tumor suppressor protein.
57
 pVHL regulates 
the transcription factor hypoxia-inducible factor (HIF). HIF is a heterodimer consisting of 
an α and β subunit. During normoxia, pVHL will bind to HIF1-α which will result in the 
subsequent polyubiquitination and proteasomal degradation of HIF1-α. When pVHL is 
absent or abnormally functioning, HIF1-α will accumulate and bind to HIF1-β. The 
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heterodimer will then bind to the DNA sequences which will result in the overexpression 
of angiogenic factors. The most notable of these factors are the vascular endothelial 
growth factor A (VEGF-A), platelet derived growth factor β, and transforming growth 
factor alpha (TGF-α) (Figure 3).58 This series of events can lead to tumorigenesis.   
Affected individuals are predisposed to develop tumors in various organs 
including the brain, spine, eyes, adrenal glands, pancreas, inner ear, epididymis, and 
kidney. Forty percent of those affected by von Hippel-Lindau syndrome develop bilateral 
tumors or cysts in their kidneys.
59
  These tumors consist of clear cell renal carcinoma.  
 
 
Figure 3. VHL pathways: normal VHL function (left) and loss of VHL (right). (Adapted from 
Tang PA, et al.)
60
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1.3.2 Hereditary Papillary Renal Carcinoma 
Hereditary papillary renal cell carcinoma (HPRC) increases the risk of 
development of type 1 papillary RCC in affected individuals.
33
 
The gene responsible for HPRC is the MET proto-oncogene which is located on 
chromosome 7.
61
  The gene produces an intracellular tyrosine kinase that is bound to a 
membrane bound receptor for hepatocyte growth factor (HGF).  Certain mutations in the 
MET gene cause the tyrosine kinase domain to be constantly active and predispose 
individuals to HPRC.
62
 
1.3.3 Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome 
Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC) is an 
inherited autosomal dominant syndrome that predisposes affected individuals to develop 
leiomyomas and/or papillary type 2 RCC. Studies have indicated that HLRCC is linked to 
the bi-allelic inactivation of the fumarate hydratase (FH) gene.
63
  However, how these 
abnormalities lead to the disease is not understood. FH is an enzyme involved in the citric 
acid cycle and it is thought that inactive FH can lead to pseudohypoxia which is the 
aberrant activation of hypoxia response pathways under normal condition. This condition 
leads to an increase in expression of HIF-1α which can lead to tumor formation.64,65 
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1.3.4 Birt-Hogg-Dube Syndrome  
 Birt-Hogg-Dube (BHD) syndrome is inherited in an autosomal dominant fashion. 
Persons affected with this disease may develop dermatologic and pulmonary lesions as 
well as renal cell carcinoma.
66
  This condition is caused by mutations in the folliculin 
(FLCN) gene.
67
  Although the exact mechanism is not understood, FLCN may be 
involved in the mammalian target of rapamycin (mTOR) pathway.
68
  Inhibition of mTOR 
decreased kidney pathology and increased survival in a mouse model.
69
  The tumors of 
people with BHD consist mainly of chromophobe and oncocytic renal cancers. 
 
1.4 PAST AND CURRENT TREAMENTS FOR METASTATIC RENAL CELL 
CARCINOMA 
1.4.1 Classical cytotoxic agent 
 Renal cell carcinoma is curable if the disease is localized and surgically resected 
before metastasis. However, more than a third of the patients that undergo surgery for 
localized disease will have a reoccurrence and will have to be treated with 
chemotherapy.
1
  A small number of patients, however, can be cured with high dose 
interleukin-2 therapy. The following is a short review of the past and current options for 
the treatment of metastatic renal cell carcinoma (mRCC). 
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 Since the 1960’s, a number of cytotoxic compounds have been used in an 
attempt to treat metastatic renal cell carcinoma. In 1988, Josef Kuhbock wrote a review 
of the literature which was a compilation of three surveys of the cytotoxic chemotherapy 
of metastatic renal cell carcinoma (mRCC).
70
  The review covers a number of trials and 
includes the data from different classes of anti-neoplastic agents used. The agents are 
representative of the alkylating agents, anti-metabolites, vinca alkaloids, cytotoxic 
antibiotics and platinum analogues. The data includes the use of these compounds as both 
single agents and in combination therapy. The conclusion of the review was that although 
the use of a few substances such as vinblastine, lomustine, hydroxyurea, and ifosfamide 
is associated with some success (10-20% response rate) there was no specific agent 
available for the successful treatment of mRCC. A more extensive review of the literature 
was conducted by Yagoda.
71
  This review analyzed the results from clinical trials 
conducted from 1983 to 1993 using both hormonal and cytotoxic agents. The author lists 
the response rate as a percent of patients that have either a complete response or a partial 
response. It should be noted that a complete response does not mean a cure because the 
tumor can recur. These trials consisted of single agent, two agent and multiple agent 
combinations. Also, some of the trials included the use of modulating agents along with 
chemotherapy in an attempt to modulate or enhance intracellular drug activity. Some 
examples of the enhancing agents used were cyclosporine-A, quinidine and verapamil. 
Also, in other trials, biological modulating agents such as interferon and leucovorin were 
used along with cytotoxic chemotherapy. The clinical trials used the agents that were 
available at the time of the studies. The classes of agents used were antimitotics and 
spindle inhibitors, hormones, alkylating agents, metals, antifolates, pyrimidines, purines, 
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anthracyclines, immunological agents and miscellaneous agents whose, mechanism of 
actions had yet to be determined. In all, the review covered 83 clinical trials in which 
4,542 patients were enrolled and 4,093 patients completed the trails. Of the 4,093 
evaluable patients 3,329 had no prior chemotherapy. The overall results of the study 
showed a response rate of 6% (95% CI of 5.3-6.8%) and the duration of the responses 
were short, generally only lasting a few months. Alkylating agents, antifolates, purines 
and intercalating agents had an overall response rate of 4%. Hormones, vinca alkaloids 
and antimitotic spindle inhibitors had response rates of 6.9%, 5.9%, and 5.0%, 
respectively. Also, drugs used to reverse multidrug resistance were found to be 
ineffective when administered with the cytotoxic agents. Immunologic agents showed a 
response rate of 11.3%.  The drugs with the highest response rate of 14.6% and 10% were 
floxuridine and 5-fluorouracil, respectively. The authors suggest that these drugs should 
be the first cytotoxic chemotherapeutic choice for treating mRCC. Also, they believed 
that the high level of expression of Pgp, glutathione-S transferase, down regulation of 
topoisomerase 2 and lack of intracellular tumor drug concentration were likely reasons 
for the poor responses. 
72
 
 
1.4.2 Immunotherapy – Interleukin-2 
Interleukin-2 (IL-2) was first used to treat mRCC in the mid-1980’s. The results 
from 21 institutions showed that the use of high dose IL-2 (HD) could produce an 
objective response rate of up to 20%. Of the 20%, complete remission was seen in 7 to 
10% of patients with very durable results, disease free up to 20 years.
73
   This led the U.S. 
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Food and Drug Administration (FDA) to approve the use of HD IL-2 to treat mRCC in 
1992. HD IL-2 is defined as a dose of 720,000 IU/kg administered intravenously over 15 
minutes every 8 h as tolerated up to a maximum of 12 doses. Although HD IL-2 has 
cured a small percentage of patients, the treatment is limited based on health status. Since 
high dose IL-2 produces high grade toxicities, it is reserved for those individuals with 
healthy organ function.
74
  Since IL-2 administered alone has displayed a high response 
rate, there have been several attempts to increase the efficacy of IL-2 by either adjusting 
the dosages or by combining IL-2 with other agents, most notably interferon alpha (INF-
α). Because of the increased toxicities associated with the combination, without survival 
benefit, these studies proved not to be more advantageous than HD IL-2 administered 
alone
74
 
 
1.4.3 Targeted Therapy 
1.4.3.1 VEGF Inhibitors 
Increased understanding of the molecular biology and pathogenesis of RCC has 
led to several targeted therapeutic approaches. The most notable of these is the discovery 
of the VHL tumor suppressor gene role in the plausible causation of RCC through the 
HIF pathway. During normoxia in the blood, the VHL protein complex regulates 
proteasome mediated degradation of HIF-α. Loss of function of the VHL protein causes 
accumulation of HIF-α and the resultant overexpression of a number angiogenic growth 
factors such as vascular endothelial growth factor (VEGF) and platelet derived growth 
factor (PDGF).
58
  VEGF is a growth factor that binds to a family of VEGF receptors 
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(VGFR). The VEGFR consists of a membrane receptor and an intracellular tyrosine 
kinase domain. Binding to the receptor causes growth and migration of endothelial cells. 
Overexpression of VEGF and subsequent binding to the VEGFR can lead to over-
proliferation of endothelial cells. This discovery has led to the development of VEGF 
ligand and receptor binding antibodies and tyrosine kinase inhibitors that block the action 
of VEGFR in RCC.  
 Bevacizumab is a humanized recombinant monoclonal antibody developed from 
murine anti-VEGF.
75
  Bevacizumab acts by preventing the binding of VEGF to VEGFR. 
There were two large phase III clinical trials that compared the safety and efficacy of 
bevacizumab. In the first trial (the AVOREN trial), 649 patients from 18 countries were 
randomized 1:1 to either interferon plus 10 mg/kg bevacizumab every two weeks or 
interferon plus placebo. The results of the trial showed that the progression free survival 
(PFS) was increased in the bevacizumab arm compared to the interferon/placebo arm 
(10.2 months compared to 5.4 months, P = 0.0001).In addition, the partial responses were 
greater in the bevacizumab arm (31% vs 13%) although the overall survival was not 
different between the two arms (23.3 vs 21.3 months, P = 0.1291). The Cancer and 
Leukemia Group B (CALGB) 90206 trial was the second randomized trial. This trial 
enrolled 732 persons with mRCC that were administered interferon plus bevacizumab or 
interferon alone. The results of this trial were similar to the first trial. The PFS of the 
interferon plus bevacizumab arm was longer than the interferon alone arm.
76
  The results 
of these data led to the FDA approval of bevacizumab for the treatment of RCC in 2009. 
Bevacizumab is the first VEGFR monoclonal antibody approved for the use in RCC. In 
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addition, there are three VEGFR tyrosine kinase inhibits that have been recently 
approved by the FDA for the use in RCC.
77
  These are sunitinib, sorafenib and pazopanib. 
 Sunitinib is an inhibitor of VEGFR tyrosine kinase as well as other tyrosine 
kinases.
75,78
  In a phase III clinical trial, 759 patients were administered either 50 mg/day 
sunitinib only for six weeks or interferon alpha (IFN-α) three times a week for three 
weeks. An increase in objective response rate (47 vs 12%), PFS (11 vs 5 months, HR= 
0.54) and overall survival (26.4 vs 21.8 months, HR= 0.82, 95% CI 0.67 – 1.00, p=0.051) 
was seen in the sunitinib arm.
79
  Sorafenib is an orally administered small molecule 
inhibitor of VEGFR and other tyrosine kinases.
75
  Sorafenib has shown clinical activity in 
a phase III, randomized double-blind trial in which 903 patients who failed previous 
chemotherapy were randomized to receive either sorafenib or placebo.
80-82
 The results of 
this trial showed that the PFS was significantly longer in those receiving sorafenib (5.5 vs 
2.8 months, HR 0.44, 95% CI 0.35 – 0.55) while the overall survival was not 
significantly prolonged (17.8 vs 15.2 months, HR 0.88, 95% CI 0.74 – 1.04).81  
Pazopanib is another oral VEGFR tyrosine kinase inhibitor that also inhibits other 
tyrosine kinases. A phase III trial of pazopanib vs placebo in 435 patients demonstrated a 
significant increase in progression free survival with the patients that received pazopanib 
(9.2 vs 4.2 months, HR 0.46, 95% CI 0.34 - 0.62). Although an increase in survival was 
not seen (22.9 vs 20.5 months, HR 0.91, 95% CI 0.71 – 1.16).83  
1.4.3.2 mTOR Inhibitors 
 Another pathway recently discovered pathway involved in RCC tumorigenesis is 
the serine/threonine kinase mammalian target of rapamycin (mTOR) pathway. mTOR is 
ubiquitously expressed in mammalian cells and is involved in cell metabolism and 
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protein synthesis, and frequent hyperactivation of the mTOR pathway has been found in 
human malignancies.
84,85
  mTOR is involved in two separate protein complexes, 
mTORC1 and mTORC2. These protein complexes differ on their protein constituents 
except for the mTOR tyrosine kinase itself. Activation of the mTORC1 pathway leads to 
the production of many proteins such as cyclin D1, c-MYC and HIF-α that are 
responsible for cell cycle progression.
84
  The function of mTORC2 is less understood, 
however, it too activates HIF-α. The overexpression of HIF-α is known to occur in RCC.  
The drug rapamycin (sirolimus) is an antifungal antibiotic that was isolated from 
bacteria in the 1970s.
77
  In addition, rapamycin proved to inhibit T cell function. This led 
to its use as an immunosuppressant drug for organ transplantation. Rapamycin has also 
displayed antitumor activity. Analogs of rapamycin have been developed to increase 
bioavailability. These analogs are termed “rapalogs”. Two rapalogs, temsirolimus and 
everolimus were approved by the FDA for the treatment of mRCC in 2007 and 2009, 
respectively.
84
  Rapamycin and its analogs do not bind nor inhibit mTOR directly. They 
exhibit their activity by binding to FK-binding protein 12 (FKBP-12). The binding to 
FKBP-12 causes an inhibition in the kinase activity of mTORC1. It is also known that 
these compounds do not affect the mTORC2 complex nor its pathway.
77
  
There have been many cancer clinical trials conducted using temsirolimus and 
everolimus.
85
  The Global Advanced Renal Cell Carcinoma trial was a three armed phase 
III trial that compared the efficacy of either temsirolimus iv alone, temsirolimus iv plus 
IFN-α iv or IFN-α alone in 626 patients. The PFS was significantly longer in the arms 
that received temsirolimus (1.9 months for IFN-α, 3.7 months for temsirolimus alone and 
3.8 months for the combination, P<0.001).  However, the overall survival was not 
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significantly different (7.3 months for IFN-α, 8.4 months for temsirolimus alone, and 
10.9 months for the combination). The Renal Cell Cancer Treatment with Oral Rad001 
given daily (RECORD-1) trial was a phase III trial that enrolled 410 patients with mRCC. 
The aim of this trial was to test the efficacy of everolimus (RAD001) against placebo. 
Patients were randomized 2:1 to receive either 10 mg po daily everolimus or placebo. 
The median PFS for the everolimus group was 4.0 months compared to 1.9 months for 
the placebo group. The results from these trials led the FDA to approve these drugs for 
the treatment of mRCC. There have been efforts to combine the VEGFR inhibitors with 
the mTOR inhibitors. However, these trials were stopped due to toxicities even at low 
doses.
77
  
In summary, there was a lot of optimism about treating mRCC with targeted 
agents. The discovery of pathways that led to the development of mRCC led to the 
tyrosine kinase inhibitors and the mTOR inhibitors described above. Although these 
agents often produce fewer side effects than conventional cytotoxic agents, the response 
from these agents are relatively short lived. Despite the efforts of clinicians and 
researchers, the five year survival rate remains poor. mRCC is one of the most resistant 
forms of cancer. 
1.5 DRUG RESISTANCE IN RCC 
Although most cancers become resistant to chemotherapy, mRCC is one of the 
most resistant of all cancers.
86
  Traditional chemotherapeutic agents such as the 
alkylating agents, plant alkaloids and taxanes show very little activity against mRCC as 
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response rates with these agents are less than 4%. Drugs that are not affected by 
multidrug resistance proteins such as 5-fluorouracil have a response rate of 6%.
71
  mRCC 
also develops resistance to the newer targeted therapeutics (i.e. VEGF and mTOR 
inhibitors). There are a number of factors that are thought to be involved in the drug 
resistance of mRCC, however, the reasons for drug resistance is not clear cut or fully 
understood.
87
  The contributing factors that have been uncovered thus far that are thought 
to make mRCC resistant to therapy are multidrug resistance (MDR) proteins, including 
the major vault protein, and glutathione-s-transferase (GST).
88-94
  
1.5.1 Multidrug Resistance Proteins 
mRCC tumors arise from the proximal tubule cells. The proximal tubule is 
involved in the active transport of endogenous and xenobiotic substrates from the kidney 
into the urine. Not surprisingly, these cells are known to contain every class of drug 
transporters. Furthermore, these transporters are expressed at high levels.
95
  The classes 
of transporters that are located in the renal epithelial cells are; the organic anion 
transporters (OATs), the ATP-binding cassette (ABC) family which include multidrug 
resistance proteins (MRPs) and the P-glycoprotein (Pgp), organic cation transporters 
(OCTs), the peptide transporters, and the nucleoside transporters.
95
  Many of the 
chemotherapeutic agents that are used today are known substrates for these transporters. 
Of these transporters, the most widely studied in cancer pharmacology is the ABC family 
of transporters. The ABC transporter family consists of 48 genes and is subdivided into 
seven subfamilies. The subfamilies are named ABC-A to ABC-G.  The Pgp (ABCB1) 
and the multidrug resistant protein 1 (MRP-1, ABCC1) are two of the most studied in this 
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family of transporters and probably play the largest role in the clearing of 
chemotherapeutic agents from renal cells.
89,90,95
  
These ATP dependent efflux pumps have demonstrated the ability to remove a 
large number of different anti-neoplastic agents out of tumor cells. There is a correlation 
between high levels of these transporters and drug resistance in lung, pancreatic and 
breast cancer,
89
 although the correlation of Pgp and MRP-1 levels and drug resistance in 
mRCC remains a little more uncertain. A study conduct by Gamelin et al. measured the 
mRNA expression and efflux capabilities of Pgp and MRP-1 in primary tumors and 
metastatic tumors from 19 patients. It was determined that the primary site had high 
levels of Pgp expression while the more differentiated tumors of the metastases had lower 
levels of Pgp. The study suggested that the Pgp levels and efflux in the metastatic 
samples analyzed were not sufficient to contribute to drug resistance in the tumors. In 
addition, they found that MRP-1 did not contribute to drug resistance in these tumors.
87
  
A more recent and larger study conducted by Walsh et al. assessed the levels of Pgp and 
MRP-1 in the primary RCC tumors of 95 patients. The method employed was a semi-
quantitative immunohistochemical technique that was able to determine low, medium and 
high levels of protein expression. The study determined that all tumors had detectable 
levels of Pgp and MRP-1. Furthermore, a majority of tumors had moderate to high levels 
of both transporter presents.
89
  A search of the literature backs the findings of the 
previous two studies. Primary RCC tumors have high levels of Pgp and MRP-1 levels 
while more differentiated tumors have lower levels of these transporters.
96-99
  It may be 
that the primary tumors are resistant to chemotherapy in large part due to the high levels 
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of transporters in the tumor cells while more differentiated distant metastasis have other 
mechanisms of resistance that make them unresponsive to conventional chemotherapy. 
Another possible mechanism of resistance in RCC may be in part due to the 
presence of the major vault protein (MVP) also known as the lung resistance related 
protein (LRP). LRP, which is located in the cytoplasma and nuclear membrane, has 
shown the ability for membrane trafficking, bidirectional nucleocytoplasmic exchange 
and transport of compounds.
88,93
  It is thought that LRP acts to carry compounds out of 
the nucleus. LRP is known to transport a wider range of compounds than either Pgp or 
MRP-1, including platinum compounds. A positive correlation has been shown between 
the expression of LPR and resistance to a number of antineoplastic agents. Many studies 
have been conducted in various tumors to show the correlation of LPR and drug 
resistance, but very few have been conducted using RCC. One such study conducted by 
Hodorova et al. compared the expression of LPR in 47 RCC tumor samples. The study 
used immunohistochemistry to measure Pgp, MRP-1 and LPR protein expression in 
samples from patients who had not previously received any chemotherapy. The study 
determined that the protein expression of LPR was greater than that of both Pgp and 
MRP-1 in the tumor samples. In addition, it was determined that the more differentiated 
tumors had less Pgp expression, but had higher levels of LPR expression.
93
  This study 
demonstrated that LPR may play a part in the resistance of RCC to drugs. It also implies 
that the drug resistance of more differentiated tumors may be due in part to LPR, 
although more studies have to be completed to lend credence to this theory.  
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1.5.2  Glutathione-s-Transferase 
Another possible reason for the resistance of RCC to drugs is the presence of 
glutathione s-transferases (GSTs).  The GSTs are a family of phase II enzymes that are 
involved in detoxifying environmental chemicals and endogenous compounds.
100
  The 
GSTs are divided into seven different classes, Alpha, Mu, Pi, Omega, Theta, Zeta and 
microsomal, however, the human kidney is known to contain three isoforms, Alpha, Mu 
and Pi. GST Alpha is the predominant isoform in the proximal tubule where RCC is 
thought to be derived from.
101,102
  GSTs have several functions. They detoxify potentially 
damaging electrophilic endogenous and exogenous compounds by catalyzing the 
conjugation of glutathione to electrophiles. The resulting conjugates are more polar and 
increase the excretion of the compound. In addition to being a detoxifying mechanism, 
the GSTs are involved in cellular signaling. The GSTs are involved in the c-Jun-N-
terminal kinase (JNK), mitogen activated protein kinase (MAPK) and apoptosis signal-
regulating kinase pathways. Cysteine residues on GSTs bind to kinases in these pathways 
and regulate apoptosis. Overexpression of GSTs, which happens frequently with 
chemotherapy, can cause suppression in these pathways which can lead to increased cell 
survival.
100,101
  
 In normal cells, GSTs prevents carcinogenesis by detoxifying exogenous 
chemicals. In tumor cells, however, the GSTs are thought to render chemotherapeutic 
agents inactive.
103
  A wide variety of anti-neoplastic agents are substrates for the GSTs 
and have been shown to be detoxified by the GSTs.
101
  Furthermore, overexpression of 
GSTs and high levels of glutathione in various tumor types such as lung and breast are 
linked to multidrug resistance.
101
  In the past 20 plus years there have been a number of 
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studies that have tried to determine the mRNA and protein expression levels and/or the 
enzyme activity of GST in RCC tumors. These studies have used northern blots, enzyme 
assays, immunoblots and immunohistochemical assays.  Most of the studies conducted in 
the 1990s found decreased levels of expression and/or enzyme activity of GST in RCC 
compared to adjacent normal kidney tissue.
104-109
  A more recent study, however, that 
used cDNA microarray chips to measure mRNA and antibody to measure protein 
expression in 70 RCC tumors (clear cell n = 43, papillary n = 6, oncocytoma n = 8, other 
n = 9) found GST Alpha to be over expressed in a majority of RCC samples that were 
clear cell tumors, while the other types of tumor cells did not have high levels of GST 
Alpha.
102
 The more recent study differentiated tumor types where earlier studies did not 
differentiate between different tumor types. In summary it appears that there are 
conflicting results regarding the contribution of GSTs to the drug resistance displayed in 
RCC. It may be that RCC tumors that are of the clear cell type are partly resistant to drug 
therapy due to high levels of GSTs.  
 
1.5.3 Topoisomerase 
 Another possible mechanism of multidrug resistance in RCC may be due to 
decreased levels of Topoisomerase-II alpha (TOPO-IIα).110  However, it appears again 
that the results of the studies that have analyzed the correlation of these enzymes in RCC 
with regards to drug resistance are conflicting at least with TOPO-IIα.   
 TOPO-IIα is an enzyme that catalyzes the breaking and rejoining of DNA in order 
to straighten the DNA for many different cellular functions such as replication and 
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transcription.
111
  It has been shown that expression of TOPO-IIα is increased in cells that 
are in a growth and replicating phase.
112
  There are a number of antineoplastic agents 
such as doxorubicin and etoposide that target TOPO-IIα.  There is evidence that suggests 
that cell lines that over express TOPO-IIα are hypersensitive to TOPO-IIα 
inhibitors.
113,114
  Also, there is evidence that renal carcinoma cell lines that express low 
levels of TOPO-IIα are more resistant to TOPO-IIα inhibitors.115  It also has been 
determined that the level of protein expression of TOPO-IIα in primary breast carcinoma 
tissue and bladder cancer tissue increase with increasing tumor grade.
116
  However, there 
are conflicting reports in regards to TOPO-IIα expression in RCC tumors. A study 
conducted by Dekel et al. examined the TOPO-IIα protein expression in 27 RCC clear 
cell tumors from patients. They classified the tumors into different grades. They found 
that the TOPO-IIα protein levels increased greatly with increasing tumor grade.111 
Conversely, another study conducted by Oudard et al. examined the TOPO-IIα gene 
expression of 30 RCC tumors along with the adjacent normal tissue from 16 of the tumor 
biopsies. They found no significant difference in the expression levels of TOPO-IIα 
between the tumor samples and the normal adjacent tissues.
110
  It should be noted that the 
authors of both studies claim that their sample sizes were small, and larger studies are 
required to confirm their findings. It may be that the level of TOPO-IIα plays a part in the 
drug resistance of RCC especially with regards to TOPO-IIα inhibitors. The TOPO-IIα 
inhibitors have had very little success against RCC with response rates between 4 and 
6%.
71
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1.5.4 Resistance to Molecular Targeted Drugs 
 Drugs that target the VEGF and mTOR pathways have become the first choice 
when treating patients with mRCC that do not respond to IL-2 therapy. These targeted 
agents have shown activity especially in those who have clear cell renal carcinoma. 
Although these agents do show activity, the response is generally not durable and short-
lived. The reason for the short-lived activity of these targeted therapies is thought to be 
due to the tumor’s ability to develop resistance. It has been shown that treatment with the 
VEGF inhibitor sorafenib causes a decrease in tumor vascularization shortly after the 
start of treatment.
117
 The tumor vascularization however, does return suggesting that 
alternative pathways less dependent on VEGF are activated in response to VEGF 
inhibition. Proteins have been identified that are modulated due to VEGF inhibition. 
Some of the proteins that have been identified are fibroblast growth factor, angiopoietin 
family proteins, interleukin-8 and placental growth factor.
118
 
Temsirolimus and everolimus are the two mTOR inhibitors that have been 
approved for the use for mRCC. The response to these agents however, is also short-
lived. These compounds inhibit the mTORC1 protein complex which acts to inhibit HIF-
α and reduce tumor angiogenesis. The resistance developed to these agents is thought to 
be due to the lack of activity against the mTORC2 protein complex. The mTOR 2 protein 
complex can also cause over expression of HIF-α which can lead to tumor growth.84 
In summary, there has been a lot of excitement recently in regards to the treatment 
of mRCC with the advent of the VEGFR and mTOR inhibitors and these agents have 
become the first line of treatment in individuals who are not able to tolerate or do not 
show activity with the use of IL-2. The therapeutic response generated by these agents, 
 28 
 
however, is short-lived and are generally not durable. There is a need for new therapeutic 
agents for the treatment of mRCC. 
 
1.6 ALTERNATIVE TREATMENTS FOR RCC 
1.6.1 Bone Marrow Transplantation 
  Allogeneic bone marrow transplantation has been performed on patients with 
mRCC that did not respond to conventional treatment. The results of these trials proved 
that the toxicities involved and the limited applicability of this approach reduced its 
usefulness as only a small percentage of patients achieved a response to treatment.
119,120
  
 
1.6.2 Tumor Vaccine 
The development of a vaccine for the treatment of mRCC is currently being 
explored.
74
  The early tumor vaccine trials used tumor lysates or irradiated tumors in 
order to induce an immunologic antitumor response. The results from these trials so far 
have been mixed. The first clinical trial using this type of tumor vaccine proved to be 
ineffective as there was not an increase in overall survival.
121
  A recent review by 
Brokman-May et al. examined the results from the vaccine clinical trials in RCC 
conducted from 2002 to 2010, and reported a low response rate. 
122
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1.6.3 Alkylating agents for the treatment of renal cell carcinoma 
Alkylating agents act by attaching an alky group to DNA. This causes an 
interruption of DNA replication and leads to cell death. There are a number of alkylating 
agents used in the treatment of cancer. However, as previously explained in section 1.4.1, 
alkylating agents such chlorambucil, melphalan and busulfan have been used in the 
treatment of RCC but the response rate was less than 6 percent. 
 
 
1.7 IDENTIFICATION OF BENZALDEHYDE DIMETHANE SULFONATE 
FOR THE TREATMENT IN RENAL CELL CARCINOMA 
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) (Figure 4) was 
selected by the National Cancer Institute (NCI) from the NCI drug screen data base 
which consists of over 80,000 cytotoxic agents. The selection was because BEN 
exhibited in vitro activity against renal lung cancer cell lines in the NCI 60 cell line 
panel.
123
  The NCI 60 cell line consists of leukemia, melanoma, lung, colon, renal, breast, 
and prostate cancer cell lines. BEN is from a family of dimethane sulfonates (Figure 5) 
that showed activity against lung and renal cancer cell lines.  
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Figure 4. Benzaldehyde dimethane sulfonate 
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Figure 5. Structures of BEN (NSC281612) and related compounds. The dimethane sulfonate 
alone is NSC 102627. R1 and R2 are predicted alkylating groups while R3 is a hydrophobic moiety. 
(Reprinted from Molecular Cancer Therapeutics with permission from American Association for Cancer 
Research©).
124
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Two dimethane sulfonates that displayed activity against RCC were NSC281617 
and 281817. It was discovered however, that these compounds quickly dissociated in 
aqueous solution into an inactive aniline compound (NSC 281610) and an active 
aldehyde compound (BEN, NSC281612) which displayed activity against the NCI 60 cell 
line screen (Figure 6). 
 
 
Figure 6. The fingerprint of BEN (NSC281612), NSC281817 and doxorubicin obtained from the 
60 cell line NCI panel, with the mean IC50 for all cell lines tested plotted as the center of each bar graph and 
the deviation from the mean provided as a bar for each cell line, with bars to the left and to the right 
indicating resistance and sensitivity, respectively. (Reprinted with permission from Dr. Susan D. Mertins 
PhD) 
 
 33 
 
1.7.1 The mechanism of action of BEN 
A number of studies were conducted in order to determine the mechanism of 
action of BEN and related dimethane sulfonates. These studies include COMPARE 
analysis, DNA-protein crosslinking, P53 induction experiments, sperm DNA denaturing 
assay and cell cycle arresting assay. In addition, BEN was analyzed and compared to 
other compounds using Self-Organizing Maps (SOM). 
 The dimethane sulfonates have a hydrophobic moiety attached to a predicted 
alkylating group (Figure 4).  It has been previously shown that the cytotoxicity pattern in 
the NCI 60 cell line screen can be used to compare the mechanism of action of various 
compounds by using the COMPARE algorithm.
125
 A COMPARE analysis was conducted 
that calculates the Pearson Correlation Coefficient between the IC50 of dimethane 
sulfonates with IC50s of chosen compounds in the NCI database. Similarities were found 
amongst the dimethane sulfonates along with the alkylating agents Yoshi 864 (NSC 
102627), busulfan (NSC750), chlorambucil (NSC3088), and melphalan (NSC8806) 
however, there was little similarity to the alkylating agent carmustine (NSC409962) 
(Figure 7). In order to obtain a unique fingerprint to the non-alkylating portion of the 
dimethane sulfonates, a COMPARE analysis was made after subtracting the component 
of the correlation attributed to the alkylating agent moiety. The same COMPARE 
analysis was made with Yoshi 864 (NSC 102627), busulfan (NSC 750), chlorambucil 
(NSC 3088), melphalan (NSC 8806) and carmustine (NSC 409962) (Figure 8). The 
analysis showed that when the alkylating moiety was removed, BEN had very little 
correlation with the other alkylating agents. In addition, BEN had very little similarity 
with the other dimethane sulfonates.  
 34 
 
 
Figure 7. COMPARE analysis of Dimethane Sulfonates with various alkylating agents. Top: GI50 
(IC50) patterns of whole compound. Bottom: GI50 (IC50) pattern without alkylator. (Reprinted from 
Molecular Cancer Therapeutics with permission from American Association for Cancer Research©).
124
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Figure 8. The structures of BEN compared to other alkylating agents. 
 
In summary, the COMPARE analysis determined that BEN had a similar 
cytotoxic fingerprint to alkylating agents, with greatest similarity to the nitrogen mustards 
and the least to carmustine. 
A number of experiments were conducted by Mertins et al. to determine the 
possible mechanism of action of BEN and the dimethane sulfonates.
124
  The authors 
found that the dimethane sulfonates induced DNA-protein crosslinks, induced P53, and 
caused cell cycle arrest. These experiments showed that BEN possessed a similar 
mechanism of action as alkylating agents except for the fact that BEN has displayed 
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activity against renal cell carcinoma where as other alkylating agents do not have activity 
against these cells. 
Self-Organizing Maps (SOM) are used to create clustering patterned data.
126
  
SOM are used to analyze IC50 data obtained from the NCI 60 cell line screen. 
Compounds are arranged in three dimensional space based on IC50 data. This type of data 
allows for the comparison of similar agents that might not be apparent from a linear 
comparison and it allows the mechanism of action to become regionalized. Classes of 
anti-cancer drugs are regionalized based on mechanism. The regions consist of: the M 
region (mitosis), P region (phosphatase and kinase inhibitors), S region (nucleic acid 
targeting), and N region (membrane active compounds; ion channel inhibitors). The 
dimethane sulfonates cluster in a region near to, but separate from, the classical 
alkylating agents (Figure 9). This suggests that the dimethane sulfonates may have a 
different mechanism than the classical alkylators. 
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Figure 9. Self organizing map grouping GI50 fingerprints in the NCI Drug Screen data base 
(Reprinted with permission from Dr Susan D. Mertins PhD) 
 
1.8 SUMMARY AND INTRODUCTION TO DISSERTATION 
In 2011, 65,000 people acquired RCC in the United States and in the same year 
nearly 13,500 died from the disease.
2
 In 2008, there were 270,000 cases and 116,000 
deaths worldwide.
3
 Despite recent advancements in the treatment of renal cell carcinoma 
(RCC) the 5 year survival remains poor. There is a need for new treatments of RCC. 
Benzaldehyde dimethane sulfonate (BEN) has shown both in vitro and in vivo 
activity against RCC. This has led to the clinical development of BEN for the treatment 
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of RCC. BEN is a bifunctional alkylating agent. It was shown that the dimethane 
sulfonate groups are replaced by hydroxyl groups in aqueous medium.
127
 It has not been 
determined if a similar occurrence takes place in biological media. If the degradation 
occurs, the activity of the resulting analytes against renal carcinoma cells is not known. In 
addition, the rate of the degradation of BEN in biological medium is currently not known. 
Also, the pharmacokinetics and metabolism of BEN is not known.  
We hypothesized that BEN will undergo hydrolysis in blood to form less active 
products. We tested this hypothesis by characterizing the stability of BEN in both blood 
and plasma and determined the activity of degradation products in renal carcinoma cell 
lines (Chapter 2). During the stability testing we determined that BEN was metabolized 
in blood by aldehyde dehydrogenase (ALDH) to a carboxylic acid and that the acid was 
chemically converted into six different analogs which were less active than BEN .  We 
determined the activity of BEN in renal cell carcinoma cell lines and characterized the 
metabolism of BEN in red blood cells (Chapter 3). We administered BEN to mice with 
and without the aldehyde dehydrogenase inhibitor disulfiram in order to characterize the 
pharmacokinetics of BEN and to determine if the exposure to BEN was increased after 
inhibition of ALDH (Chapter 4). Lastly, we determined the pharmacokinetics and 
metabolism of BEN administered to humans as part of a first in human phase I trial 
(Chapter 5). 
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2.0  IN VITRO AND EX VIVO CHARACTERIZATION OF BENZALDEHYDE 
DIMETHANE SULFONATE 
 
 
 
 
 
 
 
 
 
 
Robert A. Parise, Bean N. Anyang, Julie L. Eiseman, Merrill J. Egorin, Joseph M. Covey, 
Jan H. Beumer, Formation of active products of benzaldehyde dimethane sulfonate 
(NSC 281612, DMS612) in human blood and plasma and their activity against renal 
cell carcinoma lines. Cancer Chemother Pharmacol. 2013 Jan;71(1):73-83.  
 
 
 
 40 
 
2.1 ABSTRACT 
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is a 
bifunctional alkylating agent with activity against renal cell carcinoma, and is being 
evaluated clinically. It was previously shown that BEN hydrolyzes in aqueous solution. 
We hypothesize that BEN will hydrolyze in human plasma to form potentially active 
compound. We developed an LC-MS/MS assay to detect and quantitate BEN and its 
metabolites/decomposition products in biological fluids. We tested the stability and 
degradation of BEN and benzoic acid dimethane sulfonate (BA) in plasma and blood. 
The assay was accurate, precise and reproducible. BEN and its metabolite BA were 
incubated in human blood and plasma at 37 °C or 4 °C. The generation and degradation 
of up to 12 analytes were monitored, and structures confirmed with available authentic 
standards. BEN was stable at both 4 °C and 37 °C, while BA was only stable at 4 °C. 
Lowering the pH of plasma greatly slowed the degradation of BA. The half-lives of BEN 
and BA in plasma were 220 and 4.8 min, respectively. Further, we determined the IC50 of 
BEN and BA, and revealed degradation products in five renal carcinoma cell lines. The 
IC50 for BEN was 5 to 500-fold lower than any of its products, while the cellular 
metabolic activity towards BEN correlated with ALDH activity and IC50s. We detected 
six of the in vitro products and 6 glucuronides in murine plasma after iv dosing BEN. 
Most of the products have structures allowing continued ability to alkylate. The assay and 
knowledge of the stability and activity of BEN, BA and their products will be 
instrumental in the evaluation of the pharmacology of BEN in ongoing human trials. 
 41 
 
2.2 INTRODUCTION 
Approximately 13,000 people die from metastatic renal cell carcinoma (mRCC) 
in the United States every year.
2
  Only 10-12% of patients achieve durable complete 
remission with high dose interleukin-2 therapy.
128
  Agents targeting vascular endothelial 
growth factor and its receptor along with mTOR inhibitors have shown clinical 
activity.
94,129
  However, responses to these agents are generally transient,
130
 and there is a 
need for new treatment options for patients with mRCC. 
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is one of a 
family of dimethane sulfonates that have demonstrated activity in the NCI 60 cell line 
screen. BEN is proposed to be a bifunctional alkylator with structural similarities to 
chlorambucil, busulfan and melphalan (Figure 10). However, unlike these compounds, 
BEN has specific activity against renal carcinoma cells in the NCI 60 cell line screen.
124
  
BEN causes cell cycle arrest in the G2-M phases,
124
 and increases P53 levels, indicating 
DNA damage, in the renal carcinoma cell line 109, and in the breast cell line MCF-7. In 
addition, BEN has demonstrated antitumor activity in mice with orthotopic renal 
carcinoma xenografts, specifically, against human A498 and RXF-393 implanted 
subcutaneously or orthotopically under the renal capsule [Personal communication, Dr. 
M. Hollingshead, unpublished data].
131,132
  The significant in vitro and in vivo activity 
against renal carcinoma has led to the ongoing evaluation of BEN in NCI-sponsored 
phase I clinical trials. 
BEN, based on its structure, likely forms an aziridinium intermediate that is 
attacked by nucleophilic molecules such as DNA, proteins or water. Jumaa et al. reported 
hydrolysis of BEN in aqueous solution whereby the dimethane sulfonate groups are 
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replaced by hydroxy groups.
127
  The hydrolysis of BEN, in vivo and in vitro, may lead to 
the formation of compounds that are less active as alkylating agents than BEN.  In 
addition to BEN related analogues, we found benzoic acid (BA) analogues of BEN with 
their own reactivity. 
In order to elucidate the pathways for decomposition and metabolism of BEN and 
to support ongoing clinical trials of BEN, we developed an LC-MS/MS assay for the 
detection and quantitation of BEN and its metabolites in plasma. Using this assay, we 
characterized the in vitro decomposition of BEN in plasma and blood, and compared the 
in vitro BEN products to products that were identified in the plasma from mice that were 
administered BEN. We suspect that aldehyde dehydrogenase (ALDH) in red blood cells 
is the enzyme responsible for the metabolism of BEN to BA and that BA may be the 
cytotoxic metabolite. Because BEN displays selective activity against renal cell 
carcinomas, we determined the IC50 of BEN and its metabolites in five different human 
renal carcinoma cell lines which were used in the NCI 60 cell line screen, and we 
correlated the metabolism of BEN to its carboxylic acid metabolite BA in renal 
carcinoma cells with the IC50 in these cells. The results of these studies will help to 
understand the activity of BEN and will aid in elucidating the pharmacology of BEN in 
the ongoing clinical trial. 
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Figure 10. Chemical structures of BEN (A), busulfan (B), melphalan (C) and chlorambucil 
(D). 
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2.3 METHODS 
2.3.1 Chemical and reagents 
4-[bis[2-[(methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzaldehyde (BEN, NSC 
281612), 4-[bis[2-[(methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzoic acid (BA, NSC 
733609), 4-[bis[2-chloro-ethyl]amino]-2-methyl-benzaldehyde (BEN-Cl2), 4-[bis[2-
chloro-ethyl]amino]-2-methyl-benzoic acid (BA-Cl2),  4-[bis[2-[(methylsulfonyl)-
oxy]ethyl]amino]-benzaldehyde (desmethyl-BEN), and 4-[bis[2-chloro-ethyl]amino]-
benzaldehyde (desmethyl-BEN-Cl2) were obtained from the National Cancer Institute 
(NCI, Bethesda, MD).  All solvents used for LC-MS/MS were high purity Burdick & 
Jackson and purchased from Fisher Scientific Co. (Fair Lawn, NJ). Formic acid was 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Control human blood was 
obtained from the Central Blood Bank, Pittsburgh, PA and plasma was prepared by 
centrifugation of whole blood at 2000 x g at room temperature for 20 min. Nitrogen gas 
for the mass spectrometer was purified with a Parker Balston Nitrogen Generator 
(Haverhill, MA), and nitrogen gas for the sample evaporation was purchased from Valley 
National Gasses, Inc. (Pittsburgh, PA). 
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2.3.2 Generation of reference compounds 
4-[bis[2-hydroxy-ethyl]amino]-2-methyl-benzaldehyde (BEN-(OH)2 was 
generated by heating approximately 13.6 mg BEN in approximately 4 mL of 0.05 N 
aqueous NaOH for 48 h at 50 °C. The progression of the reaction was monitored by mass 
spectrometry. 4-[bis[2-hydroxy-ethyl]amino]-2-methyl-benzoic acid (BA-(OH)2 was 
generated by heating approximately 13.2 mg BA in a solution of 0.03 N NaOH in 7 mL 
of acetonitrile/water (1:1, v/v) for 48 h at 50 ºC. The progression of the reaction was 
assessed by mass spectrometry and the conversion was 100% in both cases. The final 
solutions were neutralized with hydrochloric acid and acidified with formic acid for a 
final concentration of 1 mg/mL of the respective product. 
 
2.3.3 Qualitative determination of metabolites 
In order to determine the structures of the products generated by the in vitro 
decomposition experiments and by mice administered BEN, we established an LC-
MS/MS system using both MS scan mode and enhanced product ion scan mode (EPI). 
The LC-MS/MS system consisted of an Agilent (Wilmington, DE, USA) 1200 SL 
thermostated autosampler, binary pump, DAD, thermal column compartment, and an ABI 
SCIEX (San Jose, CA, USA) 4000Q hybrid linear ion trap tandem mass spectrometer. 
The liquid chromatography was performed with a gradient mobile phase consisting of A: 
acetonitrile/0.1% formic acid (v/v) and B: water/0.1% formic acid (v/v).  The mobile 
phase was pumped at a flow rate of 0.2 mL per minute and separation was achieved using 
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a Phenomenex (Torrance, CA) Hydro Synergi-RP 4 micron 100 x 2mm column.  The 
gradient mobile phase was as follows: at time zero, solvent A was 15% and was increased 
linearly to 40% in twenty minutes.  The percentage of solvent A was increased linearly to 
80% at 21 minutes and the flow rate was increased to 0.4 mL. This was maintained for 
two minutes at which time solvent A was decreased linearly to 15% at 24 minutes.  This 
was maintained for six minutes.  The total run time was 30 minutes. During the first two 
minutes and the last six minutes of the LC run the flow leaving the column was diverted 
to waste.  The parameters of the mass spectrometer were as follows; curtain gas 20, IS 
voltage 5500V, probe temperature 400 ºC, GS1 40, GS2 30, declustering potential 50V, 
collision energy 40V, collision energy spread of 10V, and scan rate of 1000 amu/sec. 
 
 
2.3.4 Qualitative Analytical Method 
This LC-MS/MS assay was modified to quantitate or monitor the metabolites 
generated in the decomposition study and in the mouse metabolism experiments.  The 
instrumentation, mobile phase and column were the same as the qualitative method 
described above. First, BEN and BA were diluted to a concentration of 1 µg/mL in 
acetonitrile and each was continuously infused at a rate of 10 µL/min into the HPLC 
flow, which was an isocratic mobile phase of acetonitrile:water:formic acid (50:50:0.1, 
v/v/v) pumped at 0.2 mL/min. The tuning parameters of the mass spectrometer were 
adjusted to maximize the intensity of the [M + H]
+
 ion of the analyte.  After the largest 
[M +H]
+
 ion was obtained, the mass spectrometer was operated in MRM mode and the 
 47 
 
collision voltage was adjusted so that the largest product ion was determined. This 
procedure was repeated for BEN-Cl2, BA, BA-Cl2, BEN-(OH)2, BA-(OH)2 desmethyl-
BEN, and desmethyl-BEN-Cl2. For MRM transitions, see Table 1.  
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Table 1. MRM transitions and retention times of analytes. 
Analyte MRM transition 
 
Internal Standard Retention Time 
(min) 
BEN
a
 380.0 → 160.0 Demethyl-BEN 15.5 
BEN-OH-OSO3 302.0 → 162.0 Demethyl-BEN 12.1 
BEN-Cl2
a
 260.0 → 120.0 Demethyl-BEN-Cl2 22.4 
BEN-Cl-OH 224.0 → 120.0 Demethyl-BEN 15.3 
BEN-Cl-OSO3 336.0 → 132.4 Demethyl-BEN 16.9 
BEN-(OH)2
a
 224.0 → 134.0  Demethyl-BEN 9.0 
BA
a
 396.0 → 300.0 Demethyl-BEN 14.1 
BA-OH-OSO3 318.0 → 160.0 Demethyl-BEN 7.9 
BA-Cl2
a
 276.0 → 213.0 Demethyl-BEN-Cl2 21.1 
BA-Cl-OH 258.0 → 164.0 Demethyl-BEN 8.3 
BA-Cl-OSO3 336.0 → 132.4 Demethyl-BEN 16.9 
BA-(OH)2
a
 240.0 → 178.0 Demethyl-BEN 7.9 
Demethyl-BEN (IS) 366.1 → 270.4 - 14.0 
Demethyl-BEN-Cl2 (IS) 246.1 → 106.4 - 20.9 
BA-Gluc 572.0 → 300.0 Demethyl-BEN 10.9 
BA-Cl2-Gluc 452.0 → 276.0 Demethyl-BEN 15.4 
BA-Cl-OH-Gluc 434.0 → 240.0  Demethyl-BEN 10.5 
BA-OH-OSO3 494.0 → 300.0 Demethyl-BEN 8.3 
BA-(OH)2-Gluc 416.0 → 300.0 Demethyl-BEN 5.6 
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2.3.4.1 Standard Curve 
Stock solutions of BEN, BEN-Cl2, BA, BA-Cl2, BEN-(OH)2 and BA-(OH)2 were 
prepared separately at concentrations of 1.0 mg/ml in acetonitrile containing 0.1% formic 
acid. A mixture was made containing all six analytes at a concentration of 0.1 mg/ml by 
adding 100 µl of each analyte to 400 µl of acetonitrile with 0.1% formic acid.  All stock 
solutions were stored at -80 °C in the dark. On assay days, this solution was diluted with 
acetonitrile to obtain the lower calibration working solutions of 0.01, and 0.001 mg/ml.  
These calibration working solutions were diluted in plasma with 2 M H2SO4 (5%, v/v) to 
produce 200-μl aliquots of the following concentrations: 10, 30, 100, 300, 500, 750, and 
1000 ng/ml. Ten μL of a mixture of desmethyl-BEN and desmethyl-BEN-Cl2 (1 μg/mL 
of both in acetonitrile) were added as internal standards. The analyte-to-internal standard 
ratio (response) was calculated for each standard by dividing the area of the compound 
peak area by the area of the compound’s respective internal standard peak. Standard 
curves of each compound were constructed by plotting the analyte-to-internal standard 
ratio versus the nominal concentration of each analyte in each sample. Standard curves 
were fit by linear regression with weighting by 1/y
2
, without forcing the line through the 
origin, followed by the back-calculation of the concentrations.  The deviations of these 
back-calculated concentrations from the nominal concentrations, expressed as percentage 
of the nominal concentration, reflected the assay performance over the concentration 
range studied. 
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2.3.4.2 Auto-sampler stability 
In order to determine the stability of the compounds in the auto-sampler, we 
injected samples that contained 500 ng/ml of all six reference standards extracted from 
human plasma. The samples were reconstituted with acetonitrile:water (20:80), with  
either 5% 2M H2SO4 or 0.1% formic acid.  The temperature of the autosampler was 
maintained at 4 °C, and 48 sequential injections were performed. The extent of 
decomposition at various times was assessed by comparing the peak area with the area 
observed at time zero. 
 
2.3.5 Stability of BEN and products in human blood 
We evaluated the stability of BEN, BEN-Cl2, and BEN-(OH)2 in blood (n=3). 
Each of the compounds was added separately to 10 mL of human blood (Central Blood 
Bank, Pittsburgh, PA, sodium citrate anti-coagulated) to achieve a concentration of 10 
μg/mL. This was performed in triplicate. The samples were incubated in a shaking water 
bath at 37 ºC for 0, 5, 10, 15, 30, 45, 60, 120, 180, 240, 360 minutes, and 24, and 48 
hours.  At the specified time points, a 500 µL aliquot of blood was removed, and 
centrifuged at 12,000 x g for 2 minutes at 4 °C.  Two hundred µL of the resultant plasma 
was removed and added to 10 μL 2M H2SO4. The sample was briefly vortexed and 10 μL 
of internal standard solution and 1 mL of acetonitrile were added.  The samples were then 
vortexed on a vortex genie on a setting of high for one minute, and then were centrifuged 
at 12,000 x g for 5 minutes. The resultant supernatant was blown to dryness at room 
temperature under a stream of nitrogen. The samples were reconstituted with 100 μL of 
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20:80 acetonitrile/H2O with 5% 2 M H2SO4 (v/v/v) and 10 μL was injected into the LC-
MS/MS system. The extent of decomposition at various times was assessed by comparing 
the peak area with the area observed at time zero. 
 
2.3.6 Stability of BEN, BA, and products in human plasma 
BEN or BA was added to plasma to achieve a concentration of 10 μg/mL. Triple 
200 µL aliquots were removed at the following time points:  0, 5, 15, 30, 60, 120, 180, 
and 240 minutes. The samples were immediately frozen at -80 ºC until they were 
analyzed by LC-MS/MS.  The stability was assessed for each compound under the 
following conditions: room temperature, 4 ºC, with the addition of 5% (v/v) of either 
formic acid (95%) or 2 M H2SO4 to the plasma. Stability at each time point was evaluated 
relative to time zero. 
 
2.3.7 BA degradation in phosphate buffered saline 
To confirm that the observed degradation of BA in plasma was chemical, and did 
not require endogenous components in plasma, we compared the rate of decomposition of 
10 μg/mL BA in plasma to the rate of degradation of BA in PBS with and without 50 
mg/mL human albumin. Triplicate aliquots of 200 μL were taken at 5, 10, 15, 20, 25, and 
30 minutes.  The aliquots were added to a microcentrifuge tube that contained 10 μL of 
2M H2SO4. The samples were then frozen at -80 °C until processed as described above. 
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2.3.8 Half-life of analytes 
To determine the half-lives of the analytes in blood and plasma, we analyzed the 
data from the experiments with the software PK Solutions 2.0, using the log trapezoidal 
method (Summit Research Services, Montrose, CO; www.summitPK.com). In order to 
determine statistical parameters, half-lives and relative rates in PBS were determined by 
analysis of all the data with ADAPT5 based on a 1 compartmental model.
133
 
 
2.3.9 Protein binding 
In order to determine the protein binding of BA, a method used by Ehrsson et al. 
was modified and employed with the data generated in section 2.3.7.
134
  They used their 
method to calculate the protein binding of chlorambucil to albumin using the equation 
kobs = k1fbound + k2ffree. Where k1 is the rate constant of the degradation of compound that 
is bound to protein and k2 is the rate of degradation of free compound. They found that 
free compound degrades approximately 100 times faster than bound compound. Our 
assumption is that only free compound is able to react with other material present in the 
matrices. The data generated was analyzed with Adapt 5.0 assuming first order 
elimination. 
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2.3.10 Cell Lines 
Human renal carcinoma cell lines, ACHN, 786-0, A498, SN12K1 and CAKI-1 
were obtained from the Developmental Therapeutics Program, Division of Cancer 
Treatment and Diagnosis, National Cancer Institute, National Institutes of Health 
(Bethesda, MD). Human non-small cell lung adenocarcinoma A549 cells for ALDH 
positive control were obtained from Dr. Pam Hershberger, University of Pittsburgh 
Cancer Institute (UPCI). Human colorectal carcinoma HCT116 cells used for ALDH 
negative control were obtained from Dr. Su-Shu Pan UPCI. 
 
2.3.11 MTT assay 
Human renal carcinoma cells (NCI, Bethesda, MD) were grown in RPMI 1640 
complete medium containing 10% fetal bovine serum (FBS), containing penicillin and 
streptomycin at 37 ºC with 5% CO2 at 95% humidity.  On day 1, 100 µL of appropriate 
cell seeding density of each cell line was added to 96 well plates.  SN12K1, CAKI-1 and 
A498 cells were plated at 2500 cells/well and, ACHN and 786-0 cells were plated at 1500 
cells/well. Plates were incubated at 37 ºC at 5% CO2 at 95% humidity. After 24 hours, 
BEN, BEN-Cl2, BEN-(OH)2 BA, BA-Cl2 or BA-(OH)2 was added to wells separately 
such that the final concentrations ranged between 1 and 30,000 ng/mL in medium 
containing 0.1% acetonitrile.  The MTT assay was performed following the 
manufacturer’s instructions using a TAC3 MTT cell proliferation assay (Trevigen, 
Gaithersburg, MD). As a control, acetonitrile 0.1% in medium was used. The absorbance 
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at 570 nm of each well was read on a Dynex NRX Revelation microplate reader (Dynex 
Technologies, Chantilly, VA). Readings from the quadruplicate wells for each treatment 
concentration were averaged and were compared with the average readings from wells 
containing vehicle-treated cells. The results were expressed as percentage of inhibition. 
The IC50s of BEN and other products for each cell line were calculated from triplicate 
experiments using the Hill equation and the computer program ADAPT 5.  
 
2.3.12 BEN metabolism in renal carcinoma cells 
SNI2K1, ACHN, CAKI-1, 786-0 or A498 cells (3 × 10
5
 cells) in logarithmic 
growth were plated separately into each well of 6-well culture plates in a total volume of 
2 mL RPMI 1640 complete medium containing 10% FBS, penicillin and streptomycin. 
The cells were allowed to acclimate for 24 h and BEN was added to obtain a 
concentration of 1,000 ng/mL. 100 µL aliquot of cell medium was taken at 0, 2, 4, 6 and 
24 hours.  The aliquot was placed into a microcentrifuge tube that contained 5 µL 2M 
H2SO4.  The sample was stored at -80 ºC until analysis. 
 
2.3.13 Aldehyde dehydrogenase (ALDH) activity in renal carcinoma cells 
SN12K1, A498, human colorectal HCT116, and human non-small cell lung 
cancer A549 cells were grown as described. Cells were harvested by scraping, washed 
with PBS and spun at 900 x g. Cells (1 x 10
8
) were homogenized in 100 mM Tris HCl 
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buffer (pH 8.0) with a dounce homogenizer on ice. The resulting homogenate was 
centrifuged at 9,000 x g for 15 min at 4 ºC. The 9000 x g supernatant (300 µL) was added 
to 1.5 mL of 100 mM Tris HCl buffer pH 8.0, with 3 mM β-nicotinamide adenine 
dinucleotide (NAD), 4 mM acetaldehyde, 100 mM potassium chloride and 10 mM 2-
mercaptoethanol. As a control, 9000 x g supernatants were added to the sample without 
the addition of acetaldehyde which served as the blank in the reaction. Absorbance at 340 
nm was recorded for 5 min in a Beckman Coulter DU 640 spectrophotometer 
(Indianapolis, IN, USA) maintained at 37 ˚C. The rate of absorbance increase at 340 nm 
per minute was used to quantitate the reduction of NAD to NADH, which 
stochiometrically corresponds to the conversion of acetaldehyde to acetic acid. The 
activity is reported as the number of units per 1 x 10
7
 cells. The experiment was 
performed thrice for each cell line. 
 
 
2.3.14 In vivo products of BEN 
In order to determine whether the products observed in vitro would be generated 
in vivo, we administered vehicle or BEN to mice.  Mice were obtained and handled in 
accordance with the guide for the Care and Use of Laboratory Animals as previously 
described (Beumer et al., 2011).
135
  Briefly described, mice were allowed to acclimate to 
the University of Pittsburgh Cancer Institute Animal Facility for ≥1 week before being 
used. To minimize infection, mice were maintained in micro-isolator cages in a separate 
room and handled in accordance with the Guide for the Care and Use of Laboratory 
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Animals (National Research Council, 1996) and on a protocol approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh. Ventilation 
and air-flow were set to 12 changes per h. Room temperatures were regulated at 22 ± 
1°C, and the rooms were kept on automatic 12-h light/dark cycles. Mice received Prolab 
ISOPRO RMH 3000 Irradiated Lab Diet (PMI Nutrition International, St. Louis, MO) 
and water ad libitum, except on the evening before dosing, when all food was removed. 
Adult female CD2F1 mice were administered 20 mg/kg i.v. bolus of BEN (2 mg/ml BEN 
in 50% hydroxyl-propyl-β-cyclodextrin in saline) or the 50% hydroxyl-propyl-β-
cyclodextrin vehicle at 0.01 ml/g body weight.  The mice were euthanized 30 minutes 
post dose. Blood was removed by cardiac puncture and the blood removed was 
immediately placed on ice.  Plasma was obtained by centrifuging blood for 2 min at 
14,000 x g at 4 ºC.   A 200 μL aliquot of the resulting plasma was added to 10 μL 2M 
H2SO4 and frozen at -80 °C until analysis.  Plasma obtained from the BEN-treated mouse 
was compared with plasma obtained from the vehicle-treated mouse. 
 
2.4 RESULTS 
2.4.1 Method development and performance 
2.4.1.1 Chromatographic method 
Our goal was to provide adequate separation for all 6 of the analytes and all the 
other possible products while minimizing the run-time. In order to achieve this, we 
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assessed three different columns; a Phenomenex Luna C18(2) 150 x 2 mm, Phenomenex 
Synergi 4µ Polar-RP 100 x 2 mm and a Phenomenex Synergi 4µ Hydro-RP 100 x 2 mm. 
In addition, the percentage of acetonitrile and water was varied over time. We found that 
the Synergi Hydro-RP and the gradient described above resulted in adequate separation 
with the shortest run time at 30 min. As expected, the BA analogs eluted before their 
respective BEN analogs, and modifications of the side chains resulted in the OH – 
OSO2CH3 – Cl elution order. We found that using two internal standards, desmethyl-
BEN for the early eluting compounds and desmethyl-BEN-Cl2 for later eluting peaks, 
resulted in a more precise and reproducible assay. A representative chromatogram is 
shown in Figure 11. 
 
 
Figure 11. Representative LC-MS/MS chromatogram of BEN, BA, BEN-Cl2, BA-Cl2, BEN-
(OH)2, BA-Cl2 and internal standards (Desmethyl-BEN and Desmethyl-BEN-Cl2). 
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2.4.2 Plasma calibration curve and lower limit of quantitation (LLOQ) 
The assay proved to be linear and had regression coefficients >0.989 for each of 
the three standard curves for each analyte. The lower limit of quantitation (LLOQ) was 1 
ng/mL for BEN, BEN-Cl2, BA, BA-Cl2 and BA-OH2 and 10 ng/mL for BEN-OH2, at a 
signal-to-noise>10. The assay was accurate and precise with CV%< 15% at all 
concentrations. The mean and standard deviations of the back-calculated values in the 
standard curves of each analyte are displayed in Table 2. 
 
Table 2. Accuracy and precision of BEN, BEN-Cl2, BA, BA-Cl2 and BA-OH2 from 1 to 1000 
ng/mL and 10 to 1000 ng/mL for BEN-OH2. 
 
Analyte Accuracy 
(%) 
Intra-assay precision 
(%) 
Inter-assay precision 
(%) 
BEN 92.3-111.8 3.1-14.4 4.0-12.9 
BA 98.4-107.0 1.8-8.6 2.4-12.6 
BEN-Cl2 93.6-109.9 1.5-9.0 2.7-11.3 
BA-Cl2 91.9-116.1 2.8-11.0 3.0-14.1 
BEN-(OH)2 98.4-105.8 1.8-7.0 2.4-9.4 
BA-(OH)2 92.7-110.3 2.4-6.8 4.6-9.3 
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2.4.3 Autosampler stability 
Analytes, neat or extracted from plasma, decomposed in the autosampler after 
reconstitution in acetonitrile or water. We found that 5% (v/v) of 2 M H2SO4 slowed 
down decomposition sufficiently to allow quantitation. The % loss after 48 sequential 
injections over 24 h in the presence of acid was:  BEN 4.6%; BEN-Cl2 6.3%; BEN-(OH)2 
9.3%; BA 5.2%; BA-Cl2 2.2%; and BA-(OH)2 4.0%. 
 
2.4.4 Plasma stability 
After 4 h at 4 °C in plasma, BEN and BA had not degraded (100% and 102% 
remaining), respectively, relative to time 0 h. At 37 ºC, while 92% of BEN was intact, 
only < 1% for BA remained intact. At 37 ºC with 2 M H2SO4 (5% v/v) the degradation of 
BEN and BA in plasma was slowed and the amounts of BEN and BA remaining after 4 h 
were 105% and 91%, respectively, see Figure 12. 
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Figure 12. Stability of BEN (A) and BA (B) in plasma at room temperature (○), 4 °C (■), and at 
room temperature with 5% (v/v) 2 M sulphuric acid (Δ). 
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2.4.5 Incubation of BEN and products in human blood 
In whole blood at 37° C, BEN had an overall apparent half-life of 18 min.  BEN 
decomposed into at least eleven different products that were structural analogs of either 
BEN or BA. In addition, the BA analogs had peak areas much larger than the BEN 
analogs. These compounds were identified by LC-MS/MS and their structures are 
depicted in Figure 13. 
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Figure 13. Proposed metabolic scheme for BEN in blood. BEN analogs can also be converted to 
their corresponding BA analogue. In plasma there is no conversion of BEN to BA. BEN is converted only 
to BEN analogs and BA is converted to BA analogs, respectively. 
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For both BEN and BA, we observed and structurally elucidated products in which 
one or both of the methane sulfonate leaving groups was replaced by either a chlorine 
(from plasma chloride ions) or hydroxyl (from plasma water) moiety, resulting in a total 
of 12 analytes, including parent compounds. We quantitated the absolute amount for 
compounds where standards were available or we used the peak area/IS area ratio for 
compounds in which standards were not available (Figure 14 and Figure 15).  
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Figure 14. The disappearance of BEN in whole blood at 37° C from 0 to 1440 minutes. A: BEN 
(■), BEN-Cl2 (♦), BEN-(OH)2 (▲), BA (□), BA-Cl2 (◊) and BA-(OH)2 (∆). B: BEN-Cl (■), BEN-OH (♦), 
BEN-Cl-OH (▲), BA-Cl (□), BA-OH (◊) and BA-Cl-OH (∆) 
0.1
1
10
100
1000
10000
0 240 480 720 960 1200 1440
Time (min)
C
o
n
c
 (
n
g
/m
L
)
A
0.00001
0.0001
0.001
0.01
0.1
1
0 240 480 720 960 1200 1440
Time (min)
R
a
ti
o
B
 65 
 
 
 
 
Figure 15. The disappearance of BEN in whole blood at 37° C from 0 to 240 minutes. A: BEN 
(■), BEN-Cl2 (♦), BEN-(OH)2 (▲), BA (□), BA-Cl2 (◊) and BA-(OH)2 (∆). B: BEN-Cl (■), BEN-OH (♦), 
BEN-Cl-OH (▲), BA-Cl (□), BA-OH (◊) and BA-Cl-OH (∆) 
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In addition, BEN-Cl2, BA-Cl2 and BEN-(OH)2 were also incubated separately and 
their conversion to respective products was determined. When BEN-Cl2 was placed into 
blood, BA-Cl2 and BA-(OH)2 were detected. The addition of either BA-Cl2 or BEN-
(OH)2 to blood resulted in the detection of only BA-(OH)2. 
 
2.4.6 Incubation of BEN, BA, and products in human plasma 
To test whether the decomposition of BEN and BA were related to the presence of 
red blood cells, we repeated the blood experiment in plasma. Incubated in plasma at 37 
°C, BEN generated only BEN analogs (Figure 16) and BEN had an apparent half-life of 
220 min. Incubation of BA only generated BA analogs (Figure 16 and Figure 17) and BA 
had an apparent half-life of 5 min. In both cases the levels of BEN-(OH)2 and BA-(OH)2 
plateaued. This would indicate that these products are at the end of the metabolic 
pathway and that these compounds are stable. Plasma incubation of BEN-Cl2 or BA-Cl2 
generated the respective Cl-OH and (OH)2 analogs.   
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Figure 16. BEN 0-96hrs (A) and BA 0-72hrs (B) decomposition in plasma at 37 °C and formation 
of structural analogs. (A): BEN (■), BEN-Cl2 (●), BEN-OH2 (▲), BEN-Cl (□), BEN-Cl-OH (∆)and BEN-
OH (○). (B): BA (■), BA-Cl2 (●), BA-OH2 (▲), BA-Cl (□), BA-Cl-OH (∆) and BA-OH (○). For the 
analytes in which no reference compound was available the ng/mL BEN equivalents were calculated by 
using the analyte to internal standard ratio back-calculated with the equation of the BEN standard curve. 
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Figure 17. BA 0-4 hrs decomposition in plasma at 37 °C and formation of structural analogs. BA 
(■), BA-Cl2 (●), BA-OH2 (▲), BA-Cl (□), BA-Cl-OH (∆) and BA-OH (○). For the analytes in which no 
reference compound was available the ng/mL BEN equivalents were calculated by using the analyte to 
internal standard ratio back-calculated with the equation of the BEN standard curve. 
 
2.4.7 BA degradation in phosphate buffered saline 
BA was added to human plasma, PBS, and 5% human albumin in PBS. The rate 
of BA disappearance was greatest in PBS with an apparent half-life of 4 min compared to 
5 min in plasma and 8 min in PBS with albumin (Figure 18). Under the assumption that 
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of BA to 5% albumin was determined to be 49% (36.4-61.4% 95% CI). BEN is 74-85% 
protein bound in human plasma.
136
 
 
 
 
Figure 18. Degradation of BA in PBS (●), Plasma (■) and PBS/albumin (○). 
 
2.4.8 Growth inhibitory potential of BEN and products 
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BEN-(OH)2 and BA-(OH)2 could not be determined in the concentration range tested. 
The growth inhibitory potential for BEN in the cell lines was A498 > CAKI-1 > ACHN > 
786-0 > SN12K1. 
 
Table 3. Growth inhibition (IC50) for BEN and related analogs in human renal carcinoma cell 
lines. (SD) 
 
 
 
2.4.9 BEN metabolism in human renal carcinoma cells 
BEN underwent either metabolism or chemical conversion to both BEN-(OH)2 
and BA-(OH)2 in all cell lines. In contrast, BEN was converted to only BEN-(OH)2 in 
control, cell-free medium (Figure 19). The rate of disappearance of BEN was greatest in 
A498 (t1/2 = 32 min) cells followed by 786-0 (t1/2 = 54 min), ACHN (t1/2 = 56 min), 
CAKI-1 (t1/2 = 60 min)and lastly SN12K1 cells (t1/2 = 63 min). 
 
Compound \ Cell 786-0 ACHN SN12K1 CAKI-1 A498 
BEN 0.267 (0.097) 0.263 (0.047) 0.790 (0.105) 0.202 (0.133) 0.0463 (0.0119) 
BEN-Cl2 6.88 (2.77) 6.13 (2.06) 10.4 (1.2) 1.30 (0.65) 0.0677 (0.0072) 
BEN-(OH)2 >10 >10 >10 >10 >10 
BA 9.23 (5.53) 18.9 (8.9) 19.7 (5.6) 15.8 (8.1) 23.5 (9.6) 
BA-Cl2 4.74 (0.70) 5.72 (0.51) 9.35 (2.76) 6.60 (1.35) 6.57 (3.49) 
BA-(OH)2 >10 >10 >10 >10 >10 
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Figure 19. Metabolism of BEN (A) and formation of BA (B), BEN-(OH)2 (C) and BA-(OH)2 (D) 
in intact human renal carcinoma cells. SN12K1 (○), ACHN (□), CAKI-1 (∆), 786-0 (▲), A498 (■), blank 
media (●) 
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2.4.10 Aldehyde dehydrogenase activity in cell lines 
To explain the different fate of BEN incubated with different cell lines, we 
measured ALDH activity in human renal carcinoma A498 cells and SN12K1 cells, 
human lung tumor A549 cells and human colorectal HCT116 cells. These cell lines were 
chosen because the A498 cells generated the most BA-(OH)2 and the SN12K1 cells 
generated the least amount of BA-(OH)2 after incubation of BEN. As a positive and 
negative control we used the A459 and HCT116 cells which have been shown to have 
high and low levels of ALDH activity, respectively, in a screen of the NCI 60 cell lines 
for ALDH activity.
137
  The A498 cell line had an aldehyde dehydrogenase activity 38 
times greater than the SN12K1 cell line, 6.25 (±0.17) units/10
7
 cells versus 0.163 
(±0.102) units/10
7
 cells, respectively. The A549 cells, used as a positive control, had an 
activity of 26.2 (±0.3) units/10
7
 cells while HCT116 displayed no ALDH activity. 
 
2.4.11 BEN products in plasma from a mouse dosed with BEN 
We detected 12 different BA-derived products in plasma of a mouse dosed with 
BEN, 6 of which were glucuronides. Each of the BA products generated had a 
corresponding glucuronide. The non-glucuronide products were identical to the BA 
products generated in human blood and plasma. 
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2.5 DISCUSSION 
BEN is an alkylating agent currently being investigated in phase I clinical trials, 
with structural similarities to busulfan and melphalan. BEN is reported to undergo 
hydrolysis in aqueous environment.
127
 This led us to hypothesize that BEN likely 
undergoes hydrolysis in plasma and blood. The hydrolysis of BEN was expected to 
decrease the alkylating activity. In order to better understand the pharmacology of BEN 
and its products, we aimed to characterize the generation and growth inhibitory potential 
of BEN products. 
First, we developed an assay that would allow us to quantitate BEN and its 
presumed products. The degradation of the analytes could be slowed by lowering 
temperature and pH. BEN and its analogs were found to be more stable than BA and its 
respective analogs. 
In whole blood, but not in plasma, BEN was rapidly converted to its carboxylic 
acid analogue BA, suggesting conversion by an enzyme present in red blood cells. BA 
rapidly decomposed in plasma with a half-life of approximately 5 min. The rate of BA 
degradation in plasma was slightly slower than in PBS, which is not surprising since only 
free BA can react.  However, the rate of degradation in plasma was greater than in PBS 
with human albumin at physiological concentrations. This may be due to the chemical 
environment of plasma. Plasma may have other components that enable BA to react 
faster than in PBS with albumin. Under the assumption that only free BA is subject to 
degradation, we can conclude that BA is likely approximately 15% protein bound, and 
that the decomposition of BA in plasma is most likely chemical in nature, not enzymatic.  
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In plasma, BEN and BA decomposed according to a parallel pathway to a number 
of hydroxylated and chlorinated analogs, as depicted in Figure 13. The relatively fast rate 
of production of BA products relative to the generation of BEN products is likely 
indicative of the relative reactivities of the acid analogs relative to the aldehyde analogs. 
We hypothesize that the unbound electron pair on the analine nitrogen is the initiator of 
an SN2 attack on the β-carbon, generating the reactive aziridinium intermediate. 
Mesomeric withdrawal of the analine unbound electron pair by the para-aldehyde moiety, 
or occupation of the electron pair by a proton under acidic conditions would be expected 
to decrease the generation of the aziridinium intermediate and thereby decrease the 
reactivity. (See Figure 20) 
 
 
Figure 20. Hypothesis of the stability of BEN, BA and BA in the presence of acid. 
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The abundance of BA analogs and lack of BEN analogs after incubation of BEN 
in whole blood can be attributed to the relative rates of the competing pathways of BEN 
conversion. The conversion of BEN to BA is much more rapid than conversion of BEN 
to downstream aldehyde analogs. In addition, any aldehyde products formed may also be 
converted to their respective acid counterparts by the same enzymatic pathway that 
converts BEN to BA, as was shown for the conversion of BEN-(OH)2 to BA-(OH)2 in 
whole blood. 
Intravenous administration of BEN to a mouse confirmed the presence of the BA 
related analytes and their glucuronides, but not BEN, 30 min after dosing. The detection 
of glucuronides of BA analogs without hydroxyethyl moieties suggests that 
glucuronidation takes place on the carboxylic acid functionality. A more complete 
assessment of the pharmacokinetics and metabolism of BEN in mice is currently being 
conducted. 
Although ten of the 12 entities observed in plasma have the potential to alkylate 
DNA (all except the di-hydroxy metabolites), and BEN-Cl2 has been shown to be 
cytotoxic in the NCI 60-cell line screen, the BEN products that are generated in plasma 
and blood had IC50 values that were several fold higher than those of BEN in a panel of 
human renal carcinoma cells. During incubation with human renal carcinoma cells, BEN 
undergoes chemical conversion to BEN-(OH)2 or metabolism to BA and subsequent 
conversion to BA-(OH)2 in all cell lines tested. A498 cells displayed the greatest 
metabolism of BEN to BA as shown by the amount of BA-(OH)2 generated; in fact, no 
BEN-(OH)2 could be detected. In contrast, SN12K1 cells generated very little BA-(OH)2. 
The ratio of BEN disappearance for A498/SN12K1 was 35-fold. It is noteworthy that the 
 77 
 
A498 cell line was the most sensitive to BEN demonstrated by the lowest IC50 value. To 
test whether ALDH may be responsible for the metabolic conversion of BEN to BA we 
measured the ALDH activity in A498 and SN12K1 cells. We found that A498 cells had 
ALDH activity ~40-fold greater than SN12K1 cells, paralleling the BA-(OH)2 generating 
activity and conversely the metabolism of BEN to BA. These results are in line with 
previously reported ALDH activities.
137
 These data support the notion that intracellular 
ALDH is responsible for the metabolism of BEN to BA in these cells, and that this 
intracellular conversion mediates its cytotoxic effects. ALDH may also be responsible for 
the observed metabolism of BEN to BA in whole blood as red blood cells contain 
ALDH.
138
 
We hypothesize that the A498 cell line is able most efficiently to metabolize BEN 
to its more reactive metabolite BA by ALDH inside the cell, which then rapidly alkylates 
cellular constituents resulting in cell damage. The high IC50s of BA added to medium 
suggest that BA reacts with other nucleophiles in the medium before it is able to reach its 
intracellular targets. BEN-Cl2 and BA-Cl2 had intermediary IC50s. This suggests that 
BEN-Cl2 gets into the cells and is locally converted to BA-Cl2 which reacts with cellular 
targets. However, because BA-Cl2 is not as reactive as BA, a fair amount likely diffuses 
out of the cell without exerting cytotoxic effects. Conversely, when BA-Cl2 was added to 
the cell incubation, the relative stability of BA-Cl2 allowed enough of it to diffuse into the 
cells to cause intracellular damage. Taken together, these data suggest that BEN is a pro-
drug that requires intracellular activation to the highly reactive BA, which likely exerts 
rapid and localized damage via alkylation inside the cells. 
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In summary, we developed an analytical assay that will prove instrumental in 
defining the preclinical and clinical pharmacology of BEN in ongoing clinical trials. We 
have identified a number of products and metabolites of BEN and characterized their 
relative growth inhibitory properties. In addition, we have shown that ALDH may be 
responsible for the metabolism of BEN to BA, and that BEN is more active in cell lines 
that express high levels of ALDH. The potential importance of this finding lies in the 
reported overexpression of ALDH in stem cells of many tumor types making these stem 
cells potential targets for BEN therapy, existing polymorphisms in ALDH, and potential 
drug-drug interactions with inhibitors of ALDH such as disulfiram and metronidazole.
139-
142
 More complete in vitro and in vivo studies are underway to define BEN 
pharmacokinetics and metabolism, and the relative contribution of BEN and metabolites 
to plasma exposure of alkylating species. 
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3.0  CHARACTERIZATION OF THE METABOLISM OF BENZALDEHYDE 
DIMETHANE SULFONATE IN RED BLOOD CELLS 
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3.1 ABSTRACT 
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is a 
bifunctional alkylating agent with activity against renal cell carcinoma, and is being 
evaluated clinically. We have previously characterized the degradation of BEN in plasma 
and blood. In plasma, BEN chemically degrades into five different analogs in which the 
dimethane sulfonate groups are replaced by either chlorine or hydroxyl groups. In whole 
blood, but not in plasma, BEN is rapidly converted to its carboxylic acid analogue BA, 
which then chemically converts to chlorine or hydroxyl intermediates similar to the 
degradation of BEN in plasma. The conversion of BEN to BA in whole blood, but not 
plasma, suggests that an enzyme in RBCs may be responsible for this conversion. BEN 
was also converted to BA in renal carcinoma cells. We have demonstrated a correlation 
between the generation of BA from BEN and the activity of with aldehyde 
dehydrogenase (ALDH) as determined by acetaldehyde metabolism, in renal carcinoma 
cell lines. To better understand the pharmacology of BEN we aimed to further 
characterize the conversion of BEN to BA in blood.  
 We evaluated the conversion of BEN to BA in six different lots of blood and 
calculated the average apparent Vmax and apparent Km to be 68 ng/mL•min
-1•[10% RBC]-
1
 and 373 ng/mL, respectively. The conversion of BEN to BA in blood was not inhibited 
by carbon dioxide, nitrogen gas or menadione, an inhibitor of aldehyde oxidase. The 
conversion in blood was, however, inhibited by disulfiram, an inhibitor of ALDH. 
Furthermore, we performed studies with available purified ALDH isoforms ALDH1A1, 
ALDH3A1, ALDH2, and ALDH5A1. We found that BEN was converted to BA only by 
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ALDH1A1, which is reportedly present in the red blood cells. The work presented here 
contributes to a better understanding of the pharmacology of BEN. 
3.2 INTRODUCTION 
Approximately 13,000 people die from metastatic renal cell carcinoma (mRCC) 
in the United States every year.
1,143
 Only 10-12% of patients achieve durable complete 
remission with high dose interleukin-2 therapy.
128
 Agents targeting vascular endothelial 
growth factor and its receptor along with mTOR inhibitors have shown clinical 
activity.
94,129
 However, responses to these agents are generally transient
130
, and there is a 
need for new treatment options for mRCC patients. 
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is one of a 
family of dimethane sulfonates that have demonstrated activity in the NCI 60 cell line 
screen. BEN is proposed to be a bifunctional alkylator with structural similarities to 
chlorambucil, busulfan and melphalan. However, unlike these compounds, BEN has 
specific activity against renal carcinoma cells (RCC) in the NCI 60 cell line screen.
124
 
BEN causes cell cycle arrest in the G2-M phases
124
, and increases P53 levels, indicating 
DNA damage, in the renal carcinoma cell line 109, and in the breast cancer cell line 
MCF-7. In addition, BEN has demonstrated antitumor activity in mice with renal 
carcinoma xenografts, specifically against human A498 and RXF-393 implanted 
subcutaneously or orthotopically under the renal capsule [Personal communication, Dr. 
M. Hollingshead, unpublished data].
131,132
 The significant in vitro and in vivo activity 
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against renal carcinoma has led to the ongoing evaluation of BEN in NCI-sponsored 
phase I clinical trials. 
BEN, based on its structure, likely forms an aziridinium intermediate that is 
attacked by nucleophilic molecules such as DNA, proteins or water. Jumaa et al. reported 
hydrolysis of BEN in aqueous solution whereby the dimethane sulfonate groups are 
replaced by hydroxy groups.
127
  In order to better understand the pharmacology of BEN 
we tested whether BEN would undergo hydrolysis in blood and plasma. In whole blood, 
but not in plasma, BEN was rapidly converted to its carboxylic acid analogue (BA).
144
 
Furthermore, BEN decomposed into at least eleven different products that were structural 
analogs of either BEN or BA.  These compounds were identified by LC-MS/MS and their 
structures are depicted in Figure 13 (chapter 2). For both BEN and BA, we observed and 
structurally elucidated products in which one or both of the methane sulfonate leaving 
groups was replaced by either a chlorine (from plasma chloride ions) or hydroxyl (from 
plasma water) moiety, resulting in a total of 12 analytes, including the parent compound. 
To test whether the decomposition of BEN and BA were related to the presence of red 
blood cells, we repeated the experiment performed with blood using plasma. Incubated in 
plasma at 37 °C, BEN generated only BEN analogs and had an apparent half-life of 220 
min. Incubation of BA only generated BA analogs, and BA had an apparent half-life of 5 
min. Plasma incubation of BEN-Cl2 or BA-Cl2 generated the respective Cl-OH and (OH)2 
analogs. This led us to hypothesize that the conversion of BEN to BA in whole blood is 
an enzymatic process.
144
 
BEN has shown activity against RCC lines. Because of this, we elucidated the 
metabolism of BEN in five different RCC lines. BEN underwent either metabolism or 
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chemical conversion in all cell lines to both BEN-(OH)2 and BA-(OH)2, however, at 
different rates and in blank control medium, only BEN-(OH)2 was generated.  We 
measured the aldehyde dehydrogenase (ALDH) activity of these 5 renal carcinoma cell 
lines and found that the ALDH activity correlated with the amount of BA-OH2 
generated.
144
 This is further support for the idea that the conversion of BEN to BA is 
enzymatic and that ALDH is primarily responsible for this metabolic step. 
Aldehydes are reactive electrophilic compounds that react with thiol and amino 
groups. Aldehydes are necessary for many physiologic and therapeutic processes, but 
aldehydes can also be cytotoxic, genotoxic and may be involved in carcinogenesis.
145
 We 
hypothesized that BEN is metabolized into BA by an enzyme/s that is an aldehyde 
dehydrogenase and/or aldehyde oxidase (AO). 
ALDHs are NAD(P)+ dependent enzymes that metabolize both aromatic and 
aliphatic aldehydes into carboxylic acids.
146
 This process generally makes aldehydes less 
toxic and more readily excreted. There are nineteen different known human isoforms of 
ALDH. ALDHs are involved in many biological pathways and people that are deficient 
or have polymorphic isoforms of ALDH are susceptible to various metabolic diseases or 
have intolerance to alcohol.
145-147
 
Aldehyde oxidase (AO) is a molybdoflavoenzyme that has broad specificity. 
Although the physiological function of this enzyme is unknown, it is known to oxidize a 
number of aldehydes and heterocyclic rings.
148
 Some of the substrates of AO are 
retinaldehyde, 5-fluoro-2-pyrimidinone and methotrexate. 
Disulfiram (Antabuse
TM
) is an irreversible inhibitor of certain isoforms of ALDH 
and is prescribed to treat chronic alcoholism.
141,149
 After ingestion, alcohol is converted to 
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acetaldehyde by alcohol dehydrogenase (ADH). Acetaldehyde is then metabolized to 
acetic acid by ALDH. Disulfiram causes the accumulation of acetaldehyde in the blood 
when alcohol is consumed, resulting in severe “hangover” side effects.141  
Menadione is a synthetic form of vitamin K3 and is a specific inhibitor of AO. 
Menadione functions to aid in posttranslational modification of proteins, most 
importantly for blood clotting factors. In addition, menadione has been used as an anti-
inflammatory agent and is a component of multivitamin products.
150
 Currently, 
menadione is not used because of its associated toxicities, which include hemolytic 
anemia, neonatal brain damage, allergic reactions and hepatotoxicity.
151
 
In the current chapter we describe the identification of the enzyme responsible for 
the conversion of BEN to BA, and further characterization of the reaction in biological 
fluids. 
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3.3 MATERIALS AND METHODS 
3.3.1 Chemicals and reagents 
4-[bis[2-[(methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzaldehyde (BEN, NSC 
281612), 4-[bis[2-[(methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzoic acid (BA, NSC 
733609), 4-[bis[2-chloro-ethyl]amino]-2-methyl-benzaldehyde (BEN-Cl2), 4-[bis[2-
chloro-ethyl]amino]-2-methyl-benzoic acid (BA-Cl2),  4-[bis[2-[(methylsulfonyl)-
oxy]ethyl]amino]-benzaldehyde (desmethyl-BEN), and 4-[bis[2-chloro-ethyl]amino]-
benzaldehyde (desmethyl-BEN-Cl2) were obtained from the National Cancer Institute 
(NCI, Bethesda, MD). 4-[bis[2-hydroxy-ethyl]amino]-2-methyl-benzaldehyde (BEN-
(OH)2) was generated by heating approximately 13.6 mg BEN in approximately 4 mL of 
0.05 N aqueous NaOH for 48 h at 50 °C. The progression of the reaction was monitored 
by mass spectrometry. 4-[bis[2-hydroxy-ethyl]amino]-2-methyl-benzoic acid (BA-(OH)2) 
was generated by heating approximately 13.2 mg BA in a solution of 0.03 N NaOH in 7 
mL of acetonitrile/water (1:1, v/v) for 48 h at 50 ºC. The progression of the reaction was 
assessed by mass spectrometry and the conversion was 100% in both cases. The final 
solutions were neutralized with hydrochloric acid and acidified with formic acid for a 
final concentration of 1 mg/mL of the respective product. All solvents used for LC-
MS/MS were high purity Burdick & Jackson and purchased from Fisher Scientific Co. 
(Fair Lawn, NJ). Formic acid was purchased from Sigma-Aldrich Chemical Co. (St. 
Louis, MO). Control human blood was obtained from the Central Blood Bank, 
Pittsburgh, PA and plasma was prepared by centrifugation of whole blood at 2000 x g at 
room temperature for 20 min. Nitrogen gas for the mass spectrometer was purified with a 
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Parker Balston Nitrogen Generator (Haverhill, MA). Nitrogen gas for the sample 
evaporation, and nitrogen gas and carbon monoxide gas was purchased from Valley 
National Gasses, Inc. (Pittsburgh, PA). Reduced nicotinamide adenine dinucleotide 
(NADH), reduced nicotinamide adenine dinucleotide phosphate (NADPH), and 
disulfiram used for metabolism studies were purchased from Sigma-Aldrich Chemical 
Co. (St. Louis, MO). Cellgro phosphate buffered saline. (PBS 1x) was purchased from 
Mediatech (Manassas, VA). 
 
3.3.2 Analytical Equipment 
We employed two LC-MS/MS assays. One to quantitate the metabolites 
generated in the blood metabolism experiments, and one to quantitate BEN and BA in the 
purified enzyme experiments. For the blood metabolism experiments we used a 
previously developed assay to quantitate the analytes in plasma (Assay1). The LC-
MS/MS system consisted of an Agilent (Wilmington, DE, USA) 1200 SL thermostated 
autosampler, binary pump, thermal column compartment, and a ABI SCIEX (San Jose, 
CA, USA) 4000Q hybrid linear ion trap tandem mass spectrometer (ABI system). For the 
purified enzyme experiments we developed an assay to quantitate the analytes in PBS 
(Assay2). The LC-MS/MS system consisted of an Agilent (Wilmington, DE, USA) 1100 
thermostated autosampler, binary pump, and a Waters (Milford, MA) Quattromicro 
desktop tandem mass spectrometer (QM system). 
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3.3.3 Assay 1 
Assay 1 was the LC-MS/MS assay used for the experiments in chapter 2 and is 
detailed in that chapter. Briefly described, the liquid chromatography was performed with 
a gradient mobile phase consisting of A: acetonitrile/0.1% formic acid (v/v) and B: 
water/0.1% formic acid (v/v).  The mobile phase was pumped at a flow rate of 0.2 
mL/min and separation was achieved using a Phenomenex (Torrance, CA) Hydro 
Synergi-RP 4 micron 100 x 2mm column.  The gradient mobile phase was as follows: at 
time zero, solvent A was 15% and was increased linearly to 40% in 20 min.  The 
percentage of solvent A was increased linearly to 80% at 21 min and the flow rate was 
increased to 0.4 mL/min. This was maintained for two min at which time solvent A was 
decreased linearly to 15% at 24 min.  This was maintained for six min.  The total run time 
was 30 min. During the first two min and the last six min of the LC run the flow leaving 
the column was diverted to waste. 
 The parameters of the mass spectrometer were as follows; curtain gas 20, IS 
voltage 5500V, probe temperature 400 ºC, GS1 40, GS2 30, declustering potential 50V, 
and collision energy 40V. For MRM transitions, see table 1 chapter 2. 
 
3.3.4 Assay 2 
The liquid chromatography was performed with a gradient mobile phase 
consisting of A: acetonitrile/0.1% formic acid (v/v) and B: water/0.1% formic acid (v/v).  
The mobile phase was pumped at a flow rate of 0.3 mL/min and separation was achieved 
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using a Phenomenex (Torrance, CA) Hydro Synergi-RP 4 micron 100 x 2mm column.  
The gradient mobile phase was as follows: from time zero to until 4.5 min solvent A was 
maintained at 40% with a flow rate of 0.3 mL/min. At 4.6 min solvent A was increased 
linearly to 90% and the flow rate was increased to 0.5 mL/min. These conditions were 
maintained for 2.4 min at which time solvent A was decreased to 40%. The run time was 
12 min.  During the first two min and the last six min of the LC run the flow leaving the 
column was diverted to waste. 
To develop the mass spectrometric assay, BEN, BA, and desmethyl-BEN were 
diluted to a concentration of 1 µg/mL in acetonitrile and each was continuously infused at 
a rate of 10 µL/min into the HPLC flow, which was an isocratic mobile phase of 
acetonitrile:water:formic acid (50:50:0.1, v/v/v) pumped at 0.3 mL/min. The tuning 
parameters of the mass spectrometer were adjusted to maximize the intensity of the [M+ 
H]
+
 ion of the analyte.  After the largest [M+H]
+
 ion was obtained, the mass spectrometer 
was operated in product mode and the collision voltage was adjusted so that the largest 
product ion was determined. The parameters for the mass spectrometer were as follows: 
Capillary voltage 4.0 kV, cone voltage 20 V, source temperature and desolvation 
temperature were 120 ˚C and 450 ˚C, respectively. Desolvation gas was 550 L/h and 
LM1, LM2, HM1 and HM2 were set to 12. The entrance, exit and collision voltages were 
1, 23, and 6 respectively. The mass transitions for BEN, BA and desmethyl-BEN were 
380>160, 396>300 and 366>270, respectively. 
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3.3.5 Standard curve for blood metabolism assays 
Stock solutions of BEN, BEN-Cl2, BA, BA-Cl2, BEN-(OH)2 and BA-(OH)2 were 
prepared separately at concentrations of 1.0 mg/mL in acetonitrile containing 0.1% 
formic acid. A mixture was made containing all six analytes at a concentration of 0.1 
mg/mL by adding 100 µL of each analyte to 400 µL of acetonitrile with 0.1% formic 
acid.  All stock solutions were stored at -80 °C in the dark. On assay days, this solution 
was diluted with acetonitrile to obtain the lower calibration working solutions of 0.01, 
0.001 and 0.0001 mg/mL.  These calibration working solutions were diluted in plasma 
with 2 M H2SO4 (5%, v/v) to produce 200-μL aliquots of the following concentrations: 1, 
3, 10, 30, 100, 300, 500, 750, and 1000 ng/mL. 10 μL of a mixture of desmethyl-BEN 
and desmethyl-BEN-Cl2 (1 μg/mL of both in acetonitrile) were added as internal 
standards. The analyte-to-internal standard ratio (response) was calculated for each 
standard by dividing the area of the compound peak area by the area of the compound’s 
respective internal standard peak. Standard curves of each compound were constructed by 
plotting the analyte-to-internal standard ratio versus the nominal concentration of each 
analyte in each sample. Standard curves were fit by linear regression with weighting by 
1/y
2
, without forcing the line through the origin, followed by the back-calculation of the 
concentrations.  The deviations of these back-calculated concentrations from the nominal 
concentrations, expressed as percentage of the nominal concentration, reflected the assay 
performance over the concentration range. 
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3.3.6 Standard curve for purified enzyme assays 
The procedure for the preparation of standard curves in PBS was the same as the 
procedure for the preparation of the standard curves in plasma except for the following; 
PBS was used instead of plasma, and only BEN and BA where quantitated from 1 to 
1000 ng/mL and desmethyl-BEN was used as the internal standard. 
 
3.3.7 Sample processing 
For all blood metabolism assays the aliquots taken were processed as described. 
At the specified time points, a 500 µL aliquot of blood was removed, and centrifuged at 
12,000 x g for 2 min at 4 °C.  200 µL of the resultant plasma was removed and added to 
10 μL 2M H2SO4. The sample was briefly vortexed and 10 μL of internal standard 
solution and 1 mL of acetonitrile were added.  The samples were then vortexed on a 
vortex genie on a setting of high for one minute, and then were centrifuged at 12,000 x g 
for 5 min. The resultant supernatant was blown to dryness at room temperature under a 
stream of nitrogen. The samples were reconstituted with 100 μL of 20:80 
acetonitrile/H2O with 5% 2 M H2SO4 (v/v/v) and 10 μL was injected into the LC-MS/MS 
system. 
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3.3.8 Determination of the effect of RBC concentration on BEN metabolism 
To determine the effect of increasing RBC concentrations on BEN metabolism 
and to determine an adequate amount of RBCs in further experiments, metabolism was 
performed with different amounts of RBCs. BEN was added separately to 10 mL of 
plasma, 0.1% RBCs, 1% RBCs, 10% RBCs and whole human blood to achieve a 
concentration of 10 μg/mL. The samples were incubated in a shaking water bath at 37 ºC. 
At 0, 5, 10, 15, 30, 45, 60, 120, 180, 240, 360 min, and 24 h, aliquots were taken and 
processed as described above. 
 
3.3.9 Experiments with carbon monoxide and nitrogen gas 
Carbon monoxide (CO) gas and nitrogen (N2) gas were used to determine whether 
a heme group is involved in the metabolism of BEN. Either carbon monoxide (CO) or 
nitrogen gas was passed through a mixture of 10% RBCs in plasma at 37 ºC for 5 min in 
a shaking water bath. The reaction vessels were sealed with a septum. The gasses were 
continuously passed into the reaction vessel using a stainless steel needle 5 minutes prior 
and throughout the experiment. In addition, there was a second needle in the septum to 
allow the gasses to escape. BEN was added to obtain a concentration of 3 µg/mL and 200 
µl aliquots were taken at 0, 60, 120 and 180 min and processed as described above. 
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3.3.10 Experiments with ALDH and AO inhibitor 
Disulfiram and menadione were used to determine the effect of ALDH and 
aldehyde oxidase inhibitors on blood metabolism of BEN. 90 µL of 10 mM disulfiram in 
acetonitrile or 90 µl of 10 mM menadione in DMSO was added to 6 mL of 10% RBCs to 
obtain a concentration of 150 µM of these compounds.  
Additional experiments were conducted with increasing concentrations of 
menadione of 750 µM and 3 mM. 90 µL of DMSO were added to separate tube as a 
solvent control. The resulting mixtures were incubated at 37 ºC for 10 min in a shaking 
water bath before BEN was added to obtain a concentration of 1 µg/mL.  Five hundred 
µL aliquots were taken at 5, 15, 30, 45 and 60 min and processed as described above. 
 
3.3.11 BEN in lysed blood 
To determine the effect of hemolysis on the metabolism of BEN in blood we 
performed the metabolism of BEN with lysed RBCs. To lyse RBCs a mixture of 10% 
RBCs in plasma was freeze-thawed 3 times. 6 mL of both lysed and unlysed RBCs in 
plasma was incubated separately at 37 ºC on a shaking water bath before BEN in 
acetonitrile was added to obtain a concentration of 10 µg/mL. Aliquots were taken at 5, 
60, 120, and 180 min and processed as described above. 
We hypothesized the activity of the enzyme in RBCs could be affected by lysis 
through dilution of cofactors. To determine whether NADH or NADPH would restore the 
metabolism in lysed RBCs, we performed the metabolism in lysed RBC in the presence 
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of either NADH or NADPH.  Either NADH or NADPH was added at a final 
concentration of 500 µM to 10% lysed RBCs in plasma and incubated at 37 ºC in a 
shaking water bath. Five hundred µL aliquots were taken at 5, 30, 60, 90 and 120 min and 
processed as described as above. 
 
3.3.12 Determination of BEN blood partitioning 
To determine the amount of BEN in blood compared to plasma we determined the 
blood to plasma partitioning ratio. Ten mL of blood containing 50% RBCs was placed 
into a 15 mL conical tube and placed on ice. Disulfiram was added to obtain a 
concentration of 1 mM. After 10 minutes BEN was added to obtain a final concentration 
of 1000 ng/mL. Five hundred μL aliquots of blood were taken at 5, 10, 15, 20 and 30 
minutes and centrifuged at 12,000 x g for 2 minutes. Two hundred μL of the resulting 
plasma was pipetted into micro-centrifuge tubes that contained 10 μL of 2M H2SO4. The 
amount of BEN in the plasma samples was determined by LC-MS/MS as described 
above. The procedure was performed in parallel in 100% plasma to determine the total 
amount of BEN obtained in plasma without blood. Both experiments were performed in 
triplicate. The blood to plasma concentration partitioning was determined by dividing the 
concentration of BEN obtained in the 100% plasma experiment divided by the 
concentration of BEN in the plasma from the BEN added to 50% RBC experiment.  
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3.3.13 Vmax and Km determination 
In order to determine the apparent Vmax and Km of human blood, different 
amounts of BEN in acetonitrile were added to 10% RBCs and the amount of BEN 
remaining was determined at various time points. BEN was added to RBCs that were pre-
incubated at 37 ºC for five min to achieve a final concentration of 10,000, 5,000, 2,000, 
1,000, 800, 600, 400 and 200 ng/mL. 500 µL aliquots were taken at 5, 15, 30, 45, 60, 75, 
90, 105 and 120 min and processed as described above. These reactions displayed the 
saturation of the enzyme and allowed us to determine more optimal and fewer 
concentrations to use in future reactions for apparent Vmax and Km determination.  
We determined the apparent Vmax and Km in six different lots of human blood. 
Plasma with 10% RBCs was pre-incubated at 37 ºC for five min followed by addition of 
BEN to achieve final concentrations of 5,000 and 400 ng/mL. 500 µL aliquots were taken 
at 5, 15, 30, 45, 60, 75, 90, 105 and 120 min and processed as described above 
(experiments were performed in triplicate). The resulting concentration versus time data 
was analyzed with a one compartmental model with saturable elimination using 
ADAPT5. In ADAPT we used the equations XP(1) = -Vmax/(Km + 
X(1)/V400)*(X(1)/V400) and XP(2) = -Vmax/(Km + X(2)/V5000)*(X(2)/V5000) to 
determine the Km and Vmax of each experiment. 
To determine if time had an effect on enzyme activity we determined the apparent 
Vmax and Km of 7 day old blood compared to freshly obtained blood. Plasma with 10% 
RBCs was pre-incubated at 37 ºC for five min followed by addition of BEN in to achieve 
final concentrations of 5,000 and 400 ng/mL. Aliquots of 500 µL were taken at 5, 15, 30, 
45, 60, 75, 90, 105 and 120 min and processed as described above. 
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3.3.14 Immunoprecipitation of RBCs 
To determine if ALDH was responsible for the metabolism of BEN, we 
performed immunoprecipitation of ALDH1A1 enzyme and performed BEN metabolism 
in RBCs. One hundred µL of 50 % lysed RBCs in plasma were added to 900 µL of 
immunoprecipitation buffer which consisted of 5 mM EDTA, 0.02% sodium azide and 18 
µL of 50x protease cocktail inhibitor (BD baculogold). The sample was briefly vortexed 
and centrifuged for 10 min at 12,000 x g at 4 ˚C. Either 5 µL of ALDH1A1 purified 
MaxPab rabbit polyclonal antibody (Abnova, Taipei, Taiwan) or IgG polyclonal rabbit 
control antibody (abcam, Cambridge, MA) was added. To a third control sample nothing 
was added. The samples were placed on a rotary agitator at 4 ˚C.  After 24 h, 100 µL of 
protein A sepharose B conjugate was added to each tube and the sample was placed on a 
rotary agitator for 4 h at 4 ˚C. The sample was then centrifuged at 2,000 x g for 5 min and 
the resulting supernatant was used for BEN metabolism. 
The samples were placed in a shaking heated water bath at 37 ˚C. After 10 min, 
BEN was added to each sample to achieve a concentration of 1000 ng/mL and NADH 
was added to achieve a concentration of 3 mM. Aliquots of 100 µL were taken at 0, 15, 
30 and 60 min and added to microcentrifuge tubes that contained 5 µL 2 M H2SO4. 10 µL 
of 1 µg/mL internal standard and 500 µL of acetonitrile were added and the samples were 
briefly vortexed and centrifuged at 12,000 x g for 5 min. The resulting supernatant was 
transferred to 12 x 75 mm glass tubes and evaporated under a stream of nitrogen at 37 ˚C. 
The samples were reconstituted in 100 μL of 20:80 acetonitrile/H2O with 5% 2 M H2SO4 
(v/v/v) and 10 μL was injected into the LC-MS/MS system. 
 96 
 
3.3.15 Western blot 
To determine if RBCs had ALDH1A1 we performed Western blot analysis as 
previously described.
152
 One hundred µL of 50 % lysed RBCs in plasma was added to 
890 µL of cell lysate buffer containing 200 mM Tris–HCl, pH 7.4, 100 μM 4-(2-
aminoethyl) benzenesulfonyl fluoride, 1 mM EGTA, and 1% Triton X-100. Protein 
concentration was determined using the BCA Protein Assay kit (Pierce, Invitrogen, 
Grand Island, NY, USA), and 10, 20, 40 and 80 µg protein were subjected to SDS–PAGE 
electrophoresis followed by electrotransfer to nitrocellulose membranes. Membranes 
were blocked with 5% nonfat milk in Tris-buffered saline and then probed with primary 
antibodies ALDH1A1 purified MaxPab rabbit polyclonal antibody (Abnova, Taipei, 
Taiwan), or GAPDH, followed by anti-rabbit secondary antibodies conjugated to 
horseradish peroxidase (Bio-Rad, Hercules, CA, USA). The enhanced 
chemiluminescence (ECL) Western blotting detection system (Amersham Biosciences, 
Piscataway, NJ, USA) was used to facilitate detection of protein bands. 
 
3.3.16 Metabolism using purified ALDH 
To determine whether BEN is a substrate for metabolism by different isoforms of 
ALDH we performed metabolism studies of BEN with purified human ALDH1A1, 2, 
3A1, and 5A1 (PROSPEC, Israel) enzymes. In addition, we performed metabolism 
studies of BEN with these enzymes in the presence of their respective antibodies, if 
available, and disulfiram in an effort to inhibit metabolism.  
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Enzyme incubation mixtures contained 200 µM Tris-HCl buffer pH 7.4, 200 mM 
KCl, 4 mM DTT, 5 µg/mL purified enzyme and 1000 ng/mL BEN. After pre-incubation 
at 37 ˚C for 10 min, NAD or NADPH (depending on the cofactor that was required for 
each isozyme) was added to obtain a concentration of 1 mM. Aliquots of 100 µL were 
taken at 0, 10, 20, 30, 45, and 60 min. The aliquots were pipetted into a microcentrifuge 
tube that contained 5 µL of 2 M H2SO4. 10 µL of 1 µg/mL internal standard and 500 µL 
of acetonitrile were added and the samples were briefly vortexed and centrifuged at 
12,000 x g for 5 min. The resulting supernatant was transferred to 12 x 75 mm glass tubes 
and evaporated under a stream of nitrogen at 37 ˚C. The samples were reconstituted in 
100 μL of 20:80 acetonitrile/H2O with 5% 2 M H2SO4 (v/v/v) and 10 μL was injected 
into the LC-MS/MS system. 
 
3.3.17 Positive control using aldehyde dehydrogenase isoforms 
To ensure that the ALDH enzymes were active we performed the positive controls 
as described by the manufactures instructions. The reaction mixtures contained 200 µM 
Tris-HCl buffer pH 7.4, 200 mM KCl, 4 mM DTT, 5 µg/mL purified enzyme and 5 mM 
NAD (for ALDH2 and ALDH5A1) and 5 mM NADP (for ALDH3A1). For ALDH2, 
acetaldehyde was added to obtain a final concentration of 2 mM and for ALDH5A1, 
succinic semialdehyde was added to obtain a final concentration of 2 mM. 4-nitro 
benzaldehyde was added at a concentration of 4 mM for the ALDH3A1 reaction. The 
tubes were vortexed and the sample was transferred into glass cuvettes and placed into a 
spectrophotometer along with a control sample that contained no enzyme. Absorbance at 
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340 nm was monitored for 5 min to measure the reduction of NAD or NADP to NADP or 
NADPH. 
 
3.4 RESULTS 
3.4.1 LC-MS/MS chromatography and curves. 
Assay performance and chromatography has been described before in Chapter 2. A 
representative chromatogram of quantitatable analytes is displayed below. 
 
 
Figure 21. A representative chromatogram of BEN, BA, BEN-Cl2, BEN-(OH)2, BA-Cl2, BA-
(OH)2 and desmethyl-BEN. 
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3.4.2 The effect of RBCs on BEN metabolism 
The rate of disappearance of BEN increased as the percentage of RBCs was 
increased. After one hour the reaction that contained no RBCs had 99% of BEN 
remaining whereas the reaction with 10% RBCs had only 54% BEN remaining. After 6 
hours the reaction with no RBCs had 59% remaining while the reaction with 10% RBCs 
had only 5% BEN remaining (Figure 22). Another measure of metabolism is the 
formation of BA-(OH)2 or lack of metabolism is the formation of BEN-(OH)2. The 10% 
RBC reaction produced the most BA-(OH)2 and the least amount of BEN-(OH)2  (Figure 
23 and Figure 24). 
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Figure 22. The disappearance of BEN with different percentages of RBCs. 0% RBCs (■), 0.1% 
RBCs (□), 1% RBCs (▲), and 10% RBCs (∆). 
 
 
 
Figure 23. The production of BA-(OH)2 when BEN is added to different concentrations of RBCs. 
0% RBCs (■), 0.1% RBCs (□), 1% RBCs (▲), and 10% RBCs (∆). 
100
1000
10000
0 60 120 180 240 300 360
B
E
N
 (
n
g
/m
L
) 
Time (min) 
0
50
100
150
200
250
300
350
400
0 60 120 180 240 300 360
B
A
-(
O
H
) 2
  
(n
g
/m
L
)  
 
TIme (min) 
 101 
 
 
Figure 24. The production of BEN-(OH)2 when BEN is added to different concentrations of 
RBCs. 0% RBCs (■), 0.1% RBCs (□), 1% RBCs (▲), and 10% RBCs (∆). 
 
3.4.3 Effects of  carbon monoxide and nitrogen gas on BEN metabolism 
We performed incubations of BEN in 10% RBCs in the presences of either carbon 
monoxide or nitrogen gas to determine if a heme group was involved in the metabolism 
of BEN. The metabolism of BEN was not appreciably inhibited by the presence of the 
gasses as the rate of disappearance of BEN appeared a little greater in the presence of the 
gasses. The half-life of BEN in the incubations up to 120 min was 56, 47 and 22 minutes 
for the control, CO gas and N2 gas incubations, respectively  
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Figure 25. The disappearance of BEN in 10% RBCs: alone (■), in the presence of CO gas (□), 
and in the presence of nitrogen gas (▲). 
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3.4.4 Effects of disulfiram and menadione on BEN metabolism 
To determine whether the metabolism of BEN in RBCs was due to ALDH or AO 
we performed incubations of BEN with RBCs in the presence of the ALDH inhibitor 
disulfiram or the AO inhibitor menadione. The incubation performed with the ALDH 
inhibitor disulfiram saw almost a complete inhibition of BEN metabolism, whereas the 
AO inhibitor menadione appeared to have only a partial inhibitory effect on metabolism 
of BEN. The amount of BEN remaining in the control, disulfiram and menadione sample 
was 0.5%, 92% and 18% respectively (Figure 26 and Figure 27).  
Since menadione caused a partial inhibition of BEN metabolism, we performed 
additional experiments with increasing concentrations of menadione, in order to increase 
the inhibition of BEN. These experiments showed that DMSO alone (1.5% DMSO v:v) 
caused the same amount of inhibition of BEN in RBCs as 3 mM menadione (Figure 27).   
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Figure 26. BEN added to 10% RBCs with and without inhibitors. BEN added to 10% RBCs (◊), 
BEN added to 10% RBCs in the presence of menadione (■), and BEN added to 10% RBCs in the presence 
of disulfiram (▲). 
 
 
Figure 27. BEN added to 10% RBCs with and without different amounts of menadione. BEN 
alone(■), BEN + DMSO (□), BEN added after 1x menadione (▲), BEN added after 5x menadione (○), and 
BEN added after 20x menadione (●). 
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3.4.5 BEN in lysed blood 
We performed experiments in lysed RBCs in order to determine whether a 
complete cell structure is required for the metabolism of BEN, or whether lysing the cells 
resulted in dilution of cofactors. RBCs that had been lysed before metabolism did not 
metabolize BEN (Figure 28). Adding NADH to the lysed RBCs incubation, however, 
restored the ability of lysed RBCs to metabolize BEN. Adding NADPH partially restored 
the ability of lysed RBCs to metabolize BEN. After 120 min the control non-lysed RBC 
reaction had 0.1% BEN remaining. Lysed RBCs with BEN alone showed 67% BEN 
remaining compared to 0.7% BEN remaining when NADH was added to lysed RBCs. 
Adding NADPH also led to metabolism of BEN. In this reaction there was 18% 
remaining after 120 min (Figure 29).  
 
 
 
Figure 28. BEN added to 10% RBCs. 10% RBCs (○) and 10% lysed RBCs (■). 
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Figure 29. BEN added to lysed and non-lysed RBCs. 10% RBCs (◊), 10% lysed RBCs (■), 10% 
lysed RBCs + NADH (▲), and 10% lysed RBCs + NADPH (♦).  
 
 
3.4.6 BEN blood to plasma concentration ratio 
We determined the blood to plasma concentration ratio of BEN by measuring the 
amount of BEN added to blood that contained 50% RBCs to plasma alone as described in 
the methods section. The average partition ratio was found to be 1.25 ± 0.08. The amount 
of BEN detected in the blood remained nearly constant throughout the experiment, 
indicating that the equilibrium between RBCs and plasma was complete by 5 minutes and 
that BEN was not metabolized (Figure 30)  
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Figure 30. BEN blood to plasma partitioning. (■) BEN in the plasma portion of blood from blood 
that contained 50% RBCs and, (□) BEN in plasma.  
 
 
3.4.7 Exploratory Vmax and Km determination 
We performed metabolism of BEN at different concentrations in 10% RBCs to 
determine the concentration that would capture both the saturable and linear portion of 
the metabolism of BEN over time. We found that a starting concentration of 5000 ng/mL 
captured both the saturable and linear components of BEN metabolism (Figure 31). In 
addition, starting concentrations below 400 ng/mL appeared to mostly display linear 
metabolism. 
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Figure 31. BEN metabolism with 10% RBCs. 200 ng/mL (■), 400 ng/mL (□), 600 ng/mL (▲), 
800 ng/mL (∆), 1000 ng/mL (●), 2000 ng/mL (○), 5000 ng/mL (♦), and 10000 ng/mL (◊). 
 
 
 
 
3.4.8 Vmax and Km determination in 6 lots of blood 
We tested six different lots of blood for the metabolism of BEN. Based on the 
exploratory data we choose to perform the metabolism of BEN using 5000 and 400 
ng/mL to best capture the apparent Vmax and Km of BEN in blood. The apparent Km 
ranged from 196.3 to 799.6 ng/mL and the apparent Vmax ranged from 65.4 to 113.2 
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ng/mL
-1•min-1•[10% RBC]-1.(Table 4, Figure 32 and Figure 33). The average apparent 
Vmax and Km for the six lots of blood was 80.5 ng/mL•min
-1•[10% RBC]-1 (SD 17.8, 
CV% 22.1) and 372.5 ng/mL (SD 152.1, CV% 40.8), respectively.  
 The fresh blood had an apparent Vmax and Km of 113.4 ng/mL
-1•min-
1•[10% RBC]-1 (95% CI, 106.6 – 120.1) and 608.9 ng/mL (95% CI, 483.5 – 736.2 
ng/mL) compared to 100.2 ng/mL-1•min-1•[10% RBC]-1 (95% CI, 95.17 – 105.2) and 
699.6 ng/mL ( 95% CI, 594.5 – 804.7 ng/mL) for the seven day old blood that was stored 
at 4 ˚C for seven days. 
 
 
Figure 32. BEN (5000 ng/mL) in RBCs over time. Lot D (■), Lot E (♦), Lot F (●), Lot G (▲), Lot 
H (-), Lot I (x), and Lot G after stored at 4 C for one week (∆). 
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Figure 33. BEN (400 ng/mL) in RBCs over time. Lot D (■), Lot E (♦), Lot F (●), Lot G (▲), Lot 
H (-), Lot I (x), and Lot G after stored at 4 C for one week (∆). 
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Table 4. Km and Vmax of BEN in six different lots of human blood 
Lot 1 (D)   SE (CV%) Confidence interval (95%) 
Km 196.3 8.399 [  161.7    ,   230.9    ] 
Vmax 65.44 4.288 [  59.54    ,   71.34    ] 
V400 2.117 7.253 [  1.795    ,   2.440    ] 
V5000 1.264 4.992 [  1.132    ,   1.397    ] 
Cl 0.333 5.585 [ 0.2942    ,  0.3725    ] 
  
  
  
Lot 2 (E)   SE (CV%) Confidence interval (95%) 
Km 319.5 4.457 [  289.6    ,   349.4    ] 
Vmax 87.42 1.125 [  85.35    ,   89.49    ] 
V400 1.308 4.934 [  1.172    ,   1.443    ] 
V5000 1.112 2.521 [  1.053    ,   1.170    ] 
Cl 0.2736 3.643 [ 0.2527    ,  0.2946    ] 
  
  
  
Lot 3 (F)   SE (CV%) Confidence interval (95%) 
Km 256.2 5.414 [  227.1    ,   285.4    ] 
Vmax 72.27 2.236 [  68.88    ,   75.67    ] 
V400 1.373 4.85 [  1.233    ,   1.513    ] 
V5000 1.186 3.158 [  1.107    ,   1.264    ] 
Cl 0.282 3.978 [ 0.2585    ,  0.3056    ] 
  
  
  
Lot 4 (G)   SE (CV%) Confidence interval (95%) 
Km 609.8 10.04 [  483.5    ,   736.2    ] 
Vmax 113.4 2.865 [  106.6    ,   120.1    ] 
V400 0.9553 9.802 [ 0.7620    ,   1.149    ] 
V5000 0.8099 5.924 [ 0.7109    ,  0.9090    ] 
Cl 0.1859 7.653 [ 0.1565    ,  0.2152    ] 
  
  
  
Lot 5 (H)   SE (CV%) Confidence interval (95%) 
Km 481.8 7.136 [  410.8    ,   552.8    ] 
Vmax 76.5 2.063 [  73.24    ,   79.76    ] 
V400 1.05 6.87 [ 0.9008    ,   1.198    ] 
V5000 1.168 3.209 [  1.091    ,   1.245    ] 
Cl 0.1588 5.253 [ 0.1416    ,  0.1760    ] 
  
  
  
Lot 6 (I)   SE (CV%) Confidence interval (95%) 
Km 371.2 7.729 [  312.0    ,   430.5    ] 
Vmax 68.16 1.811 [  65.61    ,   70.71    ] 
V400 1.405 8.624 [  1.155    ,   1.655    ] 
V5000 1.063 4.026 [ 0.9745    ,   1.151    ] 
Cl 0.1836 6.142 [ 0.1603    ,  0.2068    ] 
  
  
  
Lot 4 (G) 
old   SE (CV%) Confidence interval (95%) 
Km 699.6 7.276 [  594.5    ,   804.7    ] 
Vmax 100.2 2.416 [  95.17    ,   105.2    ] 
V400 0.8615 6.687 [ 0.7426    ,  0.9804    ] 
V5000 0.9246 3.679 [ 0.8544    ,  0.9948    ] 
Cl 0.1432 5.145 [ 0.1280    ,  0.1584    ] 
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3.4.9 Immunoprecipitation of RBCs 
We performed immunoprecipitation of RBCs with antibodies for ALDH1A1. The 
purpose was to precipitate the ALDH1A1 enzyme, rendering it inactive and implicate it 
in the metabolism of BEN by RBCs. Despite our best efforts, however, the control RBC 
experiment with no antibodies added would not metabolize BEN after being subjected to 
the immunoprecipitation procedure. In an attempt to preserve metabolism of BEN with 
RBCs, we varied the amount of protease inhibitors and concentration of the different 
buffer used, without success. 
 
3.4.10 Western blot 
To determine whether RBCs have ALDH1A1 and to test whether the ALDH1A1 
antibody used for the immunoprecipitation experiment would bind to the enzyme we 
performed a western blot assay. The western blot showed a band in the 55 kD region, 
which is the size of ALDH1A1 enzyme (55 kD). The intensity of the band increased with 
the addition of more protein (Figure 34). 
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Figure 34. Western blot of ALDH1A1 from human RBCs. Lanes from left: lane 1 – ladder 
(49.9kDa), lanes 2 and 3 - blank, lanes 4 and 5 - 80 µg protein, 6 and 7 - 40 µg protein, 8 and 9 - 20 µg 
protein, lanes10 and 11 - 10 µg protein, and lane 12 ladder (49.9 kDa). 
 
 
3.4.11 Metabolism using purified ALDH 
To determine if ALDH is responsible for the metabolism of BEN we assessed the 
metabolism of BEN with the commercially available isoforms of ALDH. These included 
ALDH1A1, 2, 3A1 and 5A1. In addition, we studied the metabolism of BEN with 
ALDH1A1 in the presence of antibodies of 1A1 and disulfiram in order to inhibit the 
metabolism of BEN. ALDH1A1 was the only isoform that showed the ability to 
metabolize BEN. In three independent experiments the rate of disappearance of BEN was 
0.172, 0.224 and 0.154 ng/min/µg of enzyme (Figure 35, Figure 37, and Figure 39). Also 
in these experiments, BA was generated as BEN concentrations decreased (Figure 36, 
Figure 38, and Figure 40). Disulfiram did not inhibit the reaction of ALDH1A1. This is 
likely due to the fact that disulfiram is inactivated by the dithiothreitol present in the 
reaction mixture, thereby preventing it from inhibiting ALDH. Furthermore, the addition 
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of 100x of the ALDH1A1 and IgG antibodies did not inhibit the metabolism of purified 
ALDH1A1 (Figure 41 and Figure 42). 
 
 
 
 
Figure 35. Metabolism of BEN by purified human ALDH1A. ALDH1A1 (■) and no enzyme (□). 
Each point is the average of three measurements. 
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Figure 36. Generation of BA when BEN is added to purified human ALDH1A1. ALDH1A1 (■) 
and no enzyme (□). Each point is the average of three measurements. 
 
 
Figure 37. Metabolism of BEN by purified human ALDH1A. ALDH1A1 (■) and no enzyme (□). 
Each point is the average of three measurements. 
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Figure 38. Generation of BA when BEN is added to purified human ALDH1A1. ALDH1A1 (■) 
and no enzyme (□). Each point is the average of three measurements. 
 
Figure 39. Metabolism of BEN by purified human ALDH1A. ALDH1A1 (■) and no enzyme 
(□).Each point is the average of three measurements. 
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Figure 40. Generation of BA when BEN is added to purified human ALDH1A1. ALDH1A1 
(■) and no enzyme (□).Each point is the average of three measurements. 
 
Figure 41. Metabolism of BEN by purified human ALDH1A. ALDH1A1 (■), no enzyme (□), 
ALDH1A1 with ALDH1A1 antibody (▲), and ALDH1A1 with IgG antibody (∆). Each point is the 
average of three measurements. 
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Figure 42. Generation of BA when BEN is added to purified human ALDH1A1. ALDH1A1 (■),  
no enzyme (□), ALDH1A1 with ALDH1A1 antibody (▲), and ALDH1A1 with IgG antibody (∆). Each 
point is the average of three measurements. 
 
Figure 43. BEN metabolism with purified human ALDH2. ALDH2 (■) and no enzyme (□).Each 
point is the average of three measurements. 
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Figure 44. BEN metabolism with purified human ALDH3A1. ALDH3A1 (■) and no enzyme (□). 
Each point is the average of three measurements. 
 
Figure 45. BEN metabolism with: purified ALDH1A1 (■), no enzyme (∆), purified ALDH1A1 
and no NAD (□), and purified ALDH5A1 (●). 
 
 
10
100
0 15 30 45
B
E
N
 (
n
g
/m
L
) 
Time (min) 
10
100
0 20 40 60
B
E
N
 (
n
g
/m
L
) 
Time (min) 
 120 
 
3.4.12 Positive controls using purified ALDH isoforms on spectrophotometer 
To ensure that the purified ALDH isoforms that were obtained were active, we 
performed metabolism of purified ALDH2, 3A1 and 5A1. In all cases, the purified 
enzymes showed activity, whereas the control samples, which contained enzyme but no 
substrate, did not show activity. (Figure 46, Figure 47, Figure 48). 
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Figure 46. Measurement of the reduction of NAD to NADH by the activity of 
ALDH2. ALDH2 (■) and no enzyme (□).  
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Figure 47. Measurement of the reduction of NAD to NADH by the activity of ALDH3A1. 
ALDH3A1 (■) and no enzyme (□). 
 
 
 
Figure 48. Measurement of the reduction of NAD to NADH by the activity of ALDH5A1. 
ALDH5A1 (■) and no enzyme (□). 
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3.5 DISCUSSION 
BEN is an alkylating agent currently being investigated in phase I clinical trials. 
BEN has structural similarities to both busulfan and melphalan. As with related 
alkylators, we have previously shown that BEN undergoes hydrolysis in blood and 
plasma.
144
 In whole blood, but not in plasma, BEN is rapidly converted to its carboxylic 
acid analogue BA, suggesting conversion by an enzyme present in red blood cells. In 
plasma, BEN and BA decompose according to a parallel pathway to a number of 
hydroxylated and chlorinated analogues, as depicted in Figure 13 chapter 2. The half-life 
of BA in plasma is very short ~5 min compared to BEN. We hypothesize that BA is more 
reactive than BEN because the unbound electron pair on the aniline nitrogen in BA is the 
initiator of an SN2 attack on the β-carbon, generating the reactive aziridinium 
intermediate. Mesomeric withdrawal of the aniline unbound electron pair by the para-
aldehyde moiety on BEN would be expected to decrease the generation of the aziridinium 
intermediate and thereby decrease the reactivity.  
We previously determined that some of the BEN and BA analogues displayed 
activity against renal carcinoma cells. In addition, we showed that the generation of BA 
from BEN in renal carcinoma cell lines correlates with ALDH activity and IC50 values. 
This led us to hypothesize that the enzyme responsible for the conversion in blood and 
renal carcinoma cells is ALDH. These data suggest that BEN is a pro-drug that requires 
intracellular activation to the highly reactive BA, which likely exerts rapid and localized 
damage via alkylation inside the cells. 
In order to better understand the pharmacology of BEN, we aimed to characterize 
the enzyme responsible for the conversion of BEN to BA. This was done by evaluating 
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the metabolism of BEN in RBCs, determining the apparent Vmax and Km in blood, 
performing inhibition studies in RBCs and lastly by performing the metabolism of BEN 
by purified isoforms of ALDH. 
We tested the effect that different concentrations of RBCs had on the rate of BEN 
metabolism. This was done to determine the suitable amount of RBCs for timed 
metabolism experiments. Also, we obtained units of blood for metabolism experiments 
from the central blood bank. Individuals differ in the percentage of RBCs in whole blood, 
or hematocrit. Generally, the hematocrit range for females is 37 to 47% and for men 42 to 
52%.
153
 The goal was to show an appreciable amount of BEN metabolism in a thirty 
minute incubation time and to have the same amount of RBCs in all reaction mixtures. 
We performed BEN metabolism with 0.1, 1 and 10% RBCs and determined that 10% 
RBC in plasma was adequate for future metabolism studies. 
 Our laboratory has previously performed BEN metabolism experiments with 
mouse liver microsomes. These experiments showed that BEN was not a substrate for 
CYP450s. Carbon monoxide binds tightly to heme groups in P450s rendering them 
ineffective for metabolism. We evaluated the metabolism of BEN in the presence of 
carbon monoxide gas and the metabolism was not slowed compared to control.  ALDH 
and AO are the two major enzyme types that are responsible for the conversion of 
aldehydes to carboxylic acids. Disulfiram is an irreversible inhibitor of several ALDHs 
including ALDH1A1, the major isoform of ALDH in RBCs, and menadione is an 
inhibitor of AO. We evaluated the metabolism of BEN in RBCs in both the presence of 
disulfiram or menadione. Disulfiram almost completely inhibited BEN metabolism, while 
menadione inhibited the metabolism no more than the DMSO control. 
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 We evaluated the metabolism of BEN in RBCs that were lysed to determine 
whether a complete red blood cell was needed for metabolism. Lysed RBCs did not 
metabolize BEN, which is most likely due to dilution of the necessary cofactors that 
occurs in the lysing process. Adding NADH to lysed RBCs restored the metabolism of 
BEN. 
The apparent Vmax and Km of BEN were determined in 6 different lots of blood to 
evaluate biological central tendency and variability. BEN displayed saturable kinetics. 
We found that there was inter-subject variability between the lots of blood. The %CV for 
Vmax and Km were 22% and 41%, respectively, for the 6 lots of blood analyzed. This is 
not surprising as the inter-individual biological variability for the quantity of certain 
enzymes can be as much as 73 percent and the inter-individual activity of e.g. CYP3A4 
can range from 200 to 300 percent.
154,155
 In addition, there are two known polymorphism 
of ALDH1A1, ALDH1A1*2 and ALDH1A1*3.
156
 These polymorphisms occur in 7% 
percent of the population and are responsible for reduced enzymatic activity.
157
 Although 
there was variability, all lots of blood displayed Km values above 16 ng/mL and 197 
ng/mL which were the average Cmax concentrations in mice that were either dosed with 
20 mg/kg BEN alone or with 300 mg/kg ip of disulfiram before 20 mg/kg BEN in our 
recent study. A dose of 20 mg/kg in mouse is equivalent to 60 mg/m
2
. The patients in the 
clinical study will start at a dose of 1.5 mg/m
2
 which is 40 times less than the mice 
received. Thus we would expect linear kinetics of BEN in humans. 
 To determine if the ALDH1A1 enzyme was present and that the antibodies used 
recognized ALDH1A1 we performed a western blot assay using lysed RBCs. The 
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antibodies used did prove to be effective as ALDH1A1 was detected using the western 
blot assay.  
 To test whether ALDH1A1 is responsible for the metabolism of BEN in RBCs we 
performed immunoprecipitation experiments. The intent was to precipitate the 
ALDH1A1 enzyme from RBCs and perform metabolism experiments. The 
immunoprecipitation procedure proved to render the control RBCs ineffective for 
metabolism. We attempted to modify the immunoprecipitation procedure by changing the 
concentration of buffers used, with and without protease inhibitors and varying 
incubation times. These attempts proved to be fruitless as the positive control sample was 
never effective in metabolizing BEN. 
We performed the metabolism of BEN with the purified ALDH enzymes that 
were commercially available. These included ALDH1A1, 3A1, 2 and 5A1. BEN was 
only a substrate for ALDH1A1. We also performed the metabolism of BEN with purified 
ALDH1A1 in the presence of 1A1 antibody, which was successful in binding the enzyme 
as evidenced by the western blot experiments. The ALDH1A1 antibody was not able to 
inhibit the reaction, which is possible if the antibody binds to an ALDH1A1 epitope 
without hindering ALDH1A1 metabolic activity. Also, adding disulfiram to the reaction 
mixture did not slow the metabolism. Dithiothreitol, which is a reducing agent that is 
required in the reaction mixture to reduce ALDH, also reduces disulfiram thereby 
rendering it ineffective as an inhibitor. 
 In conclusion, BEN has shown activity both in vitro and in vivo and is currently in 
phase I clinical trials. We hypothesize that BEN is actually a prodrug and that its main 
metabolite BA is more reactive and responsible for the alkylating activity. We have 
 126 
 
previously demonstrated that the conversion of BEN to BA occurs in RBCs. In the 
current chapter we have demonstrated that ALDH1A1 likely is the enzyme that is 
responsible for this conversion. This could have implications as there are drugs that are 
known to inhibit ALDH1A1 such as disulfiram and metronidazole and also seven percent 
of the population has polymorphic ALDH1A1. Since patients that have polymorphic 
ALDH1A1 might not be able to metabolize BEN to BA in tissues, BEN may be less 
effective in these subjects Special consideration should be given when dosing patients in 
these circumstances. In addition, since BA is the more active species which is generated 
by ALDH1A1 metabolism, cancers that are known to over express this enzyme such as 
certain lung and ovarian tumors may be a target for BEN. It is noteworthy to mention that 
tumor stem cells have been found to over express ALDH1A1 and that BEN may be an 
ideal candidate for these cells as well. 
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4.0  EFFECTS OF THE ALDEHYDE DEHYDROGENASE INHIBITOR 
DISULFIRAM ON THE PLASMA PHARMACOKINETICS, METABOLISM, 
AND TOXICITY OF BENZALDEHYDE DIMETHANE SULFONATE 
(NSC281612, DMS612, BEN) IN MICE. 
 
 
 
 
 
 
 
 
 
Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, 
Smith CA, Eiseman JL. Effects of the aldehyde dehydrogenase inhibitor disulfiram 
on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde 
dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Cancer Chemother 
Pharmacol. 2013 Sep 24. [Epub ahead of print] 
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4.1 ABSTRACT 
Benzaldehyde dimethane sulfonate (DMS612, NSC281612, BEN) is an alkylator 
with activity against renal cell carcinoma, currently in phase I trials. In whole blood, 
BEN is rapidly metabolized into its highly reactive carboxylic acid (BA), presumed to be 
the predominant alkylating species. We hypothesized that BEN is metabolized to BA by 
aldehyde dehydrogenase (ALDH) and aimed to increase BEN exposure in blood and 
tissues by inhibiting ALDH with disulfiram thereby shifting BA production from blood to 
tissues. 
Female CD2F1 mice were dosed with 20 mg/kg BEN iv alone or 24 h after 300 
mg/kg disulfiram ip. BEN, BA and metabolites were quantitated in plasma and urine, and 
organ toxicities were assessed. 
BEN had a plasma t½ <5 min and produced at least 12 products. The metabolite 
half-lives were <136 min. Disulfiram increased BEN plasma exposure 368-fold, (AUC0-
inf from 0.11 to 40.5 mg•min/L), while plasma levels of BA remained similar. Urinary 
BEN excretion increased (1.0 to 1.5% of dose) while BA excretion was unchanged. 
Hematocrit, white blood cells counts and % decrease in lymphocytes all decreased 
after BEN administration, while co-administration of disulfiram appeared to enhance 
these effects. Profound liver pathology was observed in mice treated with disulfiram and 
BEN.   
BEN plasma concentrations increased after administration of disulfiram, 
suggesting that ALDH mediates the rapid metabolism of BEN in vivo, which may explain 
the increased toxicity seen with BEN after administration of disulfiram. Our results 
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suggest that the co-administration of BEN with drugs that inhibit ALDH or to patients 
that are ALDH deficient may cause liver damage. 
4.2 INTRODUCTION 
Approximately 13,000 people die from metastatic renal cell carcinoma (mRCC) 
in the United States every year.
1,143
 Only a small minority of patients achieve durable 
complete remission with high dose interleukin-2 cytokine therapy.
94,128
 Recently 
developed agents targeting the vascular endothelial growth factor or the mTOR pathway 
have shown clinical activity.
94,128,129
 However, responses to these novel agents are 
generally not durable,
130
 and there remains a need for new treatments of mRCC. 
Benzaldehyde dimethane sulfonate (dimethane sulfonate, BEN, DMS612, 
NSC281612) has structural similarities to busulfan, melphalan and chlorambucil, and is 
presumed to be a bifunctional alkylating agent. COMPARE analysis suggested that the 
mechanism of action of BEN overlapped with that of chlorambucil.
124
 However, unlike 
conventional bifunctional alkylating agents, BEN demonstrated specific activity against 
renal carcinoma cells in the NCI 60 cell line screen.
124
 In vitro, BEN treatment resulted in 
S and G2/M cell cycle arrest.
124
  BEN has demonstrated anti-tumor activity in mice with 
orthotopic renal cell carcinoma xenografts. Specifically, BEN showed significant activity 
against human 786-0 and ACHN renal cell tumors when administered to mice on a q4dx5 
schedule.
131
  Treatment of mice bearing orthotopically implanted, human RXF-393 renal 
carcinoma cell xenografts with BEN resulted in >70% cure rate whereas busulfan showed 
no activity.
131
 In addition, treatment with BEN slowed the growth of A498 human renal 
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cell cancer xenografts.
131
 It was hypothesized that BEN’s activity against renal carcinoma 
cells may be due in part to the hydrophobic moiety in the molecule which allows BEN to 
pass through the cell membrane or due to its sequence specificity for DNA alkylation.
124
 
The fact that BEN has displayed significant in vitro and in vivo activity against renal 
carcinoma cells and tumor xenografts has led to the evaluation of BEN in an ongoing 
NCI-sponsored phase I clinical trial (clinicaltrials.gov NCT00923520). 
We have shown that in plasma, BEN is chemically converted into 6 different BEN 
analogs. Further, our previous studies suggest that BEN is rapidly metabolized into its 
benzoic acid analogue (BA) by red blood cells, presumably through aldehyde 
dehydrogenase (ALDH) activity.
144
 Preliminary studies in mice suggest that BEN is 
metabolized into at least 12 different BA products,
144
 and has a very short plasma half-
life.  
ALDHs are NAD(P)+ dependent enzymes that metabolize both aromatic and 
aliphatic aldehydes into carboxylic acids.
146
 Disulfiram (trade name Antabuse) is an 
irreversible inhibitor of ALDH and is prescribed to treat chronic alcoholism.  
We showed that BA reacts faster with nucleophiles than BEN, and may therefore 
be an important effector of DNA alkylation.
144
 The conversion of BEN to BA by RBCs is 
likely an activation step. However, the short half-life of BA may limit the ability of BA 
generated in RBCs to reach and alkylate tumor DNA. Therefore, a more prolonged and 
slower generation of BA from BEN, partly in tissues as opposed to primarily in RBCs, 
might increase the effects of BEN. The purpose of this study was to determine the 
pharmacokinetics and metabolism of BEN after iv administration in mice and to test our 
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hypothesis that inhibition of ALDH with disulfiram increases the exposure to BEN and 
thereby increases its effects in mice. 
 
 
4.3 MATERIAL AND METHODS 
4.3.1 Chemical and reagents 
4-[bis[2-[(methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzaldehyde (NSC 
281612, BEN), 4-[bis[2-[(methylsulfonyl)-oxy]ethyl]amino]-2-methyl-benzoic acid 
(BA), 4-[bis[2-chloro-ethyl]amino]-2-methyl-benzaldehyde (BEN-Cl2), 4-[bis[2-chloro-
ethyl]amino]-2-methyl-benzoic acid (BA-Cl2),  4-[bis[2-[(methylsulfonyl)-
oxy]ethyl]amino]-benzaldehyde (demethyl-BEN), and 4-[bis[2-chloro-ethyl]amino]-
benzaldehyde (demethyl-BEN-Cl2) were obtained from the Developmental Therapeutics 
Program, National Cancer Institute (NCI, Bethesda, MD). 4-[bis[2-hydroxy-
ethyl]amino]-2-methyl-benzaldehyde (BEN-(OH)2) and 4-[bis[2-hydroxy-ethyl]amino]-
2-methyl-benzoic acid (BA-(OH)2) were generated as previously described in chapter 2. 
Tetraethylthiuram disulfide (disulfiram) and gum arabic were acquired from 
Sigma Chemical Co. (St. Louis, MO).  PBS and saline were purchased from Fisher 
Scientific Co. (Fair Lawn, NJ). Hydroxypropyl-β-cyclodextran was obtained from The 
National Cancer Institute (NCI) Chemotherapeutics Repository (Bethesda, MD). All 
solvents used for LC-MS/MS were high purity Burdick & Jackson and purchased from 
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Fisher Scientific Co. Formic acid was purchased from Sigma Chemical Co. Nitrogen gas 
for the mass spectrometer was purified with a Parker Balston Nitrogen Generator 
(Haverhill, MA), and nitrogen gas for sample evaporation was purchased from Valley 
National Gases, Inc. (Pittsburgh, PA). 
 
4.3.2 Animals 
Specific-pathogen-free, adult CD2F1 female mice were purchased from Charles 
River Laboratory (Wilmington, MA). Mice were allowed to acclimate to the University 
of Pittsburgh Cancer Institute Animal Facility for ≥1 week before being used for study. 
Mice were maintained in micro-isolator cages in a separate room and handled in 
accordance with the Guide for the Care and Use of Laboratory Animals (National 
Research Council, 1996) and on a protocol approved by the Institutional Animal Care and 
Use Committee of the University of Pittsburgh. Ventilation and airflow were set to 12 
changes per h. Room temperatures were regulated at 22±1 °C, and the rooms were kept 
on automatic 12-h light/dark cycles. Mice received Prolab ISOPRO RMH 3000 Irradiated 
Lab Diet (PMI Nutrition International, St. Louis, MO) and water ad libitum, except on 
the evening before dosing, when all food was removed. Mice were 6–8 weeks old and 
weighed approximately 20 g at the time of dosing. Sentinel animals were maintained in 
the room housing study mice and assayed at 3-month intervals for specific murine 
pathogens by mouse antibody profile testing (Charles River, Boston, MA). Sentinel 
animals remained free of specific pathogens, indicating that the study mice were 
pathogen free. 
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4.3.3 Pharmacokinetic Study design 
Mice were dosed iv with 20 mg/kg BEN alone or 24 h after ip administration of 
300 mg/kg disulfiram, as described before.
158
 BEN was formulated in a 20% solution of 
hydroxypropyl-β-cyclodextran (HPβCD) in water and disulfiram was formulated as a 
suspension in 5% (w/v) gum arabic in PBS at a concentration of 30 mg/mL. 
After administration of BEN, mice (three per time point) were euthanized with 
CO2 at multiple time points between 5 and 1440 min. Control animals received vehicle 
alone (0.01 mL/g fasted body weight) and were euthanized at 5 and 1440 min after 
dosing. Blood was collected by cardiac puncture in heparinized syringes and centrifuged 
for 4 min at 12,000×g at 4 °C to obtain plasma. A 200 µL aliquot of the resulting plasma 
was pipetted into a microcentrifuge tube containing 10 µL of 2 M H2SO4 and briefly 
vortexed to ensure stabilization of the analytes of interest. Plasma samples were stored at 
−70 °C until analysis. 
 
4.3.4 Urinary excretion 
Mice scheduled for euthanasia at 24 h after dosing were kept in metabolic cages. 
Urine was collected into tubes containing 2 M H2SO4 estimated to yield 5% acid by 
volume. At the end of the collection period, cages were washed with 15 mL of sterile 
water, and 2 M H2SO4 was added to all tubes in a ratio of 5 parts acid to 95 parts urine. 
Quantitation of analytes in urine and cage wash was accomplished by diluting an aliquot 
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of each sample (between 10 and 100-fold) with control plasma followed by quantitation 
relative to a plasma standard curve. 
 
4.3.5 Bioanalysis 
BEN, BEN-Cl2, BA, BA-Cl2, BEN-(OH)2 and BA-(OH)2 were quantitated by LC-
MS/MS as previously described.
159
 For intermediate metabolites (BEN-OH, BEN-Cl, 
BEN-Cl-OH, BA-OH, BA-Cl, and BA-Cl-OH), and glucuronide conjugates, for which 
there were no reference standards available, the resulting analyte peak area was divided 
by the internal standard and the resulting ratio was converted to BEN equivalents by 
back-calculation using the BEN response equation. This assay, developed in human 
plasma, was modified for mouse plasma. Control murine plasma (Lampire, Pipersville, 
PA) resulted in linear, accurate, and precise calibration curves for all analytes. However, 
when control Lampire plasma was used to quantitate quality control samples prepared in 
control study mouse plasma, the accuracy was inadequate. Further inspection of the data 
showed that this was due to a plasma source specific internal standard response, and that 
the assay displayed adequate performance when peak areas were not corrected by internal 
standard responses, suggesting a difference in matrix effect between commercially 
available control Lampire plasma and plasma obtained from our study mice. 
Consequently, all unknown plasma samples were assayed relative to a calibration curve 
prepared in control plasma obtained from untreated study mice to assure generation of 
accurate data. Sample dilution to within the linear range was also performed with control 
plasma from study mice. 
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4.3.6 Pharmacokinetic analysis 
The maximum plasma concentration (Cmax) and the time to reach Cmax (Tmax) were 
determined by visual inspection of the plasma concentration versus time data. Other 
pharmacokinetic parameters were calculated non-compartmentally using PK Solutions 
2.0 (Summit Research Services, Montrose, CO http://www.summitPK.com). The area 
under the plasma concentration versus time curve (AUC) of all analytes was calculated 
with the log-linear trapezoidal rule. Renal clearance was calculated by dividing the 
absolute amount of analyte excreted in urine by the plasma AUC0–t of the respective 
analyte. 
 
4.3.7 Data analysis 
Statistical analysis of AUC0–t values consisted of the BEN alone to BEN with 
disulfiram pretreatment AUC ratio with the associated standard error (SE).  After log-
transformation, these ratios were subjected to a two-sided Students t-test, under the null 
hypothesis of log (AUC-ratio)=0. A value of p<0.05 was considered statistically 
significant, as described previously.
160
 This approach is similar to that described by 
Bailer et al.
161
 However, instead of using a z-test, we applied a more conservative t-test 
with 2 degrees of freedom (N=3 samples per time point). 
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4.3.8 Pathology Study 
Mice, treated with a single dose of disulfiram alone at 300 mg/kg ip in gum arbic, 
BEN alone at either 20 mg/kg (the maximum tolerated dose) or 15 mg/kg iv, or mice 
treated with 300 mg/kg ip disulfiram 24 h prior to BEN at 20 and 15 mg/kg iv or the 
combination of vehicles (20% HPβCD or PBS (0.01 ml/g body weight)), were followed 
for 30 days after treatment. Mice were euthanized with CO2 and bled by cardiac puncture 
one month after treatment. Complete gross necropsies were performed, livers were 
removed, weighed, and a portion of the medial lobe of each liver was placed in 10% 
phosphate buffered formalin, fixed, paraffin embedded, cut into 5 µm sections, processed 
and stained with hematoxylin and eosin. 
 
4.3.9 Blood Counts 
Blood was collected by orbital sinus bleed or by tail vein bleed from the treated 
mice for at least 14 days following treatment with disulfiram, BEN or the combination 
using a potassium EDTA coated microhematocrit tube and run on a Scil Vet abc 
Veterinary Hematology Analyzer (Scil Animal Care Company, Gurnee, IL, 60031) to 
count platelets, white blood cells and lymphocytes. Hematocrit as percentage was 
determined with a micro hematocrit centrifuge by measuring the packed red cell height, 
dividing by the total height, and multiplying by 100. 
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4.4 RESULTS 
This study was conducted to determine if BEN is metabolized to BA by aldehyde 
dehydrogenase (ALDH) and if BEN exposure could be increased by inhibiting ALDH 
with disulfiram in blood and tissues thereby increasing BA production in tissues that 
express ALDH. 
In order to measure the analytes generated when BEN is administered to mice we 
developed an LC-MS/MS assay. The assay for BEN and BA and analytes with known 
standards had a lower limit of detection of 1 ng/mL for all analytes and was accurate and 
precise from 10 to 1,000 ng/mL (Table 5) and the correlation coefficient (R
2
) was > 0.97 
for all analytes. 
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Table 5. Assay performance of BEN, BEN-Cl2, BEN-(OH)2, BA, BA-Cl2 and BA-(OH)2 from two 
duplicate standard curves. 
 
 
There were 12 different metabolites detected in both the mice to which BEN had 
been administered alone and those to which BEN had been administered after disulfiram 
pretreatment. The plasma concentration-versus-time profiles are shown in Figure 49, 
Figure 50, and Figure 51.  Pharmacokinetic parameters associated with these profiles are 
displayed in Table 6 and Table 7.   
BEN Mean Precision Accuracy BA Mean Precision Accuracy
ng/mL  (%)  (%) ng/mL  (%)  (%)
10 9.5 7.7 95.0 10 11.0 12.1 110.2
30 25.7 9.1 85.7 30 30.0 13.9 99.9
100 113.3 6.4 113.3 100 116.5 5.5 116.5
300 335.0 9.3 111.7 300 316.5 8.4 105.5
500 526.0 6.6 105.2 500 460.8 8.0 92.2
750 856.8 14.9 114.2 750 758.8 10.6 101.2
1000 985.8 3.3 98.6 1000 923.3 5.1 92.3
BEN-di-Cl Mean Precision Accuracy BA-di-Cl Mean Precision Accuracy
ng/mL  (%)  (%) ng/mL  (%)  (%)
10 10.7 9.3 106.8 10 9.9 8.4 97.7
30 25.4 9.5 84.6 30 33.1 11.0 97.0
100 113.5 16.8 113.5 100 124.0 2.1 119.3
300 340.8 15.6 113.6 300 336.8 1.5 106.2
500 510.3 5.8 102.1 500 471.8 5.4 96.8
750 795.0 8.0 106.0 750 719.0 6.6 106.1
1000 1035.3 8.4 103.5 1000 868.0 2.6 94.6
BEN-di-OH Mean Precision Accuracy BA-di-OH Mean Precision Accuracy
ng/mL  (%)  (%) ng/mL  (%)  (%)
10 10.6 9.1 106.1 10 9.8 15.0 98.8
30 27.3 14.7 90.8 30 29.1 8.8 110.2
100 119.8 26.1 119.8 100 119.3 1.4 124.0
300 332.3 17.1 110.8 300 318.5 9.5 112.3
500 518.8 7.6 103.8 500 484.0 8.0 94.4
750 872.5 24.3 116.3 750 796.0 8.5 95.9
1000 1047.0 11.5 104.7 1000 946.0 5.3 86.8
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Figure 49. Concentration vs. time profile of BEN and quantitatable metabolites in mouse plasma. 
(A) BEN, (B) BA, (C) BA-Cl2, and (D) BA-OH2. (■) represents BEN administered alone and (□) represents 
BEN administered after disulfiram. Each point is the mean (±SD) of three mice. 
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Figure 50. BEN equivalents vs. time profile of BEN metabolites. (A) BA-Cl-OH, (B) BA-Cl, and 
(C) BA-OH. (■) represents BEN administered alone and (□) represents BEN administered after disulfiram. 
Each point is the mean (±SD) of three mice. 
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Figure 51. BEN equivalents vs. time profile of BA glucuronide metabolites. (A) BA-Gluc, (B) 
BA-Cl-Gluc, (C) BA-Cl-OH-Gluc, (D) BA-Cl2-Gluc (E) BA-OH-Gluc and, (F) BA-(OH)2-Gluc. (■) 
represents BEN administered alone and (□) represents BEN administered after disulfiram. Each point is the 
mean (±SD) of three mice. The appearance of a second peak level is a possible indication of enterohepatic 
recycling.  
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Table 6. Non-compartmental plasma pharmacokinetic parameters of BEN and metabolites 
generated from the mouse PK experiments. Parameters followed by an asterisk (*) represent the experiment 
in which disulfiram was administered to the mice before BEN. In order to calculate statistical significance 
AUC0-t values were compared at the same end time point in each study. AUC values followed by t denotes 
a p<0.05. ND: not determined, the parameter could not be defined due to fluctuation in the terminal phase 
concentrations. F is the fraction of BEN metabolized and F is not known. 
Parameter BEN BA BA-(OH)2 BA-Cl2 
BA-Cl 
(BEN Eq) 
BA-OH 
(BEN Eq) 
BA-Cl-OH 
(BEN Eq) 
Cmax (ng/mL)                 
Cmax (ng/mL)* 
16         
197 
17967 
11700 
327     
473 
48          
46 
440          
387 
847           
851 
185                
229 
Tmax (min)                     
Tmax (min)* 
5             
5 
5                       
5 
10         
10 
30                
30 
5                
10 
5                  
5 
5                
5 
Half-life (min)                    
Half-life (min)* 
1.5                      
5.2 
55                        
42 
29     
34 
136            
*** 
69               
350 
19              
11 
63              
219 
AUC0-t(mg/L•min)           
AUC0-t(mg/L•min)* 
0.11t 
40.5t 
254 
267 
9.66t 
15.3t 
4.41 
4.86 
17.8 
18.1 
15.8 
18.3 
9.21 
11.3 
AUC0-inf(mg/L•min)           
AUC0-inf(mg/L•min)* 
0.11 
40.5 
261              
275 
10.6                 
17.1 
7.01                     
8.93 
19.6             
29.8 
17.7             
21.1 
10.3                 
15.2 
Vd/F (L/kg)                     
Vd/F (L/kg)* 
ND 
120 
ND                      
ND 
ND                  
ND 
ND                    
ND 
ND             
ND 
ND                      
17 
ND                       
ND 
Cl/F (mL/min/kg)             
Cl/F (mL/min/kg)* 
ND 
0.18 
ND             
ND 
ND                     
ND 
ND                
ND 
ND                 
ND 
ND                 
ND 
ND                       
ND 
% dose in urine (0-24 hr)     
% dose in urine (0-24 hr)* 
1                           
1.5 
5.8                 
5.95 
1.36                    
3.30 
0.03
0.22 
0.12 
0.24 
0.55 
0.54 
0.15 
0.43 
Clr mL/min         
Clr mL/min*         
ND 
0.40 
0.22 
0.22 
1.25 
1.92 
0.05 
0.25 
0.06 
0.08 
0.32 
0.27 
0.17 
0.30 
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Table 7. BA glucuronide metabolites in mice from mouse PK experiments. 
Parameter 
BA-
Gluc 
BA-Cl2-
Gluc 
BA-Cl-
Gluc 
BA-Cl-OH-
Gluc 
BA-OH-
Gluc 
BA-(OH)2-
Gluc 
Cmax (ng/mL)             
Cmax (ng/mL)* 
961     
1544 
59            
212 
137         
272 
24                      
85 
155                     
284 
46                       
284 
Tmax (min)          
Tmax (min)* 
5              
15 
60             
15 
10               
15 
30                          
15 
10                   
15 
10                
15 
Half-life (min)                       
Half-life (min)* 
ND                
378 
81               
30 
ND                  
ND 
ND                         
ND 
ND
28 
ND 
44 
AUC0-t(mg/L•min)           
AUC0-t(mg/L•min)* 
12.2 
21.3 
6.06 
8.88 
2.26 
4.28 
0.77 
1.92 
2.47 
5.81 
1.17t 
2.81t 
AUC0-inf(mg/L•min)           
AUC0-inf(mg/L•min)* 
13.8                     
23.1 
3.61                           
9.33 
3.40                       
8.64 
2.27                             
8.11 
ND                           
6.79 
1.93                         
6.54 
Vd/F (L/kg)                     
Vd/F (L/kg)* 
1765                          
269 
ND                    
ND 
ND                         
ND 
ND                                  
ND 
ND
ND 
ND                          
ND 
Cl/F (mL/min/kg)             
Cl/F (mL/min/kg)* 
ND                    
0.49 
ND                                 
ND 
ND                             
ND 
ND                    
ND 
ND
ND 
ND                              
ND 
% dose in urine (0-24 hr)     
% dose in urine (0-24 hr)* 
0.99 
1.48 
0.06 
0.30 
0.17 
0.32 
0.09 
0.29 
0.25 
0.35 
0.21 
0.52 
Clr mL/min         
Clr mL/min*         
0.72 
0.67 
0.15 
0.33 
0.50 
0.38 
0.42 
0.35 
1.20 
0.55 
1.26 
0.83 
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After iv administration of BEN to mice, BEN was rapidly metabolized resulting 
in a Cmax of 16 ng/mL at 5 minutes (Figure 49A) (Table 6). While BEN became 
undetectable at 15 minutes after administration, BA was rapidly generated, had a plasma 
exposure 2300-fold greater than that of BEN, and an apparent half-life of 55 min (Figure 
49B) (Table 6). In addition to BEN and BA, 11 other metabolites including 6 
glucuronides of BA, where detected. The half-lives of the metabolites ranged from 19 
min (BA-OH) to 136 min (BA-Cl2) (Figure 50) (Table 6).  All of the analytes detected in 
plasma were also detected in the urine of the mice collected between 0-6 and 6-24 h after 
dosing with BEN (Table 6 and Table 7). 
Treatment of mice with disulfiram 24 h prior to BEN dosing increased exposure 
to BEN 368-fold. Interestingly, BA exposure was similar in both studies. The half-lives 
of the metabolites ranged from 28 min (BA-OH-Gluc) to 350 min (BA-Cl) (Figure 50 
and Figure 51) (Table 6 and Table 7). Although the exposure of all of the analytes 
appeared to increase after pretreatment with disulfiram only BEN, BA-(OH)2 and BA-
(OH)2-Gluc were found to be statistically different when comparing the AUC0-t between 
BEN administered alone and BEN administered after disulfiram (Table 6 and Table 7). 
All of the analytes detected in plasma were also detected in the urine. 
The untreated mice and vehicle treated mice did not lose body weight. The mice 
treated with disulfiram, BEN or the combination, lost approximately 12% body weight by 
day 4 and regained body weight by day 12. 
The hematocrits, white blood cells and percent lymphocytes decreased following 
treatment in mice receiving BEN alone and disulfiram before BEN (Table 8).  
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Table 8. Hematocrit (%), WBC and %Lymphocytes in mice treated with vehicle, BEN alone or 
disulfiram plus BEN. Each row represents the results of one mouse. 
Treatment Hematocrit (%) WBC (x10
3
 cells/µL) %Lymphocyte 
Day -1 Day 0 Day -1 Nadir (day) Day -1 
Nadir 
(day) Day -1 
Nadir 
(day) 
Vehicle Vehicle 47.8 51.3 (6) 10.7 6.7 (4) 75.8 60.4 (1) 
 
 
 
   
 
 
        
Vehicle 
BEN 20 
mg/kg 45.5 36.5 (4) 9.6 3.1 (4) 71.6 41.9 (8) 
 
 
 
 
 
 
 
 
Disulfiram 
BEN 20 
mg/kg 50.0 39.5(4) 4.5 1.4 (4) 83.0 28.5 (8) 
 
 
 
 
 
 
 
 
Disulfiram 
BEN 20 
mg/kg 43.8 37.0 (6) 6.4 0.4 (4) 72.6 35.5 (6) 
 
 
 
 
 
 
 
 
        
Vehicle 
BEN 15 
mg/kg 48.0 39.5 (6) 5.9 2.7 (4) 81.4 48.1 (8) 
 
 
 
 
 
 
 
 
Disulfiram 
BEN 15 
mg/kg 45.0 41.5 (6) 5.1 3.7 (8) 79.0 33.9 (6) 
 
 
 
 
 
 
 
 
Disulfiram 
BEN 15 
mg/kg 53.0 40.0 (8) 5.8 3.1 (4) 75.2 29.5 (6) 
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The hematocrits reached the lowest level at day either day 4 or 6 when dosed with 
20 mg/kg BEN or day 6 or 8 when dosed with 15 mg/kg BEN. The white blood cell count 
was the lowest on day 4 after dosing except for 1 mouse in which the low point was not 
seen until day eight.  The percent lymphocyte was lowest on either day 6 or day 8 after 
dosing. All values returned to normal by day 14 after dosing. Pretreatment with 
disulfiram before BEN appeared to deepen the percentage lymphocytes nadir compared 
to treatment with BEN alone.  
When mice were euthanized one month after single dose treatment with either 
disulfiram or BEN alone, mild hepatic lesions were present in the mice.  These lesions 
included mild focal thickening of the connective tissue capsule and mild fibrosis within 
few of the portal areas. Hepatic pathology of mice treated with the disulfiram and BEN 
combination were profound and included a regional loss of overall hepatic vascular 
architecture with prominent swelling and clearing of hepatocyte cytoplasm, likely 
associated with areas of regenerative hyperplasia (Figure 52).  The capsule was diffusely 
thickened by increased connective tissue, and scattered lymphoplasmacytic infiltrates 
were observed.  Multiple chronic adhesions existed between the thickened hepatic 
capsule and the omentum. Portal areas were severely expanded by increased fibrous 
connective tissue, hyperplastic bile ducts, and lymphoplasmacytic infiltrates. Mild to 
moderate fibrosis also existed in centrilobular areas. Early bridging fibrosis spanned 
between portal areas and from portal to centrilobular areas (Figure 52). 
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Figure 52. H&E stained liver sections from control, disulfiram-treated, BEN-treated, and 
disulfiram + BEN-treated mice. Only mild hepatic lesions are present in mice treated with either disulfiram 
or BEN alone including slight thickening of the capsule (asterix) and a mild increase in portal fibrous 
connective tissue (arrowhead). Severe lesions in animals treated with a disulfiram + BEN combination 
include swelling and clearing of hepatocytes with a loss of overall hepatic vascular architecture, extensive 
capsular thickening (C), and severe portal fibrosis with bile duct hyperplasia (arrow). 
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4.5 DISCUSSION 
The present investigation was designed to characterize the pharmacokinetics and 
metabolism of BEN in mice, and to assess the effect of ALDH inhibition with disulfiram 
on BEN pharmacokinetics, metabolism, and pharmacodynamics in mice. Previous results 
suggested that BEN is metabolized in vivo and in vitro in blood into BA, presumably by 
the action of ALDH. We have demonstrated that BA reacts faster with nucleophiles than 
BEN, and may therefore be an important effector of DNA alkylation.
144
 The conversion 
of BEN to BA by red blood cells (RBCs) is likely an activation step. However, the short 
in vitro half-life of BA (5 min),
144
 may limit the ability of BA to reach and alkylate tumor 
DNA. Therefore, a more prolonged and slower generation of BA from BEN, partly in 
tissues as opposed to primarily in RBCs, might increase the effects of BEN 
administration. Disulfiram has been used previously in a mouse study for the purpose of 
inhibiting ALDH.
158
 They found that a single 300 mg/kg dose of disulfiram administered 
ip caused the greatest inhibition of both RBC and liver ALDH activity at 24 h post dose 
in which the reductions of ALDH activity in RBC and liver were 81% and 27% 
compared to controls. Thus, we used the same dose of disulfiram 24 h prior to the dosing 
of BEN to ensure the greatest inhibition of ALDH in study mice.  
After iv BEN administration to mice, the exposure to BEN was low and there 
were at least 12 metabolites generated, including 6 BA glucuronides. In contrast, the 
exposure to BA was relatively high and the half-life of BA was 55 min. The plasma half-
life of BA in mice was much longer than the in vitro half-life of BA, (5 min).
144
 The 
possibilities for the longer in vivo half-life of BA may be due to either BA being less 
reactive in vivo or more likely that there is continued production of BA from BEN in 
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tissues which reappears in plasma. Pretreatment with disulfiram increased BEN exposure 
368-fold, suggesting that ALDH may be an enzyme responsible for metabolizing BEN 
into BA. Disulfiram is a non-specific inhibitor of multiple isoforms of ALDH and CYP 
P4502E1.
162-166
 However, while disulfiram did increase BEN exposure, BA was still the 
predominant species and its exposure was not decreased by disulfiram. This could be due 
to a number of factors. First, while disulfiram has been shown to be an effective inhibitor 
of ALDH in RBCs, disulfiram was less effective in inhibiting ALDH in the liver.
158
 This 
difference in inhibition may be explained because RBCs are not able to synthesize de 
novo ALDH, while the liver may synthesize ALDH in the 24 h between the disulfiram 
administration and BEN administration. Further, there are at least 19 different known 
isoforms of ALDH.
146
 It is possible that in tissues BEN is metabolized to BA, in part, by 
an isoform of ALDH that is not inhibited by disulfiram. For instance ALDH1B1 is 
insensitive to inhibition by disulfiram.
167
 
The 6 metabolites and their respective glucuronide conjugates that were observed 
after BEN administration were also observed when BEN was administered after 
disulfiram pretreatment. The plasma exposures of the glucuronides appeared to be higher 
after pretreatment with disulfiram, although the variability was too high to reach 
statistical significance (Table 7). This suggests that the inhibition of RBC ALDH 
increases BEN plasma exposure 368-fold driving greater BEN distribution into tissues 
where it is metabolized to BA. BA is then metabolized to downstream metabolites. In 
contrast, in the mice that were not pretreated with disulfiram, it is likely that the 
conversion of BEN to BA takes place in the RBCs to a greater extent. In this case, BA 
degrades to BA analogs in the blood and these compounds are less likely to enter tissues.  
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Most of the observed metabolites are likely relevant to BEN efficacy and/or 
toxicity because they still possess alkylating side arms.
144
 Bifunctional alkylating agents 
have two side arms consisting of either a ethyl-methane sulfonate or ethyl-chloride that 
are active.
168
 Monofunctional alkylators are much less potent than their bifunctional 
counterparts.
169
 Of the non-glucuronide metabolites observed, BA-Cl2 is bifunctional, and 
three other metabolites are monofunctional. 
In addition, we observed six BA glucuronide metabolites, two of the glucuronides 
are bifunctional and three are monofunctional. It is unclear which glucuronyltransferases 
are responsible for the conjugation of these BA analogues, and this could have an impact 
on BEN safety and efficacy. All of the metabolites that were detected in the plasma were 
also detected in the urine. The percentage of the dose of BEN excreted unchanged in the 
urine was 50% increased after disulfiram pretreatment, although there was only one 
sample analyzed. Biliary or urinary excretion could lead to high local concentrations of 
cytotoxics and result in toxicities. Known examples include ifosfamide and acrolein,
170
 
and irinotecan and SN38(glucuronide).
171
  
Toxicities associated with BEN treatment appear to be similar to those observed 
after treatment with other alkylating agents. After treatment with either busulfan or 
chlorambucil, bone marrow toxicity is observed and the nadir occurs sometime between 
day 4 and day 6 after a single treatment with these agents. The percentage decrease of all 
three measurements (hematocrit, WBC and %lymphocytes) was greater after 
pretreatment with disulfiram as compared to BEN alone. Again this could be due to the 
inhibition ALDH in blood by disulfiram allowing a greater concentration of BEN to 
reach the tissues, such as the bone marrow.  
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Although the pharmacokinetic study was conducted solely to determine the effect 
disulfiram has on the pharmacokinetic parameters of BEN, it was noted upon necropsy of 
the mice that the livers were abnormal. Further evaluation suggested that treating the 
mice with either disulfiram or BEN alone caused mild hepatic lesions, while mice that 
received the combination of disulfiram and BEN had severe and marked changes in the 
liver, as assessed 30 days after treatment.  The cause of greater liver damage upon 
pretreatment with disulfiram may be due to the inhibition of blood ALDH, leading to an 
increase of BEN, and cellular metabolism of BEN to BA in the liver. This finding could 
have implications for the dosing of BEN in subjects: 1) on antabuse (disulfiram) therapy; 
2) using other aldehyde dehydrogenase inhibitors, such as metronidazole;
142
 or 3) with 
aldehyde dehydrogenase deficiencies.  
In conclusion, BEN is rapidly metabolized to BA partly by an ALDH. BA is then 
converted into at least 11 metabolites of which 6 are glucuronides, and most of which are 
expected to have alkylating activity. The plasma half-life of BA in mice was much longer 
than the in vitro half-life of BA, (5 min). This suggest that BEN may enter tissues where 
it is converted to BA by ALDH. Inhibition of ALDH with a single ip dose of disulfiram 
before the administration of BEN slowed the metabolic degradation of BEN, however, 
BA was still the major plasma metabolite. The blood chemistry data and liver pathology 
suggests pretreatment with disulfiram and its inhibition of ALDH in RBCs and/or liver 
may cause more BEN to enter tissues. More local metabolism of BEN to BA, a more 
reactive compound, could lead to more tissue localized damage. This could be relevant to 
patients who are on antabuse therapy, have polymorphic ALDH1A1, or on a drug that 
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inhibits ALDH as these conditions could result in severe liver damage and/or 
exacerbation of BEN toxicities. 
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5.0  THE HUMAN PHARMACOKINETICS OF BEN (NSC281612, DMS612, 
BEN) AS PART OF A FIRST-IN-HUMAN PHASE I CLINICAL TRIAL. 
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5.1 ABSTRACT 
Benzaldehyde dimethane sulfonate (DMS612, NSC281612, BEN) is an alkylator 
with activity against renal cell carcinoma, currently in phase I clinical trials. In whole 
blood, BEN is rapidly metabolized into its highly reactive carboxylic acid (BA), 
presumed to be the predominant alkylating species. We have previously demonstrated 
that ALDH1A1 is the predominant enzyme responsible for the conversion of BEN to BA 
in red blood cells. BEN dosed 20 mg/kg to mice had a plasma t½ <5 min and produced at 
least 12 products. The metabolite half-lives were <136 min. In the current study we 
determined the pharmacokinetics of BEN administered to patients that had solid tumors 
as part of a phase I clinical trial that was conducted to determine the maximum tolerated 
dose (MTD) for future trials. 
BEN was administered to 33 patients with advanced solid tumors as an iv bolus 
dose ranging from 1.5 to 12 mg/m
2
. The maximum tolerated dose was determined to be 
9.0 mg/m
2
, and there were two partial responses. The dose limiting toxicities observed at 
12.0 mg/m
2
 were grade 3 thrombocytopenia and grade 4 neutropenia. Pharmacokinetics 
of BEN and metabolites were calculated non-compartmentally. BEN was detected in only 
2 patients at the earliest time point, and the half-life could not be determined in any of the 
patients. The AUC0-t and Cmax of two of the metabolites BA and BA-(OH)2 increased with 
dose. The Cmax adjusted for dose increased with dose for BA while the BA-(OH)2 Cmax 
adjusted for dose was constant with dose. Apparent clearance (Cl/F) of BA decreased 
with dose while the Cl/F of BA-(OH)2 was unchanged with dose. 
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5.2 INTRODUCTION 
Approximately 13,000 people die from metastatic renal cell carcinoma (mRCC) 
in the United States every year.
1,143
 Only a small minority of patients achieve durable 
complete remission with high dose interleukin-2 cytokine therapy.
128
 Recently developed 
agents targeting the vascular endothelial growth factor or the mTOR pathway have shown 
clinical activity.
128,129,172
 However, responses to these novel agents are generally not 
durable,
130
 and there remains a need for new treatments of mRCC. 
Benzaldehyde dimethane sulfonate (dimethane sulfonate, BEN, DMS612, 
NSC281612) has structural similarities to busulfan, melphalan and chlorambucil (Figure 
53), and is presumed to be a bifunctional alkylating agent. COMPARE analysis suggested 
that the mechanism of action of BEN overlapped with that of chlorambucil.
124
 However, 
unlike conventional bifunctional alkylating agents, BEN demonstrated specific activity 
against renal carcinoma cells in the NCI 60 cell line screen.
124
 In vitro, BEN treatment 
resulted in S and G2/M cell cycle arrest.
124
  BEN has demonstrated anti-tumor activity in 
mice with orthotopic renal cell carcinoma xenografts. Specifically, BEN showed 
significant activity against human 786-0 and ACHN renal cell tumors when administered 
to mice on a q4dx5 schedule.
131
  BEN treatment of mice bearing orthotopically 
implanted, human RXF-393 renal carcinoma cell xenografts resulted in >70% cure rate 
whereas busulfan showed no activity.
131,132
 In addition, treatment with BEN slowed the 
growth of A498 human renal cell cancer xenografts.
131
 It was hypothesized that BEN’s 
activity against renal carcinoma cells may be due in part to the hydrophobic moiety in the 
molecule which allows BEN to pass through the cell membrane or due to its sequence 
specificity for DNA alkylation.
124
 The fact that BEN has displayed significant in vitro 
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and in vivo activity against renal carcinoma cells and tumor xenografts has led to the 
evaluation of BEN in an ongoing NCI-sponsored phase I clinical trial (clinicaltrials.gov 
NCT00923520). 
We have shown that in plasma, BEN is chemically converted into 6 different BEN 
analogs (chapter 2). Further, our previous studies demonstrate that BEN is rapidly 
metabolized into its benzoic acid analogue (BA) by red blood cells, catalyzed by 
aldehyde dehydrogenase 1A1 (ALDH1A1) (chapter3). We showed that BA reacts faster 
with nucleophiles than BEN, and may therefore be an important effector of DNA 
alkylation,
144
 and the conversion of BEN to BA by RBCs is likely an activation step. The 
in vivo metabolic pathway of BEN is shown in Figure 54. 
We previously performed a pharmacokinetic study in mice dosed 20 mg/kg iv.
173
 
BEN was rapidly metabolized and became undetectable at 15 minutes after 
administration, BA was rapidly generated, had a plasma exposure 2300-fold greater than 
that of BEN, and an apparent half-life of 55 min. In addition to BEN and BA, 11 other 
metabolites including 6 glucuronides of BA analogues, were detected. The half-lives of 
the metabolites ranged from 19 min (BA-OH) to 136 min (BA-Cl2).  All of the analytes 
detected in plasma were also detected in the urine of the mice collected between 0-6 and 
6- 24 h after dosing with BEN. 
Preclinical in vivo toxicology studies in rats and beagle dogs determined that 
dose-limiting toxicities were mainly hematologic (leukopenia, thrombocytopenia, and 
reduced reticulocyte counts) and gastrointestinal (diarrhea and nausea/vomiting). The rat 
was the most sensitive preclinical species at 15 mg/m
2
.  With a safety factor of 10, this 
resulted in a proposed starting dose in humans of 1.5 mg/m
2
.
174
  The aim of the current 
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study was to determine the MTD, the dose limiting toxicities and the pharmacokinetics of 
BEN administered to humans by 10-min infusion on days 1, 8, and 15 of a 28-day cycle. 
 
Figure 53. Chemical structures of BEN (A), busulfan (B), melphalan (C) and chlorambucil (D). 
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Figure 54. Proposed metabolic scheme for BEN in murine plasma. After iv injection to mice BEN 
is rapidly converted to BA. The methane sulfonate groups on BA are replaced with either chlorides or 
hydroxyl groups. Each analyte generated is also glucuronidated. 
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5.3 PATIENTS AND METHODS 
5.3.1 Study Design 
This multicenter study (ClinicalTrials.gov Identifier: NCT00923520) was 
conducted at the NCI Clinical Center (Bethesda, MD), University of Pittsburgh Cancer 
Institute, and Penn State Hershey Cancer Center, in accordance with the Declaration of 
Helsinki, and this study was approved by the institutional review boards at the respective 
institutions.  All patients read and signed consent prior to enrollment in the protocol. 
 
5.3.2 Patient Selection 
Eligible patients were ≥18 years of age with advanced solid tumors or lymphoma 
for which effective therapy did not exist or was no longer effective. There was no limit 
on prior chemotherapy treatment, although prior radiation to more than 25% of bone 
marrow was prohibited.  Patients had to be ≥4 weeks from prior chemotherapy, 
monoclonal antibody therapy or experimental therapy, ≥2 weeks from prior sorafenib, 
sunitinib, or temsirolimus treatment, ≥6 weeks from prior mitomycin C or nitrosoureas, 
and ≥8 weeks from prior UCN01. Adequate renal, hepatic, marrow function, and 
functional status was required, as was Eastern Cooperative Oncology Group performance 
status 0-2 and life expectancy ≥3 months. Toxicities from prior treatment had to have 
resolved to ≤grade 1. Inhibitors and inducers of CYP3A4 were prohibited.  Patients with 
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uncontrolled medical illness including myocardial infarction within the past 6 months 
were excluded. 
 
5.3.3 Study Treatment and Safety Evaluation 
BEN was supplied by the Division of Cancer Treatment and Diagnosis of the NCI 
in sterile, single-use vials containing a lyophilized powder/cake of 10 mg DMS612 and 
1000 mg hydroxypropyl-beta-cyclodextrin for reconstitution in 9.3 mL water for 
injection. After dilution in 0.9% sodium chloride or 5% dextrose, DMS612 was 
administered intravenously by central or peripheral catheter over 10 minutes on days 1, 8, 
and 15 of a 28-day cycle. There was no set limit on the number of cycles of study 
treatment administered.  A standard 3+3 design was used for dose escalation. The starting 
dose was 1.5 mg/m
2
 and the dose was escalated to 3, 5, 7, 9 and 12 mg/m
2.
 In absence of 
toxicity observed at level 6, pharmacokinetic data would be analyzed before any further 
dose escalation and continuation of the study.   
 
5.3.4 Safety Assessments 
Adverse events were assessed using Common Terminology Criteria for Adverse 
Events version 4.0. Vital signs and laboratory safety assessments were performed prior to 
each study treatment, and history and physical exam were performed at the start of each 
cycle. DLT was defined as febrile neutropenia or grade 4 neutropenia without fever for 
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>5 days; grade 4 thrombocytopenia or anemia; grade 3 non-hematologic toxicity except 
for nausea, vomiting, diarrhea or electrolyte abnormality corrected within 48 hours, or 
elevated creatinine corrected within 24 hours. The MTD was defined as the highest dose 
at which ≤1 out of 6 patients experienced a DLT. 
 
5.3.5 Response Evaluation 
Response and progression was evaluated every 2 cycles (8 weeks) using the 
international criteria published by the Response Evaluation Criteria in Solid Tumors 
Committee (RECIST 1.0) [6]. 
 
5.3.6 Pharmacokinetic Study Design 
Blood samples were collected in 4 mL heparinized green top tubes. Originally, 
blood was collected prior to infusion and at 2, 5, 15, 30, 45, 60, 120, 180, 240, 360, 480, 
and 1440 min after the end of infusion. After pharmacokinetic analysis of several patients 
revealed that BEN was rapidly metabolized, the protocol was amended. A blood draw at 
5 min into infusion was added and the 180 min draw was deleted. The obtained blood 
was immediately placed on ice and centrifuged for 10 min at 2,000×g at 4 °C to obtain 
plasma. A 1 mL aliquot of the resulting plasma was pipetted into a microcentrifuge tube 
containing 50 µL of 2 M H2SO4 and briefly vortexed to ensure stabilization of the 
analytes of interest. Plasma samples were stored at −70 °C until analysis. 
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5.3.7 Bioanalysis 
BEN, BEN-Cl2, BA, BA-Cl2, BEN-(OH)2 and BA-(OH)2 were quantitated by LC-
MS/MS as previously described (Parise et al., 2012, Chapter 2). For intermediate 
metabolites (BEN-OH, BEN-Cl, BEN-Cl-OH, BA-OH, BA-Cl, and BA-Cl-OH), and 
glucuronide conjugates, for which there were no reference standards available, the 
resulting analyte peak area was divided by the internal standard and the resulting ratio 
was converted to BEN equivalents by back-calculation using the BEN response equation. 
 
5.3.8 Pharmacokinetic analysis 
The maximum plasma concentration (Cmax) and the time to reach Cmax (Tmax) were 
determined by visual inspection of the plasma concentration versus time data. Other 
pharmacokinetic parameters were calculated non-compartmentally using PK Solutions 
2.0 (Summit Research Services, Montrose, CO http://www.summitPK.com). The area 
under the plasma concentration versus time curve (AUC) of all analytes was calculated 
with the log-linear trapezoidal rule.  
 Statistical analysis to determine the relationship of dose to Cmax and AUC was 
determined linear regression by first performing log transformation of the data and then 
linear regression using SPSS as described.
175
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5.4 RESULTS 
This study was conducted to determine the pharmacokinetics of BEN 
administered to humans. Thirty-one subjects with advanced solid tumors were enrolled in 
this phase I study. Subjects with a range of solid tumors were enrolled, including 4 with 
renal cell carcinoma (RCC) and 11 with colorectal carcinoma (CRC). The median 
number of prior chemotherapy regimens was 4 (range 0-13). Subjects were treated at six 
dose levels: 1.5 mg/m
2
 (n=3), 3.0 mg/m
2
 (n=3), 5.0 mg/m
2
 (n=6), 7.0 mg/m
2
 (n=3), 9.0 
mg/m
2
 (n=12), and 12.0 mg/m
2
 (n=3). 
Myelosuppression with thrombocytopenia and neutropenia was the principal 
dose-limiting toxicity. Two of 3 subjects treated at the 12 mg/m
2
 dose level experienced 
dose limiting toxicity (DLT) with grade 4 neutropenia and prolonged grade 3 
thrombocytopenia, respectively. At the lower dose level of 9 mg/m
2
 only 1 of 12 subjects 
experienced a DLT, therefore, the MTD was determined to be 9 mg/m
2
. 
One subject with RCC and one subject with cervical cancer had a confirmed 
partial response. Both patients were treated at the MTD of 9 mg/m
2
 (dose level 4). Stable 
disease was observed in 2 additional patients. Neither the responses nor the toxicities 
observed appeared to correlate with the plasma pharmacokinetics or metabolism of BEN 
as the pharmacokinetic parameters in these patients were not different than the rest of the 
cohort (Figure 66). 
BEN was only detected in two patients at the earliest time point, and the half-life 
could not be determined in any of the patients.  BA was detected in all patients except for 
two. In addition to BEN and BA, 11 other metabolites including 6 glucuronides of BA, 
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were detected. A representative concentration versus time profile for the analytes in a 
patient is shown in Figure 55. 
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Figure 55. Plasma concentration or BA equivalents (ng/ml) versus time for a patient that received 
5.0 mg/ml BEN.  A) BA (■) and BA-OH2 (○). B) BA-Cl (■), BA-OH (□), and BA-Cl-OH (▲). C) BA-
Gluc (■), BA-Cl2-Gluc (□), BA-OH-Gluc (▲), BA-(OH)2-Gluc (∆), BA-Cl-OH-Gluc (●), and BA-Cl-Gluc 
(○). Note the second peak in the glucuronide metabolites. This could be an indication of enterohepatic 
recycling. 
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The half-life of all analytes was variable amongst dose levels (Table 9). The 
major metabolite, BA, had a half-life of 7.5 minutes when patients were dosed at 1.5 
mg/m
2
 and 770 minutes at the 9.0 mg/m
2
 dose level. The AUC and Cmax of the 
metabolites appeared to increase with dose except in a few cases (Figure 56 to Figure 66). 
The PK parameters for the metabolites are listed in Table 1. 
The AUC0-t and Cmax of BA increased more than proportionally with dose, 2.03 
(95% CI, 1.47 – 2.58) and 1.87 (95% CI, 1.37 – 2.31) respectively (Figure 56). The 
AUC0-t and Cmax of BA-(OH)2 (the end metabolite) increased proportionally with dose, 
2.08 (95% CI, 0.97 – 3.18)  and 1.13 (95%CI, 0.51 – 1.75) respectively (Figure 57). 
Apparent clearance (Cl/F) of BA decreased with dose while the Cl/F of BA-OH2 was 
unchanged with dose. The half-lives of the metabolites ranged from 7.5 min (BA) to 2634 
min (BA-Cl-OH) (Table 9). 
There were four patients that had RCC on the clinical trial. The pharmacokinetic 
parameters of these patient were not different from the other patients being administered 
BEN. Also, there were 3 patients that were dosed at 2 different dose levels. Two of these 
patients were first administered 1.5 mg/m
2
 and then 3.0 mg/m
2
 of BEN. The third patient 
was administered 3.0 and then 5.0 mg/m
2
 of BEN. There was a large variation of Cmax of 
BEN in the plasma in these patients. Upon dose escalation, the Cmax doubled in one 
patient, decreased by one half in another patient and increased by ten times in the third 
patient. 
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Table 9. The Cmax, Tmax, AUC0-t, Cl/F and half-life of BEN and its metabolites, mean (SD). 
BA           
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Cl/F (L/min) Half-life (min) 
1.5 (N=4) 99.1 (54.8) 12 (0) 2010 (1953) 1.59 (1.44) 7.5 (2.8) 
3 (N=5) 183.0 (193.1) 12.6 (1.3) 2827 (2600) 1.77 (1.24) 33.3 (29.1) 
5 (N=6) 470.6 (460.1) 13 (1.5 12857 (9469.2) 0.72 (0.60) 69.6 (66.0) 
7 (N=2) 771.5 (61.5) 42.5 (38.9) 28735 (11309) 0.26 (0.10) 26.6 (23.3) 
9 (N=11) 2430 (1725) 15.9 (17.4) 73585 (78888) 0.30 (0.33) 770.6 (1708.4) 
12 (N=2) 3742 (4126) 5 (NA) 50106 (52547) 0.53 (0.56) 20.0 (NA) 
 
BA-(OH)2 
 
      
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=1) 12.5 (NA) 12 (NA) 213.4 (NA) 44.5 (NA) 
3 (N=1) 14.5 (NA) 12 (NA) 204.0 (NA) 10.4 (NA) 
5 (N=7) 31.3 (9.9) 13.7 (1.6) 1669 (139) 48.8 (29.9) 
7 (N=2) 58.9 (NA) 12 (NA) 18878 (NA) 1700 (NA) 
9 (N=12) 102.2 (153.2) 21.2 (19.1) 13061 (22340) 126.9 (124.2) 
12 (N=2) 124.7 (NA) 15.0 (NA) 7083 (NA) 155.8 (NA) 
 
 
 
    BA-Cl2         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
9 (N=1) 43.3 25 1998 25.2 
     
     BA-Cl         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 12.8 (15.0) 12.0 (0) 220.7 (176.6) 24.9 (13.4) 
3 (N=5) 5.9 (4.7) 13.2 (1.6) 128.5 (65.0) 30.1 (0.9) 
5 (N=6) 15.6 (14.3) 14.7 (4.8) 551.8 (651.2) 454.7 (953.8) 
7 (N=2) 20.0 (NA) 42.5 (NA) 933.2 (NA) 17.3 (NA) 
9 (N=11) 72.2 (72.4) 16.5 (16.2) 3292 (4482) 233.1 (371.1) 
12 (N=2) 70.9 (NA) 8.5 (NA) 1719 (NA) 7.7 (NA) 
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BA-Cl-OH         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 4.1 (3.2) 12 (0) 180.1 (181.2) 46.4 (19.5) 
3 (N=4) 3.5 (2.0) 13.5 (1.7) 156.5 (45.1) 234.8 (206.1) 
5 (N=7) 19.6 (9.6) 18.4 (6.3) 1528 (1119) 222.0 (345.5) 
7 (N=2) 27.4 (NA) 15 (NA) 5269 (NA) 308.8 (NA) 
9 (N=12) 57.5 (40.8) 25.6 (19.0) 4739 (4770) 2634 (6402) 
12 (N=2) 277.8 (NA) 15 (NA) 4534 (NA) 52.6 (NA) 
     BA-OH         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=3) 5.6 (4.1) 12 (0) 119.7 (123.6) 41.3 (NA) 
3 (N=5) 6.9 (1.3) 12.6 (1.3) 116.4 (136.7) 27.8 (25.2) 
5 (N=6) 26.0 (19.5) 13.5 (1.6) 778.5 (500.3) 65.0 (49.0) 
7 (N=2) 38.3 (NA) 13.5 (NA) 961.5 (NA) 21.0 (NA) 
9 (N=12) 109.0 (84.8) 14.7 (16.1) 3106 (2812) 61.4 (48.4) 
12 (N=2) 182 (NA) 8.5 (NA) 2387 (2812) 16.9 (NA) 
 
BA-Gluc         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 17.3 (16.6) 36.3 (14.4) 1547 (2107) 120.9 (144.9) 
3 (N=5) 17.1 (12.1) 24.0 (10.3) 1075 (586) 166.2 (180.8) 
5 (N=6) 35.8 (26.7) 31.7 (20.9) 3474 (3561) 519.4 (947.9) 
7 (N=2) 71.9 (NA) 35 6359 (NA) 38.2 (NA) 
9 (N=11) 75.4 (65.0) 33.6 (11.4) 6545 (5239) 194.8 (223.7) 
12 (N=2) 136.1 (NA) 20 (NA) 10612 (NA) 93.6 (NA) 
     BA-(OH)2-Gluc         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 7.5 (9.9) 88.8 (48.0) 3470 (5397) 418.9 (389.6) 
3 (N=5) 3.3 (1.3) 100.0 (59.1) 1601 (1016) 319.9 (517.8) 
5 (N=7) 17.0 (8.5) 164.3 (185.1) 9767 (7667) 594.5 (201.5) 
7 (N=2) 30.9 (NA) 190.0 (NA) 14121 (NA) 575.8 (NA) 
9 (N=12) 34.2 (25.6) 236.3 (396.2) 13724 (12851) 513.4 (835.1) 
12 (N=2) 65.2 (NA) 190.0 (NA) 23697 (NA) 2381.1 (NA) 
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    BA-Cl2-Gluc         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 4.1 (4.1) 36.3 (14.4) 586.7 (749.6) 83.2 (49.7) 
3 (N=5) 3.0 (1.4) 38.4 (25.1) 267.6 (359.1) 125.7 (89.7) 
5 (N=7) 19.7 (17.4) 50.7 (16.7) 2725 (3446) 189.2 (74.3) 
7 (N=2) 32.1 (NA) 92.5 (NA) 6478 (NA) 361.6 (NA) 
9 (N=12) 30.9 (30.7) 43.8 (18.2) 4215 (4058) 283.3 (502.3) 
12 (N=2) 97.2 (NA) 47.5 (NA) 14244 (NA) 189.6 (NA) 
     BA-Cl-Gluc         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 6.5 (5.7) 26.3 (10.3) 603.0 (880.2) 84.8 (48.6) 
3 (N=5) 3.6 (1.7) 23.0 (4.5) 313.1 (161.4) 90.0 (39.6) 
5 (N=7) 18.6 (17.1) 32.9 (19.3) 1930 (2158) 152.9 (126.9) 
7 (N=2) 34.2 (NA) 35.0 (NA) 4069 (NA) 781.0 (NA) 
9 (N=10) 31.4 (22.4) 28.0 (11.1) 3002 (2431) 162.5 (3.7) 
12 (N=1) 89.2 (NA) 12.0 (NA) 10140 (NA) 121.7 (NA) 
     BA-Cl-OH-Gluc         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 3.1 (3.0) 36.3 (22.5) 767 (1228) 105.8 (65.5) 
3 (N=4) 1.9 (0.9) 47.5 (15.0) 402.0 (362.8) 137.1 (69.1) 
5 (N=7) 13.7 (9.8) 57.1 (13.5) 2727 (2204) 272.7 (100.8) 
7 (N=2) 19.6 (NA) 92.5 (NA) 4463 (NA) 693.4 (NA) 
9 (N=10) 24.4 (15.1) 92.5 (101.3) 4981 (5311) 422.9 (474.6) 
12 (N=2) 49.6 (NA) 70 (NA) 9990 (NA) 49.6 (NA) 
     BA-OH-Gluc         
Dose (mg/m
2
) Cmax (ng/mL) Tmax (min)  AUC (ug/mL*min) Half-life (min) 
1.5 (N=4) 3.5 (2.5) 26.3 (10.3) 331.6 (447.1) 311.6 (281.9) 
3 (N=5) 2.8 (2.1) 32 (15.7) 210.3 (134.0) 114.4 (90.8) 
5 (N=7) 9.1 (6.1) 36.4 (19.7) 995.6 (817.5) 115.0 (66.3) 
7 (N=2) 16.2 (NA) 35.0 (NA) 2236 (NA) 395.0 (NA) 
9 (N=8) 15.7 (11.9) 23.8 (10.9) 1599 (875) 221.6 (414.6) 
12 (N=2) 26 (NA) 18.5 (NA) 27912 (NA) 193.8 (NA) 
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5.5 DISCUSSION 
This study aimed to characterize the safety, tolerability, pharmacokinetics and 
metabolism of BEN in patients with solid tumors. Previous results suggested that BEN is 
metabolized in vivo and in vitro in blood into BA by ALDH. We have demonstrated that 
BA reacts faster with nucleophiles than BEN, and may therefore be an important effector 
of DNA alkylation.
159
 
The maximum tolerated dose of BEN was 9 mg/m
2
 when administered on days 1, 
8, and 15 of a 28-day schedule. Three patients experienced dose-limiting toxicities of 
neutropenia and thrombocytopenia which is consistent with the proposed mechanism of 
BEN as an alkylating agent. In addition, many patients exhibited prolonged but reversible 
myelosuppression. Tumor responses were seen in one subject with mRCC and in one 
subject with advanced cervical carcinoma following BEN administration. Neither the 
responses nor the toxicities observed could be correlated to the plasma pharmacokinetics 
(ie. AUC, Cmax or T1/2) or metabolism of BEN. 
BEN was rapidly metabolized in all patients and was only detected in 2 patients. 
This was similar to our previous observations in mice showed rapid metabolism of BEN 
to BA even though the dose of BEN administered to mice was 8 times higher than that 
given to patients in this trial. All of the BEN metabolites and glucuronides that were 
detected in mice were also observed in patients, which further support the translation of 
previous preclinical findings relating to BEN pharmacology. There was a large inter-
patient variability in the concentration and AUC of BA and downstream metabolites. 
This may be due in part to sample handling and processing as BA has a half-life of 5 
minutes in blood at room temperature. BA was present in all but two patients; however, 
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these two patients did have downstream BA metabolites. The BA plasma half-life was 
several-fold longer than the 5 min in vitro plasma half-life of this very reactive 
compound, suggesting continued metabolic generation of BA from BEN in tissues, 
followed by re-distribution into the plasma compartment. This finding is indirect proof of 
the ability of BEN to reach tissues with subsequent intracellular activation to BA.
159
 
The AUC and Cmax of the metabolites increased linearly with dose. The dose 
adjusted Cmax remained constant for all analytes with an increase in dose except for BA in 
which the dose adjusted Cmax increased with dose. This may be due in part to e.g. a 
saturated efflux transporter that causes more BEN to remain in the cells at higher 
concentrations which is then converted to BA. 
BEN is a lipophilic pro-drug of BA. Intracellularly generated, BA is a much more 
reactive analog and the likely alkylator of cellular targets. We previously showed that 
ALDH may be responsible for the intracellular metabolism of BEN to BA, and that BEN 
is more active in cell lines that express high levels of ALDH.
159
 Therefore, BEN appears 
to be able to target cells that over express ALDH. The potential importance lies in the 
reported overexpression of ALDH in stem cells of many tumor types making these stem 
cells potential targets for BEN therapy. The prolonged myelosuppression observed with 
BEN is suggestive of toxicity to bone marrow stem cells. Hematopoietic stem cells 
express high levels of aldehyde dehydrogenase,
176
 potentially facilitating the rapid 
conversion of BEN to BA, with ensuing intracellular alkylation and cytotoxicity. 
This trial produced a response rate of 2/16 in a heavily pre-treated population. 
One of the responses was from a patient had RCC. There were a total of 4 patients 
enrolled in the trial that suffer from RCC. The responses that were observed were at the 9 
 176 
 
mg/m
2
 dose level in which a total of 12 patients were treated. All of which suggests that 
further investigation of anti-tumor activity is warranted. While a predictable pattern of 
reversible myelosuppression was observed, toxicities such as alopecia and peripheral 
neuropathy were not, and gastrointestinal toxicity was relatively modest. In addition, an 
alternative schedule of drug administration on day 1 and 2 on an every 21-day schedule is 
being currently investigated in a phase I cohort of patients with advanced solid tumors.  
We hypothesize that a prolonged (20-day) interval of this modified schedule would allow 
for greater hematopoietic recovery, and would potentially be associated with reduced 
myelosuppression at clinically effective doses. 
In conclusion, the maximum tolerated dose of BEN on a weekly times 3 every 4 
weeks schedule was 9.0 mg/m
2
. There were 3 subjects that experienced dose limited 
toxicities and two subjects exhibited partial responses. Neither the toxicities nor the 
responses correlated with the plasma pharmacokinetics of BEN.  BEN was very rapidly 
metabolized to BA, and the same metabolites that were detected in mice were also 
detected in humans. 
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Figure 56. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA. (▲toxicity ■ 
partial response).    
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Figure 57. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-(OH)2. 
(▲toxicity ■ partial response).   
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Figure 58. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-OH. (▲toxicity 
■ partial response).    
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Figure 59. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-Cl. (▲toxicity ■ 
partial response).   
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Figure 60. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-Cl-OH. 
(▲toxicity ■ partial response).   
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Figure 61. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-Gluc. (▲toxicity 
■ partial response).   
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Figure 62. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-Cl-Gluc. 
(▲toxicity ■ partial response).   
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Figure 63. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-Cl2-Gluc. 
(▲toxicity ■ partial response).   
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Figure 64. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-(OH)2-Gluc. 
(▲toxicity ■ partial response).   
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Figure 65. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-OH-Gluc. 
(▲toxicity ■ partial response).   
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Figure 66. A) AUC vs dose B) Cmax vs dose and C) Cmax/dose vs dose for BA-Cl-OH-Gluc. 
(▲toxicity ■ partial response).   
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6.0    MAJOR FINDINGS, LIMITATIONS, AND FUTURE DIRECTION 
6.1 CONCLUSIONS 
The work in this dissertation was conducted to gain a better understanding of the 
preclinical and clinical pharmacology of benzaldehyde dimethane sulfonate (BEN), an 
alkylating agent that was shown to have activity against renal carcinoma cell lines and 
was to be administered to patients in a phase I clinical trial. 
Limited basic metabolism and pharmacokinetic data was available to successfully 
implement the clinical studies. We first studied the characteristics of BEN in various 
biological matrices including plasma and blood (Chapter 2 and 3). We then conducted 
studies in renal carcinoma cells to evaluate its effect and mice to determine the 
metabolism and pharmacokinetics in animals (Chapters 2 and 4). Lastly, we assessed the 
pharmacokinetics of BEN administered to people as part of a first in humans clinical trial 
(Chapter 5). 
In whole blood, but not in plasma, BEN was rapidly converted to its carboxylic 
acid analogue BA, suggesting conversion by an enzyme present in red blood cells. BA 
rapidly decomposed in plasma with a half-life of approximately 5 min. In plasma, BEN 
and BA decomposed according to a parallel pathway to a number of hydroxylated and 
chlorinated analogs. The relatively fast rate of production of BA products relative to the 
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generation of BEN products is likely indicative of the relative reactivities of the acid 
analogs relative to the aldehyde analogs. We hypothesize that the unbound electron pair 
on the aniline nitrogen is the initiator of an SN2 attack on the β-carbon, generating the 
reactive aziridinium intermediate. Mesomeric withdrawal of the aniline unbound electron 
pair by the para-aldehyde moiety, or occupation of the electron pair by a proton under 
acidic conditions would be expected to decrease the generation of the aziridinium 
intermediate and thereby decrease the reactivity. The abundance of BA analogs and lack 
of BEN analogs after incubation of BEN in whole blood can be attributed to the relative 
rates of the competing pathways of BEN conversion. The conversion of BEN to BA is 
much more rapid than conversion of BEN to downstream aldehyde analogs. In addition, 
any aldehyde products formed may also be converted to their respective acid counterparts 
by the same enzymatic pathway that converts BEN to BA, as was shown for the 
conversion of BEN-(OH)2 to BA-(OH)2 in whole blood. During incubation with human 
renal carcinoma cells, BEN undergoes chemical conversion to BEN-(OH)2 or metabolism 
to BA and subsequent conversion to BA-(OH)2 in all cell lines tested. A498 cells 
displayed the greatest metabolism of BEN to BA as shown by the amount of BA-(OH)2 
generated; in fact, no BEN-(OH)2 could be detected. In contrast, SN12K1 cells generated 
very little BA-(OH)2. The ratio of BEN disappearance for A498/SN12K1 was 35-fold. It 
is noteworthy that the A498 cell line was the most sensitive to BEN demonstrated by the 
lowest IC50 value. To test whether ALDH may be responsible for the metabolic 
conversion of BEN to BA we measured the ALDH activity in A498 and SN12K1 cells. 
We found that A498 cells had ALDH activity approximately 40-fold greater than 
SN12K1 cells, paralleling the BA-(OH)2 generating activity and conversely the 
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metabolism of BEN to BA. These results are in line with previously reported ALDH 
activities.
137
  These data support the notion that intracellular ALDH is responsible for the 
metabolism of BEN to BA in these cells, and that this intracellular conversion mediates 
its cytotoxic effects. ALDH may also be responsible for the observed metabolism of BEN 
to BA in whole blood as red blood cells contain ALDH. 
We hypothesize that the A498 cell line is able to most efficiently metabolize BEN 
to its more reactive metabolite BA by ALDH inside the cell, which then rapidly alkylates 
cellular constituents resulting in cell damage. The high IC50s of BA added to medium 
suggest that BA reacts with other nucleophiles in the medium before it is able to reach its 
intracellular targets. BEN-Cl2 and BA-Cl2 had intermediary IC50s. This suggests that 
BEN-Cl2 gets into the cells and is locally converted to BA-Cl2 which reacts with cellular 
targets. However, because BA-Cl2 is not as reactive as BA, a fair amount likely diffuses 
out of the cell without exerting cytotoxic effects. Conversely, when BA-Cl2 was added to 
the cell incubation, the relative stability of BA-Cl2 allowed enough of it to diffuse into the 
cells to cause intracellular damage. Taken together, these data suggest that BEN is a pro-
drug that requires intracellular activation to the highly reactive BA, which likely exerts 
rapid and localized damage via alkylation inside the cells. 
The second part of our work focused on the determination of the enzyme 
responsible for the metabolic conversion of BEN to BA. Also we performed Km and Vmax 
experiments to better understand the metabolism of BEN. 
We performed the metabolism of BEN with the purified enzymes that were 
commercially available. These included ALDH1A1, 3A1, 2 and 5A1. Of the ALDH 
isoforms we tested BEN was only a substrate for ALDH1A1.  Although we found that 
 191 
 
ALDH1A1 was the only enzyme that metabolized BEN there may be other ALDH 
isoforms that also metablize BEN as there are 19 known isoforms of ALDH. Most of 
these ALDHs are not commercially available and the substrates for these isoforms have 
yet to be determined.  
The apparent Vmax and Km of BEN were determined in 6 different lots of blood to 
evaluate biological central tendency and variability. BEN displayed saturable kinetics in 
all of the lots of blood we tested. In addition, we found that there was inter-subject 
variability between the lots of blood. However, the km values displayed are higher than 
the expected peak concentrations of BEN in humans. Therefore we expect linear 
pharmacokinetics in humans.  
The third part of this work focused on determining the pharmacokinetic 
parameters of BEN in mice and to determine whether the administration of the ALDH 
inhibitor disulfiram could change the exposure of BEN. After iv BEN administration to 
mice, the exposure to BEN was low and there were at least 12 metabolites generated, 
including 6 BA glucuronides.  
The plasma half-life of BA in mice was much longer than the in vitro half-life of 
BA, (5 min). The longer in vivo half-life of BA suggests that although BEN is 
metabolized in RBCs, BEN also enters into tissues where it is also metabolized to BA.  
The BA that is produced in the tissues then re-enters the blood where it degrades into 
downstream BA products as demonstrated in the in vitro experiments. Pretreatment with 
disulfiram increased BEN exposure 368-fold, giving further evidence that ALDH may be 
an enzyme responsible for metabolizing BEN into BA. 
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The last part of this dissertation was to determine the plasma pharmacokinetics of 
BEN administered to humans as part of a phase I clinical trial. The maximum tolerated 
dose of BEN was 9 mg/m
2
 when administered on days 1, 8, and 15 of a 28-day schedule. 
Three patients experienced dose-limiting toxicities of neutropenia and thrombocytopenia 
which is consistent with the proposed mechanism of BEN as an alkylating agent. In 
addition, many patients exhibited prolonged (14 days) but reversible myelosuppression. 
Tumor responses were seen in one subject with mRCC and in one subject with advanced 
cervical carcinoma following BEN administration. Neither the responses nor the 
toxicities witnessed could be correlated to the pharmacokinetics or metabolism of BEN. 
BEN was rapidly metabolized in all patients and was only detected in 2 patients. This was 
similar to our previous mouse study which resulted in the rapid metabolism of BEN to 
BA even though the dose of BEN administered to mice was 8 times higher than that 
given to patients in this trial. All of the BEN metabolites and glucuronides that were 
detected in mice were also observed in patients. In addition, a decrease in the white blood 
cell count and the percent lymphocytes in mice administered BEN showed that BEN is 
toxic to the bone marrow. This was also demonstrated in humans as many patients 
exhibited neutropenia and thrombocytopenia, which further support the translation of 
previous preclinical findings relating to BEN pharmacology. There was a large inter-
patient variability in the concentration and AUC of BA and downstream metabolites. BA 
was present in all but two patients; however, these two patients did have downstream BA 
metabolites. The BA plasma half-life was several-fold longer than the 5 min in vitro 
plasma half-life of this very reactive compound, suggesting continued metabolic 
generation of BA from BEN in tissues, followed by re-distribution into the plasma 
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compartment. This finding is indirect proof of the ability of BEN to reach tissues with 
subsequent intracellular activation to BA.
173
 
The AUC and Cmax of the metabolites increased linearly with dose. This is 
expected with linear kinetics. The dose adjusted Cmax remained constant for all analytes 
with an increase in dose except for BA in which the dose adjusted Cmax increased with 
dose. This may be due in part to e.g. a saturated efflux transporter that causes more BEN 
to remain in the cells at higher concentrations which is then converted to BA. BEN is a 
lipophilic pro-drug of BA. Intracellularly generated, BA is a much more reactive analog 
and the likely alkylator of cellular targets. We previously showed that ALDH may be 
responsible for the intracellular metabolism of BEN to BA, and that BEN is more active 
in cell lines that express high levels of ALDH. Therefore, BEN appears to be able to 
target cells that over express ALDH. The potential importance lies in the reported 
overexpression of ALDH in stem cells of many tumor types making these stem cells 
potential targets for BEN therapy. The prolonged myelosuppression observed with BEN 
is suggestive of toxicity to bone marrow stem cells. Hematopoietic stem cells express 
high levels of aldehyde dehydrogenase, potentially facilitating the rapid conversion of 
BEN to BA, with ensuing intracellular alkylation and cytotoxicity. 
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6.2 FUTURE DIRECTION 
1). Although multiple clinical trials with various agents for the treatment of RCC have 
been performed the outcome has been poor. More research needs to be conducted to 
elucidate why RCC is so resistant to current therapies.  
 
2). Benzaldehyde dimethane sulfonate has proven to be more active in vitro and in vivo 
against RCC than other alkylating agents. One reason may be because certain RCC cells 
have high levels of ALDH activity, however, it may also be due in part to the structure of 
BEN. Specifically, the hydrophobic moiety on the molecule is better able to enter into the 
cell. Transporter experiments testing this theory should be conducted. 
 
3). We hypothesize that BEN acts as a prodrug and that BA actually causes the 
cytotoxicity to RCC cells. Future experiments should be performed that more precisely 
measures the levels of BEN and BA in tissues. These experiments could include mass 
spectrometric determination of DNA alkylation by BEN and BA or 
14
C-labeled BEN 
studies. 
 
4). We have shown that BEN has greater activity in RCC cell lines that have higher levels 
of ALDH. Experiments to determine the effects of BEN on other cell lines that have high 
levels of ALDH such as certain lung cancer cell lines and tumor stem cells may prove to 
be beneficial. In addition, patients for BEN treatment could be selected based on the 
ALDH levels in their tumor. Studies can then relate ALDH expression levels and clinical 
outcome. 
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5). A large inter individual variability was displayed in the pharmacokinetic parameters 
of BEN and its metabolites in the clinical trial. Part of this variability may be due to the 
metabolism of BEN and degradation of BA during sample collection. In future trials, 
there should be more emphasis on sample collection to ensure that both BEN and BA are 
stabilized. First, the addition of disulfiram to the blood collection vials should be 
considered. This would ensure that the metabolism of BEN to BA would be inhibited. In 
addition, experiments that limit the degradation of BA into BA degradation products 
should be considered. One example of this would be to immediately centrifuge the 
collected blood at 4 ºC as soon as the blood is drawn from the patient. Another method 
would be to add acetonitrile that contained sulfuric acid directly to the blood sample 
immediately after sample collection 
  
6). In the current human clinical trial of BEN, many patient experienced neutropenia and 
thrombocytopenia. The dosing schema in any future clinical trials should consider a 
longer wash out period between dosing.  
 
7). In the current clinical trial 16 different analytes where measured. These included 
BEN, BA, their analogs and the glucuronides of the BA products. Since most of the 
analytes are not active or not detected the LC-MS/MS method should be modified to 
measure fewer analytes. An assay to quantitate BEN, BA, BA-(OH)2 and BA-(OH)2-
glucuronide should be adequate to characterize the pharmacokinetics of any future 
clinical trial of BEN administered to patients. 
 196 
 
8). The current clinical trial of BEN prevents enrolled patients from taking drugs that are 
substrates for CYP3A4. Since BEN is not a substrate for CYP3A4, future trials should 
remove this exclusion criterium. 
 
9). The pharmacokinetics, metabolism and resulting toxicity of BEN administered to 
mice was similar to that of BEN administered in humans. This is an indication that 
CD2F1 mice are a good model for any future experiments of BEN in an animal study. 
 
9). This trial produced a response rate of 2/16 in a heavily pre-treated population. One of 
the responses was from a patient had RCC. There were a total of 4 patients enrolled in the 
trial that suffer from RCC. The responses that were observed were at the 9 mg/m
2
 dose 
level in which a total of 12 patients were treated. All of which suggests that further 
investigation of anti-tumor activity is warranted. The recommended phase II dose should 
be at least 9.0 mg/m2 as the response witnessed in the phase I trial was at this dose level. 
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